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WITNESS SEMINARS: 
MEETINGS AND PUBLICATIONS 1
In 1990 the Wellcome Trust created a History of Twentieth Century Medicine 
Group, associated with the Academic Unit of the Wellcome Institute for the 
History of Medicine, to bring together clinicians, scientists, historians and others 
interested in contemporary medical history. Among a number of other initiatives 
the format of Witness Seminars, used by the Institute of Contemporary British 
History to address issues of recent political history, was adopted, to promote 
interaction between these different groups, to emphasize the potential benefits 
of working jointly, and to encourage the creation and deposit of archival sources 
for present and future use. In June 1999 the Governors of the Wellcome Trust 
decided that it would be appropriate for the Academic Unit to enjoy a more 
formal academic affiliation and turned the Unit into the Wellcome Trust Centre 
for the History of Medicine at UCL from 1 October 2000. The Wellcome 
Trust continues to fund the Witness Seminar programme via its support for 
the Centre.
The Witness Seminar is a particularly specialized form of oral history, where 
several people associated with a particular set of circumstances or events are 
invited to come together to discuss, debate, and agree or disagree about their 
memories. To date, the History of Twentieth Century Medicine Group has held 
more than 50 such meetings at the time of publication, most of which have 
been published, as listed on pages xiii–xvii. 
Subjects are usually proposed by, or through, members of the Programme 
Committee of the Group, which includes professional historians of medicine, 
practising scientists and clinicians, and once an appropriate topic has been 
agreed, suitable participants are identified and invited. This inevitably leads to 
further contacts, and more suggestions of people to invite. As the organization 
of the meeting progresses, a flexible outline plan for the meeting is devised, 
usually with assistance from the meeting’s chairman, and some participants are 
invited to ‘set the ball rolling’ on particular themes, by speaking for a short 
period to initiate and stimulate further discussion.
1 The following is the standard introductory text to the Wellcome Witnesses to Twentieth Century 
Medicine series.
xEach meeting is fully recorded, the tapes are transcribed and the unedited transcript 
is sent to every participant. Each is asked to check his or her own contributions and 
to provide brief biographical details. The editors turn the transcript into readable 
text, and participants’ minor corrections and comments are incorporated into that 
text, while biographical and bibliographical details are added as footnotes, as are 
more substantial comments and additional material provided by participants. The 
final scripts are then sent to every contributor, accompanied by forms assigning 
copyright to the Wellcome Trust. Copies of all additional correspondence received 
during the editorial process are deposited with the records of each meeting in 
archives and manuscripts, Wellcome Library, London. 
As with all our meetings, we hope that even if the precise details of some of the 
technical sections are not clear to the non-specialist, the sense and significance 
of the events will be understandable. Our aim is for the volumes that emerge 
from these meetings to inform those with a general interest in the history of 
modern medicine and medical science; to provide historians with new insights, 
fresh material for study, and further themes for research; and to emphasize to 
the participants that events of the recent past, of their own working lives, are of 
proper and necessary concern to historians.
Members of the Programme Committee of the  
History of Twentieth Century Medicine Group, 2009–10
Professor Tilli Tansey – professor of the history of modern medical sciences,  
Wellcome Trust Centre for the History of Medicine at UCL (WTCHM) and chair
Dr Sanjoy Bhattacharya – reader in the history of medicine, WTCHM
Sir Christopher Booth – former director, Clinical Research Centre,  
Northwick Park Hospital, London
Dr John Ford – retired general practitioner, Tonbridge
Professor Richard Himsworth – former director of the Institute of Health,  
University of Cambridge
Professor Mark Jackson – professor of the history of medicine and director,  
Centre for Medical History, Exeter
Professor John Pickstone – Wellcome research professor, University of Manchester
Mrs Lois Reynolds – senior research assistant, WTCHM, and organizing secretary
Professor Lawrence Weaver – professor of child health, University of Glasgow, and 
consultant paediatrician in the Royal Hospital for Sick Children, Glasgow
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INTRODUCTION
It took nearly 150 years from Rigoni-Stern’s observation that ‘cancer of the 
uterus’ might be related to sexual lifestyle (page 83), for Human Papilloma 
Virus (HPV) to be established as the cause of cervical cancer in the 1980s. His 
observation that cancer was more common in married women than virgins and 
nuns in nineteenth-century Verona gave the first clue to aetiology. A century 
later epidemiological studies identified the sexual behavioural risks for cervical 
cancer in both women and their male partners. In parallel, gynaecologists, 
virologists and cytologists were making rapid advances in their understanding 
of the natural history of cervical cancer, the detection through cervical cytology 
of preinvasive stages of cervical cancer, and we’re beginning to explore the 
possibility of a viral cause.
This Witness Seminar volume gives fascinating insights into the science, 
serendipity, and dogged commitment of a generation of clinicians, virologists, 
cytologists, epidemiologists, and public health specialists in establishing cervical 
screening as a sensitive, specific and effective tool to reduce cancer mortality. 
Papanicolaou developed his smear test for early cancer detection in 1943 but 
it took until 1988 for a properly organised population-based service to be 
established in England.
The witnesses here trace the work leading to the discovery of HPV as a cause of 
cervical cancer through advances in detection methods which identified oncogenic 
viral types and thus paved the way for development of HPV vaccines.
But with the evolution of the science comes the determined and tireless effort of 
those who drove screening policy (such as Muir Gray, Jocelyn Chamberlain and 
Catherine Pike), those gynaecologists who were early adopters (such as Stanley 
Way and later Albert Singer) and the army of major contributors (mainly 
women) who led and executed the programmes of screening, read the smears, 
improved the accuracy and standardization of methods of sample collection, 
cytological protocols, call and recall and clinical follow-up over the course of 
several decades.
I have not been directly involved in cervical cancer research but have followed 
the unfolding story of aetiology and control from the sidelines over the last 
30 years with gratitude for what has been achieved. It is my generation who 
were among the first to benefit from cervical cancer screening and it will be 
my daughter’s generation who will be the first hopefully to benefit from the 
xx
introduction of HPV vaccination. But like the cervical screening programme 
before it, population benefit will only be achieved through high uptake and 
efficacy against all the predominant circulating oncogenic viruses.
I first became aware of the beginnings of cervical screening in the 1960s. Both 
my parents were gynaecologists and worked for Stanley Way in Newcastle in the 
1940s and 1950s. My mother recounts details of the radical surgery undertaken 
by Way for advanced case of cancer and the early experiments comparing 
outcomes of surgery and radium treatment, but mortality was high.2 
Accounts of the 1960s and 1970s abound with tales of the uncertainty 
about effectiveness of screening and the disorganization, inconsistency and 
opportunistic nature of much screening. Lamentably much of that uncertainty 
might have been circumvented if Archie Cochrane’s calls for randomized clinical 
trials had been heeded (pages 18 and 59, notes 44 and 162).
My mother, along with many women doctors of her generation, was in part-
time work in family planning and cervical cytology clinics. She lamented the 
poor technique used by many doctors and recalls teaching the importance 
of visualization of the cervix to local GPs in Manchester, and the days of 
undertaking screening of women in factories around Manchester in a mobile 
unit. But she felt her efforts detected more ovarian than cervical pathology. Too 
often they were screening the low-risk women.
Her account resonates with the report here. The 1960s and 1970s were the 
years of concerted effort to improve the specificity and consistency of tests and 
the coverage of screening by those who were the product champions of the day. 
While attempts had been made by the then Ministry of Health to establish a 
smear testing programme in 1964, it was not until 1988 that the current NHS 
Cervical Screening Programme was established, largely as an outcome of the 
efforts of the 1987 Intercollegiate Working Party (pages 26–9). An impassioned 
editorial in the Lancet, attributed to George Knox, is testimony to the frustration 
felt about the lack of substantial impact on cancer mortality between 1964 
and 1984 at least in part, because of the lack of an organised population-based 
approach: ‘No-one knows what proportion of women have been screened at 
different ages, and what proportion have not.’3
2  My mother still has an unpublished report of Way’s travels to Canada and the US in the early 1950s, where 
he recounts some of the early cytology being carried out there. These documents, along with other records 
of the meeting, will be deposited at GC/253 in archives and manuscripts, Wellcome Library, London.
3  Anon (1985): 363.
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There are parallels with another sexually transmitted infection, Chlamydia 
trachomatis, in which an ‘opportunistic’ screening programme is currently being 
‘rolled-out’, among young men and women, without randomized controlled trial 
(RCT) evidence of effectiveness, and without population coverage or defined 
screening interval. In the week in which I write, a report for the National Audit 
Office raised concerns about lack of uptake or evaluation of outcomes and poor 
value for money.4
Assessing effectiveness of the programme relied on observational data of rates 
of cervical cancer and cancer deaths. But as Sasieni set out (page 64), it was 
difficult to assess impact because it was known that cervical cancer incidence 
and cervical intraepithelial neoplasia (CIN) 3 were increasing in those born 
after 1940. Beral described this in her Lancet article of 1974. In an elegant 
analysis based on standardized cohort mortality ratios (SCMRs), she was able 
to demonstrate that SCMRs at age 20 in successive birth cohorts from 1902–
47 rose and fell in parallel with changing incidence of gonorrhoea. Risk was 
highest among women whose husbands were in occupations associated with 
higher sexually transmitted infection (STI) risk (pages 31–2).5 
The putative changes in sexual behaviour driving the growing gonorrhoea 
epidemic from the 1960s to the mid-1980s (when AIDS resulted in a rapid 
decline in incidence) were not documented in population studies until 1990. The 
first National Survey of Sexual Attitudes and Lifestyles (Natsal), of which I was 
principal investigator, was famously banned from public funding by Margaret 
Thatcher and later funded by the Wellcome Trust.6 The study documented the 
rapid decline in age at first intercourse from the 1950s onwards, the rising rate 
of sexual partner change driving the observed increase in STI incidence and, 
as we now know, the underlying silent epidemic of oncogenic HPV infection. 
No wonder, with incidence of the underlying cause rising, that it was difficult 
to demonstrate any major impact of incomplete screening on cervical cancer 
mortality. But mortality rates did decline substantially after 1988.7
4  National Audit Office (2009). Summaries available at www.nao.org.uk/publications/0809/young_peoples_
sexual_health.aspx. For news coverage of the report, see http://news.bbc.co.uk/1/hi/health/8354932.stm 
(both sites visited 24 November 2009).
5  Beral (1974).
6   Johnson et al. (1992, 1994). A Witness Seminar on ‘The history of the National Sexual Attitudes and 
Lifestyles Survey’ will be held on 14 December 2009 and will be published as volume 41 in the Wellcome 
Witnesses to Twentieth Century Medicine series.
7  Sasieni and Adams (1999).
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The idea that cervical cancer was associated with some aspect of sexual lifestyle 
was not new in the 1960s and Stanley Way and later Albert Singer and others 
were among those who studied the ‘male factor’ in the aetiology of cervical 
cancer. The idea that it might be related to a specific viral infection was gathering 
strength (pages 29–32).
In retrospect, the initial suggestion of Herpes Simplex Virus (HSV) as a cause of 
cervical cancer by Rawls et al. in 1968 diverted attention from HPV, a classical 
case of association being confused with causality.8 A range of STIs could be 
associated with cervical cancer because they shared the common route of sexual 
transmission. But the HSV hypothesis held sway through much of the 1980s, 
despite the failure to demonstrate viral DNA in malignant tissue (page 34).
This Witness Seminar report has something of the air of a detective story, with 
strands of evidence from different disciplines all contributing to the identification 
of the aetiological role of HPV. The recognition that the koilocytes were similar 
to cells from histological condylomata contributed to the identification of HPV 
in these cells. The development of virological methods in the 1970s identified the 
different types of HPV, followed by the discovery by Gissman and zur Hausen 
of HPV16 and 18 in 1980.9 Methods of hybrid capture assays and polymerase 
chain reaction all revolutionized detection, characterization, and quantification 
of infectious organisms, and knowledge of their role in health and disease. As 
Patrick Walker attests, it took some time before the ‘received wisdom’ that HSV 
had a role in cervical cancer aetiology could be put to rest (pages 33–4). It seems 
that only in the last decade with the successful development of HPV vaccines, 
that HPV has been generally accepted as a cause. 
The importance of the work of the late Jian Zhou with Ian Frazer in developing 
the underlying virological work which made the production of a vaccine possible 
is given due emphasis in the transcript (pages 43–6). It has arguably been a 
gratifyingly short time between the discovery of HPV as a cause of cervical cancer 
and the implementation of a vaccination programme in young women. The 
debate will continue about the scientific and economic factors underpinning the 
choice in the UK of a bivalent rather than quadrivalent vaccine as in the US and 
Europe,10 and thus will likely extend to the value of vaccinations in males.11
8  Rawls et al. (1968).
9  Gissmann and zur Hausen (1980).
10  Kmietowicz (2008).
11  Castle and Scarinci (2009).
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It will need another generation to measure the population uptake of vaccine and 
impact on cervical cancer, since the vaccine will not protect against all oncogenic 
viruses. The cervical screening programme will in turn need to be re-evaluated 
in successive cohorts. It is too early to measure the longer term acceptability 
and uptake of the current vaccine, which has had its proponents and detractors. 
Public concerns about vaccine safety will always cause nervousness among 
policy and programme leaders. The death of a young woman in 2009 shortly 
after receiving HPV vaccination was subsequently shown to be unrelated to the 
vaccine, but was sufficient to suspend the UK programme for a few days until 
the cause of death was known.12
The well organized population-based cervical screening programme established 
since 1988 has demonstrated its impact through secondary prevention of 
cervical cancer. The impact of the primary prevention programme through HPV 
vaccination on future generations is the culmination of a fascinating scientific 
story and one for future historians to recount.
Anne M Johnson 
Division of Population Health and Institute for Global Health, UCL
12  O’Dowd (2009).
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History of Cervical Cancer and the Role of the Human Papillomavirus, 1960–2000
3
Dr Tilli Tansey:  I would like to begin by welcoming you to this Witness Seminar 
on cervical cancer and the human papillomavirus from 1960 to 2000. These 
Witness Seminars were started by the Wellcome Trust about 15 years ago and 
they are designed to get together a group of people who have been involved in 
a particular event or discovery, or people who have seen a lot of changes in their 
professional lives, to get them together to talk and discuss among themselves, 
sometimes disagree quite drastically, about what happened and why did things 
happen. We all know that if we read conventional scientific papers and medical 
accounts, it doesn’t always tell us how things happened and why. So that is the 
purpose of these meetings. The entire meeting is recorded and transcribed and 
then the transcript is edited and published. 
Because we are going to record everything, we would like people to contribute 
informally as the meeting goes on. Nothing will be published without your 
permission, so we will ask you to assign legal copyright to the Wellcome Trust. 
This meeting was suggested by Professor David Jenkins, who is now an affiliated 
worker in the Wellcome Trust Centre for the History of Medicine at UCL, where 
he is working on this subject. We are delighted that Professor Glenn McCluggage 
from Belfast, who is a consultant pathologist there, has agreed to be our chairman 
for this meeting. So without further ado, I will hand over to Glenn.
Professor Glenn McCluggage:  Good afternoon everyone, and welcome to this 
Witness Seminar. Probably most of you in this audience don’t know me, but I 
am a gynaecological histopathologist in Belfast and I suspect everybody in this 
audience knows more about HPV than myself. My interest in HPV started 
quite a few years ago. I started off in gynaecological pathology by reporting a lot 
of cervical punch and loop biopsies1 from colposcopy clinics and so I see a lot 
of disease related to human papillomavirus and it is certainly a very important 
topic to be discussed. Hopefully, my role will be limited. It is either making sure 
that the discussion keeps going or, on occasions, to stop people talking who are 
going on for too long.
You have a list of topics that we will try to discuss and the format is going 
to be fairly open regarding each of these (Table 1).2 Without further ado, I 
am going to introduce Professor David Jenkins, who is going to set the scene. 
David worked in the University of Nottingham for many years and had a very 
1  See Glossary, page 145.
2  A general draft outline of each Witness Seminar is circulated among all participants prior to the meeting. 
The outline is flexible and not all the topics listed are covered in depth. See Table 1, page 4.
History of Cervical Cancer and the Role of the Human Papillomavirus, 1960–2000
4
firm interest in preinvasive cervical lesions, and latterly he has been working in 
Brussels, helping to organize clinical trials with one of the new HPV vaccines. 
So David, could you start us off?
Professor David Jenkins:  First of all, may I welcome everybody. It’s great that 
people have come. The gestation of this meeting has been around about two 
years, so it’s taken a while to contact everybody, to get everything established 
and to actually be able to hold this meeting. Thanks to Tilli Tansey and the 
Wellcome Trust for sponsoring and organizing the meeting and to Professor 
McCluggage for chairing it. It’s very important that the chairman is not an 
HPV person, because we need somebody, who is not too deeply involved as a 
protagonist in HPV, to be a neutral chairman for this session. 
My interest in this subject goes back a long way, and one of the attractions 
of HPV and cervical cancer for me is that it is a microcosm of relationships 
between science, medicine and society. A lot of key issues that are involved in the 
interactions between these different worlds are brought out in the study of HPV 
and cervical cancer, in the development of cervical screening and more recently 
Table 1. Outline programme for ‘The History of Cervical Cancer and  
the Role of the Human Papillomavirus, 1960–2000’ Witness Seminar 
Cervical cytology and colposcopy
How did cervical cytological screening develop 
Who became a cytologist and why
Life and interactions in a cervical screening laboratory 
The impact of colposcopy in the 1980s 
The discovery of HPV and development of HPV research
‘The unknown male factor’
Finding HPV 16 and 18
The mechanisms and genes of HPV 
p53 and VLPs 
Immune responses to HPV 
Epidemiology and the natural history and importance of HPV  
The UK national screening programme
Evidence on when screening works and when not 
The organization of a national programme and the screening centers
The public health impact of screening reorganization 
Later developments in applying understanding of HPV
HPV testing
HPV testing in triage and screening 
The personal dimension 
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now with the vaccines for preventing HPV infection and thus cervical cancer.3 
We have decided to cut this discussion off at 2000 because we don’t really want 
to get too much into the current controversies in which many people are still 
involved, and the areas where there are still big decisions to make. 
We want to look at how two parallel stories have developed: one is the evolution 
of cervical cancer prevention through screening, and the second is the HPV 
story since the early 1960s, since cervical screening was first introduced then, 
and how these two have become intertwined in relation to attempts to prevent 
cervical cancer. This has also had a lot of spin-offs. It has meant that it has been 
a very multidisciplinary activity, there are a lot of different people involved, 
and I am glad that we have been able to get a good mixture of cytologists, 
pathologists, clinicians, epidemiologists, psychologists, as well as a few medical 
historians involved in this meeting. 
It is a really interesting area, and one of the fascinating parts of it is the way 
in which it has grown up as an area in the era of sex, drugs, and rock and roll. 
Certainly we all know that sex has been heavily involved in HPV transmission, 
but it is a different sexually transmitted disease from the conventional ones. 
Some of the issues that have happened and affected HPV have seen people trying 
to draw parallels with traditional sexually transmitted diseases and particularly 
with HIV, as another new disease, but a very different one. 
The history that we want to get today, as Tilli has said, is a bit of the unofficial 
history, as well as people’s role in the official history of the development of both 
screening and HPV. We don’t want to indulge in conventional hagiography of 
some kinds of medical history. When I was researching this, I looked through 
what was available on the web about George Papanicolaou and there’s some stuff 
which really amounts to almost canonization of the guy. He was born in the same 
town as an ancient physician, Diocles (who was second only to Hippocrates), 
and he looked after a leper colony, arrived penniless in the US and, in order to 
begin to fund his academic activities, worked as a rug salesman, while his wife 
worked as a tailor. That’s wonderful, and may or may not be totally true, but we 
want to get to some of the more ordinary stories, and some of the actual ways 
in which this admittedly important initial step with screening was translated 
into the huge success of cervical screening by thousands of people – doctors, 
3  The UK national programme to vaccinate girls aged 12–13 years began in September 2008, along with 
some girls aged 17 years, using the bivalent vaccine Cervarix (GSK) giving protection against HPV subtypes 
16 and 18; girls aged 16–18 years were eligible from September 2009; and those aged 15–17 years of age 
from September 2010. See Anon (2008); Gilman et al. (2009).
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public health workers, technicians and screeners in many countries and very 
successfully in the UK. We also know that the HPV story has expanded from 
very small numbers of people in the 1970s and 1980s, up to the International 
Papillomavirus Conferences and International Papillomavirus Society meetings, 
which regularly attract over 1000 people every 18 months.4 
McCluggage:  Shall we consider how cervical cytology screening developed? 
Dr Elizabeth Mackenzie:  It is good to see so many of my colleagues from the 
past here, the great, the good and the not so good. It does give me great pleasure 
to be here. 
I had an interesting beginning: I trained at Bart’s in the dim and distant past, 
qualified in 1957, and when we got back to England from Malta in 1961, I 
think it was my husband, Campbell, who decided that there was no way that I 
was ever going to get a job and that I ought to do public health, which is what 
I duly did. I am eternally grateful, because I think that’s the thing that made me 
understand what screening was all about.5 It wasn’t taking smears and forgetting 
about them. From there I got up to Glasgow, with five sessions a week. The 
gynaecologist in Glasgow asked: ‘Would I like to do a closed community survey 
of the women in Campbeltown?’, which is where Campbell came from and 
it certainly is closed.6 I went to get trained and my first mentor was Helena 
Hughes.7 So I trained and set up the beginnings of the screening programme 
in the Southern General Hospital in Glasgow, but then, like all dutiful wives, 
moved down to London in 1967. I was introduced to Dr Nasseem Husain, 
4  For an evaluation of the early history of cytodiagnosis, and the final page of Papanicolaou’s 1928 paper, 
see Spriggs (1977): 1094. See also Papanicolaou and Traut (1943); Traut and Papanicolaou (1943); 
Fremont-Smith and Graham (1952). Dr Margaret Wolfendale wrote: ‘To make the historical context more 
comprehensive it might be worth mentioning that as a result of Aureli Babes¸ independently recognizing that 
cervical cancer could be recognized in cervical smears in Bucharest in 1927, this test was routinely used on 
a large scale by Kermauner and Schiller (Spriggs (1977)).’ Note on draft transcript, 26 November 2008. See 
Babes¸ (1931); see also note 239.
5  Dr Elizabeth Mackenzie wrote: ‘Mr James Mair, one of the more enlightened gynaecologists, suggested 
that it would be useful to train in cytology with Helena Hughes at the Glasgow Royal Infirmary and set up 
a screening programme in the small isolated town of Campbeltown in Kintyre. Dr Elizabeth Macgregor 
had already established a very successful well-organized screening programme covering the population of 
Aberdeen.’ Note on draft transcript, 26 November 2008.
6  Dr Elizabeth Mackenzie wrote: ‘This remained a paper exercise only, as we returned south to England.’ 
E-mail to Mrs Lois Reynolds, 13 September 2009.
7  See, for example, Evans et al. (1986, 1987).
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my second mentor, in a very busy laboratory at St Stephen's Hospital, Chelsea, 
who I thought was going to be here today. It was the first time I learned about 
automatic screening.8 He seemed to think that a bit of kit from Cambridge 
Instruments – a densitometer – was going to automatically screen the smears, 
which was absolute nonsense, because they were not monolayered cells. It was 
terrific fun and I had some lovely papers out of that.9 
I then moved to Bristol in 1969, and the one thing about being a trained 
cytologist was that you got a job anywhere. The hospitals were desperately short. 
I then started up in Bristol, which was a moderate sized town of about 400 000, 
and there the beginnings of my interest in screening programmes started.10 This 
business about ‘you can’t take smears and forget about it,’ is not possible. 
We had the chief accountant of the South West Electricity Board as chairman 
of Southmead Hospital board, who was interested in computers.11 We were then 
taken over by the area health authority, and, I must say, it was really interesting 
persuading our colleagues that women didn’t need to be screened at five-minute 
8  Dr Husain was unable to attend the Witness Seminar on 13 May 2008. Dr Elizabeth Mackenzie wrote: 
‘Dr Nasseem (O A N) Husain was experimenting with automated screening using normally prepared 
smears, but attempting to identify malignant cells by their staining densities. Unfortunately it took some 
years for this to progress and it wasn’t until the introduction of the preparation of monolayered samples that 
this was successful. It is interesting to note that in contrast to Scotland, England was training non-medical 
staff to undertake primary screening. Despite having no previous scientific training, many of them provided 
the major staffing in the screening laboratories and their contribution was later recognized by the British 
Society for Clinical Cytology (BSCC) with a diploma and, for the more senior, membership of the society.’ 
Note on draft transcript, 26 November 2008. See, for example, Husain (1972).
9  See, for example, Husain et al. (1970); Spriggs (1969). Further details of the Quantimet image analyser 
with densitometer can be found at www.computerhistory.org/brochures/companies.php?alpha=g-
i&company=com-42bc1cec137d6 (visited 30 April 2009).
10  Dr Elizabeth Mackenzie wrote: ‘I worked with Dr Frank Lewis in Bristol and it is interesting to note 
that none of my mentors started out with an interest in gynaecological cytology; Helena Hughes, Nasseem 
Husain and Frank Lewis were a gynaecologist and two haematologists, respectively.’ Note on draft transcript, 
26 November 2008.
11  Dr Elizabeth Mackenzie wrote: ‘Interestingly, the development of the computer programme in Bristol 
was supported by the chairman of Southmead Hospital board. His son persuaded his firm, IBM, to provide 
us with computer expertise and suitable software to screen the Avon population of 250 000 women between 
the ages of 20 and 64 every five years. The five-year interval programme in Bristol proved to be successful 
and it prevented unnecessary interval smears from overloading the laboratory, as we returned them to the 
sender unread if there were no clinical signs or symptoms. This policy was unpopular to begin with until it 
was realized that it was effective and there was a finite amount of money supporting the service.’ Note on 
draft transcript, 26 November 2008.
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intervals; you could have a reasonable sort of screening service at five-yearly 
intervals, although I might add that several people here will disagree with 
me, and certainly at that stage it was quite a miracle to get a regular screening 
interval. The other thing was to get it into proper records, so that wherever 
these women went, their screening histories followed them.12
Jenkins:  That’s a good introduction, because, I think, it raises a lot of important 
points about the start of screening, mainly how disorganized it was.
Mackenzie:  May I say one thing about screening in Scotland? What was 
interesting about Scotland is that they trained doctors to screen, and the only 
good thing that I got out of it was that you knew exactly what screening was 
all about, you didn’t treat it lightly. Your colleagues who were screeners and 
eventually everyone in the screening service deserved enormous support and 
pats on the back.13 It was a very different set-up in Scotland, which was all 
doctor-led, which was a so-called ‘waste of expertise’. I think the combination 
of screeners and medical people in the screening service made a huge difference 
to what went on.
Jenkins:  So when did you start using screeners in the screening service?
Mackenzie:  We had screeners from day one when I got to Bristol in 1969. I 
think it was quite a while before they started using screeners in Scotland.14 
Dr Ian Duncan:  The initial screeners in Scotland in the early 1960s were, as Liz 
Mackenzie has pointed out, enthusiastic female doctors. There was Elizabeth 
Macgregor in Aberdeen, Helena Hughes in Glasgow, and Helen Duguid in 
Dundee.15 They employed part-time female doctors largely, and this was 
because, of course, the nature of screening meant that you had to do it part-
time. You couldn’t spend all day screening, because you can’t maintain that 
12  For further discussion about the Lancet 1985 editorial, see pages 14 and 19. See also Threlfall et al. 
(1997).
13  See also notes 8, 21, 24 and pages 8–9, 22–23.
14  Dr Euphemia McGoogan set up the BSCC national certificate of competence in cytology 
screening examination (end-of-training exam for cytology screeners) in 1988 and ran it for three 
years. She co-authored the NHS Cervical Screening Programme (NHSCSP) training logbook for 
cytology screeners and designed a logbook and training programme for trained cytology screeners 
wishing to gain competence in reading liquid-based cytology cervical samples. See www.csi.org.nz/ 
proceedings/mcgoogan.pdf (visited 30 September 2009).
15  See Dr Elizabeth (Betty) Macgregor’s Biographical note, page 136.
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Figure 1: Presidents of the British Society for Clinical Cytology (BSCC), 1962–83.  
BSCC (1983): 2–3.
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level of concentration. It very much suited the individual who didn’t want to 
devote the whole day to medical work. I think that the cytoscreeners then were 
laboratory technicians, and that was the way that they trained, as laboratory 
technicians. They then became screeners themselves, again, very much on a 
part-time basis, and that happened in the late 1960s–early 1970s. 
Dr Margaret Wolfendale:  I started in cytology in 1962 and there are quite a 
few parallels, because I became a cytologist as I had moved with my husband.16 
In those days there was very, very little open to women in medicine, unless 
they were going to dedicate their whole life to it, full-time. The only part-time 
work was either as an assistant in general practice, or else in family planning. I 
was working at the Royal Marsden Hospital, Fulham, as a junior registrar with 
Dr Humphrey Kay in the Fetal Tissue Bank and I didn’t want to move when 
my husband moved to the country.17 At the time there was an article written 
by Geoffrey Crabbe and Mary Egerton in the BMJ, talking about cytology.18 I 
went to my old hospital, the Royal Free, to train and then wrote round, it was 
an awful cheek really, saying I had done some cytopathology and did anybody 
want a cytopathologist in the Northampton, Aylesbury, Luton or Bedford 
areas. At the time, it was the Oxford region, which was one of the forefront 
regions employing married women, that took me on as a cytopathologist and 
my mentor was Arthur Spriggs.19 I started a lot of the district general hospital 
cytopathology in the Oxford region under his supervision.
Jenkins:  One of the things that intrigues me about the very early days of cytology 
is that it really wasn’t organized in any national sense, or in any sense above 
that which was generated by the consultants themselves.20 It would be nice to 
16  See also Dr Elizabeth Mackenzie’s discussion on page 6. 
17  Lawler (1981).
18  Dr Margaret Wolfendale wrote: ‘Crabbe and Egerton (1961) was one of a spate of publications on this 
topic in 1961.’ Note on draft transcript, 26 November 2008. 
19  See Biographical note on page 140–1; see also Figure 1, page 9. 
20  Dr Margaret Wolfendale wrote: ‘Arthur Spriggs aptly pointed out that the “emergence of a body of 
trained exfoliative cytologists” resulted in population screening becoming an accepted practice before the 
general introduction of randomized controlled trials with the result that it became “a football between 
public health authorities, epidemiologists, lay pressure groups, politicians and clinical cytologists” (Spriggs 
(1977): 1095, 1096). Max Wilson, who worked at the DHSS at the time and was a great proponent of 
cervical screening, was of the opinion that “in the early 1960s mainly on the evidence of pathology…
the time when a (randomized controlled) trial…could be considered ethical had by then passed” (Wilson 
(1971): 71).’ Note on draft transcript, 26 November 2008. 
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hear a bit more about that: how people organized their own local screening 
programmes.
Professor Dulcie Coleman:  I would like to talk a little bit about that and how 
disorganized it was. In about 1964 the then Ministry of Health agreed that 
cervical smear tests should be offered, to be available, to every woman.21 There 
were really no formal plans of how this should be done, but every pathologist 
became responsible for this. I think there were four or five training schools set 
up, and that’s important to record, because these were very important.22 I know 
there was Erica Wachtel23 and Chandra Grubb in London, Betty Attwood in 
Birmingham24 and Blanche Butler in Manchester. One sort of offered oneself 
to these schools for training; there seemed to be no special funding for it, but 
21  The Ministry of Health's 1964 circular announced the introduction of a series of training courses in 
exfoliative cytology open to pathologists and medical laboratory technicians, as a result of the Standing 
Medical Advisory Committee recommendation that revision of cytological facilities in hospital pathology 
should be accelerated. The cervical cytology service was established in 1965, offering five-yearly smears to 
all women over the age of 35 years. The National Archives, Kew, holds files on the early development of 
screening (MH154/46–48). For further discussion of the efficacy of the training courses, see Wilson (1967); 
for later reports, see Farmery and Gray (1994); House of Commons, Committee of Public Accounts (1992). 
See also note 33.
22  Five training schools to teach cytodiagnosis were set up in 1964 at the Hammersmith Hospital, London, 
the Royal Free Hospital, London, Birmingham, Manchester and Newcastle. For current arrangements, see 
www.cancerscreening.nhs.uk/cervical/training.html (visited 29 July 2009). The BSCC included training 
sessions in their scientific meetings, description of which can be found in BSCC (1983): 25–62. 
23  Dr Erica Wachtel (d. 1980) was at the Postgraduate Medical School, Hammersmith Hospital in 1961. 
See also Wachtel and Plester (1952, 1954); Figure 1. 
24  Mrs Marilyn Symonds wrote: ‘In 1952 a meeting at the Royal College of Obstetricians and Gynaecologists, 
attended by Birmingham gynaecologist Professor Hugh McLaren, suggested sending two medics to visit Dr 
Papanicolaou in the US to study his technique for cervical cancer detection. Miss M E Attwood (Betty), 
a young technician working in the university department in Birmingham, was sent instead, as Professor 
McLaren and Dr Claude Taylor (pathologist) thought a technical person would be more appropriate to 
learn the technique. Betty left six weeks later by boat from Southampton and worked for 18 months 
with Papanicolaou in New York. She then worked at the Free Hospital in Boston followed by time in 
Florida working with Ayre (of the Ayre spatula). She returned to Birmingham and set up a research cervical 
screening routine, screening 2500 women. The results of this study were written up (Attwood et al. (1956); 
McLaren et al. (1958)), but no-one took much notice. They continued to screen women and eventually 
obtained funding to set up one of the first UK cytology training schools in Birmingham in the early 1960s. 
It was part of the medical school and eventually moved to the maternity hospital. Betty continued to run 
the training school together with Dennis Williams until her retirement. As a result of her early work she 
was often invited to speak at meetings all over the world and has been involved in writing several research 
papers.’ E-mail to Mrs Lois Reynolds, 11 September 2009; see also Figure 2, page 13.
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that was the way to get your training, and that was the way that I got mine, 
with Erica Wachtel. It was fairly basic training, because you were shown slides, 
and told: ‘This is abnormal and this isn’t’.25 There was no one to explain to 
you what you were looking at or to explain that the aim of the exercise was to 
detect a precancerous condition. This was in the early days of training. That was 
one aspect. 
Another aspect was that there was a preponderance of women in cervical 
cytology. Many of the pathologists, who were responsible for offering or 
arranging screening in their own hospitals, really were not in a position to cope 
with the job because it is very time-consuming, and they were willing to take 
on anyone. I remember saying: ‘Well, I have been to a training school’, like 
Margaret had, and ‘I know how to do it.’ They said: ‘All right, we will take you 
on a trial basis.’ You were put in a little hole in the corner to get on with it on 
your own. I remember I actually sat in a fireplace, my feet were in the fireplace, 
and my microscope was on the mantelpiece and I had a suitably high stool 
to sit on.26 Until I proved my worth, I wasn’t given an office or a proper desk 
or anything. This is the way it started up. But it evolved from there and now 
there is a very well-organized training programme and training is very carefully 
monitored, and, I am proud to say, there is even academic training offered, an 
MSc course which started in 1990, at St Mary’s Hospital Medical School (now 
part of Imperial College London) and continues to be offered today.27 We have 
come a long way from those early days.
Professor Albert Singer: You mentioned exclusively female screeners: well, it 
wasn’t all women. The great Stanley Way in Newcastle started off many years 
ago and I used to go and work with him, and he would tell me of the early days 
when he had been trained by Ruth Graham, who had worked with George 
Papanicolaou.28 Way came back to Gateshead and to Newcastle in the late 
1950s–early 1960s and for many years used to do all the work to prepare the 
25  A later handbook was Bloch et al. (eds) (1995).
26  Professor Dulcie Coleman wrote: ‘My first appointment was at the Hillingdon Hospital, London. 
Pathology was located in the former sitting room of an old Victorian house on the hospital site. I think the 
building has been torn down now.’ Letter to Mrs Lois Reynolds, 8 October 2009.
27  For details of the current MSc in clinical cytology, see www1.imperial.ac.uk/medicine/teaching/
shortcourses/teaching/clinicalcytology/ (visited 23 June 2009).
28  See, for example, Way (1963); Stening (1950). Dr James Andrew reflected that Mr Way described 
colposcopy as ‘the biggest confidence trick ever perpetrated in the name of gynaecology’, although Newcastle 
later acquired a colposcope (Andrew (1975): 4). 
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slides and read them himself. One day he told me this story of how it came to be 
that there was a five-year screening interval – the Government used to say it was 
five years – and he said, ‘Well, they asked me one day down to a meeting and 
they said how many years do you think there should be for an interval?’ and he 
said: ‘Well, I really didn’t know, there was no evidence, so I thought five-yearly 
was a reasonable target.’29 He would still read his own cytology until he retired; 
he was one of the originators.
Mackenzie: May I say that the other mentor I must not forget is Elizabeth 
Macgregor in Aberdeen [Figure 1].30 She was formative as far as screening in this 
country was concerned, and when you think she was at the top of Great Britain 
– we in Scotland are still part of GB, I presume, tucked away up there – and her 
work was exemplary, proper screening, properly managed. It took the rest of the 
UK about 30 years to catch up with her.
29  Glucksmann et al. (1964) suggested that mortality increased between the fifth and tenth years of follow-
up of patients treated between 1952 and 1962 (page 200); Way (1954, 1962, 1969); Guthrie et al. (1981). 
See also DHSS, Committee on Gynaecological Cytology (1981). 
30  See also notes 5, 38, 163, 164 and 174; Figure 1, page 9.
Figure 2: Mrs Marilyn Symonds, cytology laboratory,  
Stoke Mandeville Hospital, Aylesbury, 1964. 
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Dr Catherine Pike: I was going to say that Elizabeth Macgregor was my colleague 
at university, we got to know each other very well. I got into cytology when I 
came back from Africa, where I had been for ten years with my husband, and 
the phone rang one day and it was Elizabeth Macgregor saying: ‘What are you 
going to do? What about doing cytology?’ The next thing was that I arrived at St 
Thomas’ Hospital with Professor John Tighe, who took an interest in cytology.31 
I was trained there, but also went to other training sessions and trained others 
as well.32 In a very busy south London area, we were taught from the word go 
to follow up women with abnormal smears, and that it was most important; 
you didn’t let them slide through the system. We started a card system, always 
following up women with abnormal smears, making sure that they were seen by 
a gynaecologist for assessment and treatment.
Dr Amanda Herbert: Can I say something further about Stanley Way, because 
back in those days it was very often gynaecologists who were encouraging 
screening, whereas pathologists were woefully apathetic about it. When he was 
the chairman of the BSCC, he wrote a brilliant letter in the BMJ, saying how 
hopeless Kenneth Robinson’s proposal was for setting up the 1967 programme, 
largely because it wasn’t adequately funded. He went through the press release 
bit by bit, in a beautifully written letter, pointing out that it wasn’t going to 
work if it wasn’t properly funded – and if cytologists didn’t have long enough 
to train.33 Nearly 20 years later the Lancet editorial, ‘Death by incompetence’ 
fulfilled his prediction.34 
McCluggage: I am going to move to a related topic, that is, who became a 
cytologist and why, and ask Dr Gray, because this leads on very nicely from 
what we have just been talking about.
Dr Winifred Gray: I think a lot has already been said by previous speakers about 
their own experience in this particular area. Throughout the 1960s women 
31  See, for example, Tighe (1961); Fruin and Tighe (1967). 
32  Dr Catherine Pike wrote: ‘I received additional training at the Royal Free Hospital with Dr Chandra 
Grubb in a few informal sessions, as far as I remember. I always attended the well-organized workshops at 
the annual scientific meetings of the BSCC, at first relating to gynaecological cytology but soon covering all 
aspects of non-cervical cytology.’ Note on draft transcript, 29 August 2009. For a list of scientific meetings 
and the papers given, see BSCC (1983).
33  Mr Kenneth Robinson’s press conference on 21 October 1966 was reported in the BMJ (Anon. (1966)); 
Way’s ripost appeared the following February (Way (1967)). See also Glossary, pages 149–50. For later 
details of screening programme, see Spratley (1990).
34  Anon. (1985).
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doctors needing part-time work for domestic reasons were often responsible 
for the reporting of abnormal smears. Some worked within a gynaecology 
department, where an individual gynaecologist had a special interest in the work.35 
Others became involved at the time of establishing the BSCC in 1961, as already 
mentioned, such as Dr Arthur Spriggs, who was a haematologist originally. He 
was responsible for gynaecological and non-gynaecological cytology in Oxford 
and played a significant part in attempts at automating the screening of cervical 
smears.36 He also investigated the impact of the failure to follow up abnormal 
smears, with an elaborate tracing of women across the country whom his laboratory 
had found to have abnormal smears, but who hadn’t returned for treatment.37
Another factor that hasn’t come into the discussion so far is the role of the 
College of Pathologists in the training of histopathologists in cytology, and 
encouraging them to take the area of gynaecological cytology seriously. It was 
really completely separate from histology in the department in Oxford where 
I worked. It was referred to as the ‘dregs’ by those who weren’t involved at all, 
and it was certainly not looked upon as a very prestigious area to be working 
in as a histopathologist. I think the college did eventually acknowledge that 
training was required, that an examination in cytology should be included in the 
college exams. Certainly, when I took the MRCPath final in 1971, cytology was 
beginning to be included. I think when I had my finals viva, the two examiners 
were more nervous than I was, because here was this cytopathologist and they 
didn’t quite know what on earth to ask me. They got their own back in the 
afternoon by giving me an amputated penis for a histological specimen. 
Gradually, through the 1970s and 1980s, the college has become more and 
more aware of the need to have a proper qualification that involves cytology and 
particularly gynaecological cytology, along with histology. It’s interesting that 
35  Dr Winifred Gray wrote: ‘I was one of the first to have a full training in pathology at the Radcliffe 
Infirmary, starting in 1969, under the married women’s retraining scheme which was started by Dr 
Rosemary Rue, public health consultant in the Oxford NHS administration. This scheme enabled women 
with family commitments to have a part-time training post in a teaching hospital. It led to several other 
women qualifying for consultant posts where before they remained as clinical or medical assistants.’ Letter 
to Mrs Lois Reynolds, 12 September 2009. See Rue (1967); see also Colville and Wenban (1972); Duncan 
(ed.) (1992); Anon. (1968).
36  For details of Dr Arthur Spriggs’ work, see note 19, Appendix 2 and his Biographical note on 
pages 140–1.
37  Kinlen and Spriggs (1978); Spriggs and Boddington (1980). Dr Winifred Gray wrote: ‘This study 
provided convincing evidence of the ability of cervical cytology to prevent the development of cervical 
cancer.’ Note on draft transcript, 26 August 2009.
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in 1998, at an international meeting held in Oxford, the then president of the 
college apologized for the lack of support that had been given to proper training, 
particularly in cervical cytology, so I do think that has now been addressed.38
McCluggage: Certainly, cervical cytology is much more important now. The 
people who started off doing cervical cytology, were they mainly specializing in 
that, or were they also doing non-gynaecological cytology and histopathology?
Gray: No, it was usually both. With the sub-specialization that is now so 
prevalent, some pathologists are specializing solely in gynaecological cytology 
and histology. But in most district general hospitals, pathologists still have to be 
responsible for all aspects of cytology. That’s what I understand. 
Jenkins: If I can join in here? When I was training in histopathology, cervical 
cytology was certainly despised in some of the institutions in the 1970s where 
I was trained and in others there was great enthusiasm. Catherine Pike and 
John Tighe were probably the people who trained me most in cytology at St 
Thomas’, but other institutions really didn’t take it seriously at all. I think the 
examination (MRCPath) was simply six slides that were carefully selected, so 
that they were either normal or cancerous. It was very much a token effort. 
[Professor Valerie Beral raised the question of international perspective, 
as it wasn’t clear from the discussion whether the meeting was concerned 
solely with the cervical screening programme in the UK or elsewhere. 
She suggested that Jocelyn Chamberlain, Tony Miller and others could 
discuss what is going on in Scandinavia, British Columbia and elsewhere. 
38  Dr Margaret Wolfendale wrote: ‘The part played by the BSCC was inadvertently omitted in the Witness 
Seminar. Following the first International Meeting on Cytology in 1961 held in Vienna, a meeting was 
convened by a small number of enthusiasts who were already practising cytology and the BSCC was founded 
to promote the growth and development of clinical cytology in the UK. It proceeded to play a crucial role 
in promoting cervical screening by bringing together individuals struggling in comparative isolation, by 
sharing scientific information at their annual meetings, laying down standards of practice, encouraging the 
setting up of training schools and setting up a “certificate of competence” for screeners, headed by Michael 
Boddington. From the start there was a small non-medical membership which was expanded to 10 per 
cent, then 20 per cent, an innovative move that was looked down on by many medical colleagues in other 
specialties. In further recognition of the vital need for continuing education of the whole of the laboratory 
team, the setting up of regional societies was supported and by 1973 the whole of the country was covered 
by affiliated societies holding regular scientific meetings. A prime example of an initiative to raise standards 
was the publication in 1981 of a guide, Taking Uterine Cervical Smears (Macgregor (1981)), the first 10 000 
copies rapidly sold out. A new second edition was published in 1989 (revised edition 1995) accompanied 
by a video, sales of which were also extremely successful.’ Note on draft transcript, 26 November 2008. The 
BSCC Report for 1961–83 notes that 15 000 copies were initially sold (BSCC (1983): 14).
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She asked whether it was from these programmes that people in the UK 
began to understand how screening worked.]
Professor Jocelyn Chamberlain: During the same period, in Sweden and Finland 
and to a lesser extent in Denmark, but not Norway, screening was introduced 
as a coordinated public health programme, aiming to reach the whole eligible 
population.39 Elizabeth Macgregor in Aberdeen, as far as I know was the only person 
in Britain who really succeeded in doing that prior to the re-organization of the 
UK screening programme in the late 1980s.40 There’s very convincing and positive 
evidence when you compare the incidence and mortality rates of invasive cervical 
cancer in Sweden and Finland with those in Norway, where there was no organized 
screening, during the 1970s, the rates come straight down in the two countries that 
were doing it in a systemic, organized way.41 Their eligibility criteria were such that 
to be invited to be screened a woman should, I think, be aged between 25 and 69, 
and should not have had a normal test within the previous five years – between 70 
per cent and 80 per cent of women accepted their invitations. 
Professor Anthony Miller: I want to thank the organizers for bringing me here. 
I have spent all my life in terms of cervical screening in Canada and I happen 
to be visiting at the moment, although the first part of my life was spent in the 
UK. In fact I was in the Medical Research Council (MRC) tuberculosis research 
unit in 1970 – to link up with something that was said earlier – when, as I 
was going to a conference in New York, I was invited to look at an automated 
cytology set-up there. I did and came back to report to the MRC and also to 
O A N Husain – normally known as Nasseem – with whom I discussed this, 
although they didn’t think that particular mechanism worked.42 
39  Professor Jocelyn Chamberlain wrote: ‘In the 1960s and 1970s, as we have seen, cervical screening 
developed here in a haphazard way, with decisions on who should be screened and how often, being taken 
on the whim of individual clinicians working without guidance, and the cytology laboratories responding 
as best they could to this uncoordinated demand.’ Note on draft transcript, 31 July 2008. See, for example, 
Hakama (1982).
40  Macgregor et al. (1971); for a discussion of the data, see Wilson et al. (1971). For background of the 
policy changes concerning cervical screening, see note 155; Glossary, pages 148–51.
41  IARC Working Group on evaluation of cervical cancer screening programmes (1986). See also Hill and 
Adelstein (1967).
42  A combined research group of Drs N Jankey, H Ferreira, C B Cameron and O A N Husain (Chelsea 
Hospital for Women, Royal Marsden and St Stephen’s Hospital, Chelsea) gave a preliminary account of the 
use of the Coulter counter in cancer screening at the fourth annual scientific meeting of the British Society 
for Clinical Cytology in October 1965 (Anon (1965)); see also pages 90–1.
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A bit more history, because people haven’t given much history: in terms of the 
perception internationally over cervical cytology, many of you will know the paper 
of H S Ahluwalia and Sir Richard Doll, which effectively looked at the decline in 
cervical cancer mortality in a number of countries, including Canada, and concluded 
that cervical screening was not working.43 In my MRC links, before I went to the 
National Cancer Institute of Canada, I used to interact with Archie Cochrane, 
and Archie was very much of the belief that it didn’t work and he told me that I 
had to go to Canada to show that it didn’t work.44 When I went to Canada, the 
National Cancer Institute of Canada, together with the American Cancer Society, 
had started funding an evaluation of the British Columbia programme at that 
time. The British Columbia programme was established in 1949 by Herb Fidler, 
a pathologist, who brought David Boyes into his programme. Boyes, originally a 
family physician who trained as a pathologist and a gynaecologist, became a leader 
in Canada in terms of cervical cancer screening. They kept meticulous records. So 
when a group of us, including George Knox from Birmingham, started evaluating 
these records at the beginning of the 1970s, it became clear that there was a good 
resource for evaluating the natural history of cervical cancer, and that resource was 
eventually published.45 The data were published and incorporated into something 
that Professor Nicholas Day was doing – unfortunately he can’t be here today – 
who was working in the International Agency for Research on Cancer (IARC) in 
Lyons at that time in the mid-1980s. He evaluated the data in terms of models, 
and demonstrated that you didn’t have to screen annually, that you got almost the 
maximum benefit by three-yearly or five-yearly screening, and, of course, this has 
been replicated subsequently.46 Perhaps Peter Sasieni will talk about some of his 
studies in the UK. 
We were challenged nationally in Canada to try to demonstrate that screening 
worked, and we set up a study to evaluate the extent to which mortality had 
43  Ahluwalia and Doll (1968). 
44  Dr Archie Cochrane wrote: ‘Apart from the immunization programme the record of the NHS is 
patchy. There are sins of omission and commission. Of the latter the introduction of the programme of 
cervical smears in the hope of preventing carcinoma of the cervix is the saddest. It illustrates so clearly the 
consequences of assuming a hypothesis is correct, and translating the consequences into routine clinical 
practice before testing it by an RCT.’ Cochrane (1972): 26–7. See also note 162. 
45  Boyes et al. (1982); see also Shun-Zhang et al. (1982). For questions arising from the natural history of 
carcinoma in situ, see Knox (1966).
46  Hakama et al. (eds) (1986).
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fallen in different parts of the country.47 We had to use cancer of the uterus 
because there was a changing certification of whether you certify as cancer of 
the cervix specifically or the uterus unspecified, so we took the whole of uterine 
cancer, did a correlation analysis, and it was extremely clear: no matter what 
factors you took into consideration, the areas which had the greatest intensity of 
screening had the greatest reduction in mortality. This was very influential for 
convincing people in Canada that this worked. It was the Walton Committee in 
1976 that built on that.48 Eventually I think the Americans were persuaded, and 
even Archie Cochrane was eventually persuaded that it worked. 
One last point relates to the fact that very much later, through Jan Pontén, who 
was chairman of the Swedish Cancer Society, we were able to evaluate historical 
records in the Karolinska Institute. It became very clear that the introduction of 
radiotherapy, basically radium therapy, had a major impact on mortality from 
cancer of the cervix in Sweden before screening came in.49 So Richard Doll (Figure 
3, top row, right) in many respects was right, there was a reduction going on, 
largely because of improvements in treatment, but that had come to an end, and 
then when screening came in and people began to find precursors and incidence 
fell, then mortality fell not long after. So history sometimes is quite right.
Professor Jack Cuzick: I remember – I think, very much based on George Knox’s 
wonderful editorial ‘Death by incompetence’50 – in 1973 we set up the Imperial 
Cancer Research Fund (ICRF) coordinating committee on cervical screening,51 
and very much with Husain’s strong leadership, managed to put together some 
statements about what was needed, and the fact that, although Nick Day had 
shown clearly that screening could reduce mortality, it wasn’t happening in the 
UK at that time.52 We published a position paper in the BMJ in 1985 and 
then subsequently another paper, which I think was very much the basis of the 
47  Miller et al. (1976).
48  See, for example, Walton et al. (1976, 1982); Kassirer (1980).
49  Pontén et al. (1995).
50  Anon (1985).
51  ICRF, Coordinating Committee on cervical screening (1984). Members of the committee were: Walter 
Bodmer, Jocelyn Chamberlain, Gary Cook, Jack Cuzick (secretary), Gerald Draper, Stephen Erskine, Hugh 
Fisher, Rod Griffiths, David Haran, Christine Havelock, O A N Husain, E G Knox, Ann McPherson, 
Alwyn Smith, Arthur Spriggs, David Innes Williams (chair) and Margaret Wolfendale.
52  IARC Working Group on evaluation of cervical cancer screening programmes (1986).
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Figure 3: Contributors to the 1985 Banbury Center conference on  
‘The origins of female genital cancer’.  
L to R from top row: J R Schlehofer, Elke-Ingrid Grussendorf-Conen, Harald zur Hausen, 
Richard Doll; row 2: Thomas Broker, J Cairns, Richard Peto, P M Howley; row 3: Erich Burghardt; 
Attila Lörincz, Martin Vessey, Richard Reid; bottom row: Albert Singer, Louise Brinton, Richard 
Doll, Leopold Koss. (Peto and zur Hausen (eds) (1986): frontispiece).
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national programme that was set up here, identifying the requirements for that 
national programme and I think that’s an important landmark as well.53
McCluggage: I think we are going to talk more about this later. We are going to 
move on now to something we have already touched on, life and interactions in 
a cervical screening laboratory. 
Mrs Marilyn Symonds: I am speaking from the cytotechnology angle, from 
the technicians’ side. I also started in cytology a very long time ago with Dr 
Margaret Wolfendale in 1963. It was absolutely unheard of for student medical 
laboratory technicians to be employed solely in a cytology laboratory, because 
there were no formal qualifications to become associates and fellows of what is 
now the Institute of Biomedical Science (IBMS).54 So you had to qualify along 
the histology route and, just to let you know, that the cytology question in my 
histology final was to take a buccal smear (a sample of cells from inside of the 
cheek) from myself and stain it, using a Papanicolaou technique. I don’t think 
that stood me in very good stead to actually be able to diagnose abnormalities 
in cervical smears. 
I heard from all of you pioneers in cervical cytology that very soon you wanted 
to pass over all that boring screening stuff to some technical people. To start 
with, the type of people who worked in a cytology department technically were 
histology technicians, mainly female again, except for one very well-known 
exception, Dennis Williams, who I am sorry is not here to support me today. 
He started with the Birmingham crew and has done an enormous amount of 
work to help recognize the important role of the non-medical person working 
in cytology. To start with, we had people who were formally training to be 
laboratory technicians and then I think it was probably in the 1970s that we 
took on a group of women, mainly part-time, who became cytoscreeners. They 
were different to the people who were qualified with the IBMS; they didn’t have 
any formal qualifications, and they were often derided and called shopping-bag 
screeners, but they were absolutely fantastic at what they did. They were able 
to sit down quietly and concentrate and look at every cell that was being passed 
under the microscope, and I can say that that group of women now are nearly 
all retired, and it’s extremely difficult to replace them. The IBMS now think that 
53  Cuzick et al. (1998); Cuzick and Sasieni (2001).
54  For a history of the Institute, see www.ibms.org/index.cfm?method=science.history_zone&subpage= 
IBMS_history (visited 13 August 2009).
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we should have biomedical scientists with degrees, and formal qualifications in 
cytology, but I can honestly say that on the whole they are not nearly as good at 
screening as those women from the 1960s and 1970s. 
One of the most exciting things for me was the interaction, together with my 
medical colleagues, with the pathologists, and also with the GPs, because we 
were talking about setting up a screening programme in Aylesbury, Dr Margaret 
Wolfendale, myself, and a couple of other people. We set up a screening 
programme based on the electoral roll, so we wrote out invitation cards, little 
postcards, and we went round the villages in the rural district of Aylesbury, and 
delivered these personally ourselves to try to encourage the women to come to 
clinics and have their smears done. Then there were a few very, very enthusiastic 
GPs who were supporting us and they used to come in, deliver the smears they 
had taken, and meet us in the laboratory and we felt part of this wider team. 
And I think this is what cytology still is, within pathology medicine, that we all 
know our GPs, we have a lot of interaction with the practice nurses who now 
take all the smears, and we are quite different from the other laboratories.
Jenkins: One of the questions that has always intrigued me was what made 
cytoscreeners, the women who weren’t trained as technicians, become 
cytoscreeners, because as you say it is a tremendously difficult job, it involves 
enormous patience and is something that a lot of us couldn’t do. Why did 
people take up this job?
Symonds: One of the things was that we offered them part-time working, so it 
fitted in very well with the ethos of our medical pathologists. They were mainly 
married women with children, who wanted an interesting job to fit around 
their home commitments. A lot of them had had some scientific background of 
working within perhaps research, before they had their children, or perhaps had 
worked in school laboratories. 
Coleman: I wanted to add one thing that I think is not always appreciated 
and which we found – because I was very much involved in teaching – that 
you think of screening as being very dreary and routine. In fact every smear is 
different and is a challenge, and I think only screeners, people who do it every 
day, really appreciate that, and I think that’s what keeps me going.
Wolfendale: We are really talking about the backbone of the cytology laboratory, 
where these were almost all married screeners who worked part-time – they 
were paid peanuts, absolute peanuts – and the only way that we managed to 
keep them was making it teamwork, making them feel really worthwhile and 
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wanted, and they felt that it was something interesting that they could do to get 
away from their family routines.55 I think, it was an almost pastoral care that we 
gave, supporting each other through all sorts of troubles. Last year I was invited 
back, ten years after I had retired, and there were really a large number of the 
people who had worked during the 40 years that the laboratory had been going 
and had come back because it was a team effort. And I am sure many, many 
other people in laboratories would say the same.
McCluggage: I have always heard anecdotally that it is very difficult to get people 
to go into screening. Is it still difficult? And are the problems getting better 
or worse?
Miller: I would like to make the comment that Dave Boyes in British Columbia 
went out of his way to find people who couldn’t find jobs elsewhere – some of 
them, in fact, were in wheelchairs, were paraplegic – and there were many men 
who fell into that category employed in his very large laboratory that served the 
whole of the province. So it is sometimes possible, if you look, to find people 
who really need employment and are prepared to spend the time.
Symonds: I think the answer to the question whether it is easy to recruit staff 
now is ‘no’, it’s impossible. Everybody who has worked in cytology labs for 
many years is retiring, the people who are replacing them are not prepared to 
sit down quietly in the same way, and I think there are so many more demands 
on them. Especially in the south of England, it’s virtually impossible to recruit 
staff. So I would say thank goodness for liquid-based cytology (LBC). I know 
that is not what we are talking about today, but with LBC comes the possibility 
of automation, which will help reduce the staffing crisis.56
Herbert: We don’t find it impossible to recruit staff, especially now we have 
biomedical scientists (BMS), who don’t only do cervical cytology. They have 
quite a lot of other things to do and cytology screening is part of the general 
BMS qualification.57 We haven’t employed cytology screeners as such for some 
55  Wolfendale (1991).
56  Mrs Marilyn Symonds wrote: ‘My hospital, Stoke Mandeville, was involved in a five-site research project 
in 1996 comparing conventional screening to the PAPNET automatic screening method. The outcome was 
that cytoscreeners were as effective at detection of abnormalities as the machines. Twelve years later, trials 
using automated assisted screening are still taking place.’ Note on draft transcript, 28 August 2008.
57  See ‘Qualifications and training for non-medical laboratory staff in the UK cervical screening 
programmes’ (January 2000) at www.cancerscreening.nhs.uk/cervical/publications/nhscsp12.pdf (visited 
30 April 2009).
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time and we seem to have been able to recruit people reasonably easily in 
London. We have had times when it was difficult, but not impossible.
McCluggage: We will move on to another very important subject: given the 
expansion in cervical screening, obviously colposcopy has increased as well. 
Duncan: Yesterday I went into the old byre and dug out stuff that had been 
in a wheelbarrow since I retired at the end of March 2007. I found something 
I thought was quite interesting; it was published in an obscure thing called 
Colposcopy and Gynaecological Laser Surgery, published in 1987, and it was my 
observations as the then president of the British Society for Colposcopy and 
Cervical Pathology (BSCCP).58 You have asked me specifically to look at the 
1980s, rather than the 1970s when it all began. I was reflecting, if you like, 
following the annual meeting of the BSCCP. The BSCCP really was established 
in the 1970s. Albert Singer was one of the original protagonists in 1972 when 
the society was founded. The founding trio, Joe Jordan, Albert Singer and Archie 
Crompton – that was it – met in 1972. I was training in the US at the time, came 
back in 1974 and the society was formed in 1975.59 From humble beginnings, it 
grew in leaps and bounds, and by 1987 the membership was over 500. We used 
to meet annually. The BSCCP met twice a year, once on our own, and once with 
the BSCC and then we separated because there was more to talk about. The first 
problem that I was addressing in this publication was who should be undergoing 
colposcopic examination.60 We had found out that the smears themselves did not 
actually tell you what the underlying problem was. Yes, high-grade smears tended 
to indicate high-grade cervical intraepithelial neoplasia (CIN) – as we were calling 
it then – and low-grade smears tended to indicate low-grade lesions. However, 
when the patient with a low-grade smear was examined with a colposcope, she 
often had a high-grade lesion, usually, much smaller, but a high-grade lesion was 
visible also. So it was a question of should we be seeing women with originally 
positive smears? Suspicious smears? These were the class IVs and the IIIs.61 But 
then the class II smears and mild atypia, should we be seeing them? What we were 
saying at that time was that there seemed to be justification for doing it, but it 
58  Duncan (1987); see also note 59.
59  For the history of the BSCCP, see www.bsccp.org.uk/index.asp?PageID=15 (visited 13 August 2009).
60  Duncan (ed.) (1992). See also Anon (1968).
61  These classes refer to the guidelines for the interpretation of smears proposed by Papanicolaou. See Koss 
and Melamed (2006). 
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could increase our workload dramatically, and until the supply met the demand, 
patients would have to be seen on a priority basis. The question was then whether 
you should do follow-up colposcopy, or reserve your colposcopy for the primary 
problem. And then who should be carrying out colposcopy? It’s very much like 
the cytologists. At that time the vice-president of the BSCCP was a pathologist, 
so he wasn’t a gynaecologist, and at the annual scientific meeting that year, a 
general practitioner colposcopist addressed us in Aviemore, Scotland, on how 
she was operating a successful practice here in London. Then we were discussing 
what treatment was appropriate. What we agreed in the end, after quite a bit of 
work, was that it didn’t matter whether you treated them with local destruction 
using extremes of heat or cold, or whether you used some method of excision, 
these had all been shown to be equally effective. As long as you didn’t overdo the 
cervical treatment, then there was no injury to future cervical function. We all 
agreed to disagree, if you like, and found all methods were acceptable. We had 
also encountered in situ adenocarcinoma of the cervix. This was something that 
had come out of cytology, and we were wondering exactly what we should be 
doing with that. What we had also found was that women who had vulvar warts, 
about 30 per cent of them were harbouring CIN as well, and so the question 
arose should women with vulvar warts actually be seen, and should their partners 
who had penile warts, should they be examined colposcopically as a routine? 
And should they be treated as well? So these were the things that were perplexing 
us, and the last paragraph of this publication said:
I have attempted to highlight the main problems facing us. There are, of 
course, many others, from the particular (eg, what is the true significance of 
HPV16?) to the more general (eg, what public health measures are necessary 
to stem the flood of CIN?). We live in a world where the fear of pregnancy 
has been removed by the contraceptive pill, where the protective effect of 
the sheath against sexually transmitted infection has been lost due to the 
fall in popularity of barrier methods. Sexual liberty and gratification are 
regularly portrayed on television and used unashamedly by the advertising 
industry. It should come as little surprise to us that we are seeing more and 
more cases of CIN just as we are seeing more genital warts, chlamydia and 
more cases of unwanted pregnancy. It is ironic that it may take something 
like the government education programme engendered by a fear of an 
AIDS epidemic to alter public opinion and sexual practice in such a way as 
to provide primary prevention of invasive cervical cancer.62
62  Duncan (1987).
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I had attempted to highlight the main problems facing us, there were, of course, 
many others: from the particular, for example, what is the true significance 
of HPV16, to the more general, such as whether public health measures were 
necessary to stem the flood of CIN.63 I said that perhaps the government 
education programme as then being applied to the AIDS epidemic might be 
beneficial to us, but meanwhile the BSCCP would continue to have its say in 
the setting and maintaining of standards for the present-day colposcopists and 
the continued quest for tomorrow’s knowledge. And that’s really carried on in 
the same way since then. So that was the 1980s.
McCluggage: Anybody else want to comment on that?
Coleman: I can recall one important meeting, I think it was called the 
Intercollegiate Working Party on cervical cytology screening, which I think 
Albert Singer drew together and perhaps he could comment on that.64 That was 
1988 and I remember the results of that meeting were published in the BMJ 
and that seemed to transform cytology from the desperate confused situation 
into a more directive programme, and laid the foundation I thought, for what, 
in my view, is the first-class cervical screening programme that we have today.65 
Perhaps Albert could comment on that. 
Mr Patrick Walker: I’m from the Royal Free Hospital, London. I started 
working with Albert Singer in 1981 as a research fellow interested in HPV. 
To throw a little bit of light on a question that has never really been fully 
understood: why was colposcopy very slow to get off the ground in the UK? 
Hans Hinselmann’s first paper was in October 1925 and from then on it became 
reasonably popular on the mainland continent of Europe.66 The Gynaecological 
Visiting Society of Great Britain and Ireland (GVS) was founded by Blair-Bell 
in 1911, who later went on to found the Royal College of Obstetricians and 
63  Duncan (ed.) (1997).
64  Dr Ian Duncan wrote: ‘It was not Albert Singer who was the chairman, but Frank Sharp from the Royal 
College of Obstetricians and Gynaecologists.’ Note on transcript, 2 September 2008. The brief was to 
look at the clinical aspects of cervical cytopathology screening programme in the UK, see Royal College of 
Obstetricians and Gynecologists, Royal College of Pathologists, Royal College of General Practitioners and 
Faculty of Community Medicine, Intercollegiate Working Party (1987).
65  Havelock et al. (1988).
66  Hinselmann (1925); for the early history, see O’Dowd and Philipp (1994): 30–1; 550–1; 531–4; 
543–70; 640–1.
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Gynaecologists.67 The society was a travelling group; they were the elite 
travelling group of the professors from the British medical schools and they 
travelled in 1937 to Berlin, stopping off on the way in Hamburg. They were 
greeted by Professor Hinselmann who took them to his home for tea and then 
the following day took them to his colposcopy unit in Altona, the hospital 
where he practised colposcopy. These were difficult times in Europe and it is 
alleged that Hinselmann – I think it is probably true – was quite a prominent 
member of the National Socialist Party at the time. What the GVS used to 
do was to assess surgical procedures, see how to do things slightly differently, 
and as the convenor of the GVS at the moment, I have the records going back 
to that meeting. One of the operations that they saw was a sterilization at a 
time that forced sterilizations were allowed in Germany. So when they came 
back from Germany, there was no enthusiasm for either Hinselmann or his 
technique, although Fletcher Shaw arranged for one colposcope to be delivered 
to the UK, and Dr James Andrew found one in the outpatients at Bart’s in the 
1950s. By then Andrew was running a monthly colposcopy clinic there through 
the 1960s.68 
A personal remembrance: when I was a medical student at Bart’s in 1972, 
Gordon Bourne was the senior gynaecologist and there was an afternoon 
tutorial. We were all trying to rush off to the bar or somewhere else, and he 
said: ‘No, please stay behind. There’s a very nice man called Dr James Andrew 
who is coming to talk to you about a German instrument called a colposcope, 
which none of us feels has any value, but he’s an awfully nice man, why don’t 
you stay and listen to him’. And I did and I didn’t know then that later on 
in my life it would mean something. I think that until Albert Singer came 
from Coppleson’s unit, Joe Jordan had been with Per Kolstad and Archie 
Crompton with Professor Ernst Navratil, they came together to form the 
British Colposcopy Group in 1972, the previous hiatus actually had something 
of a medico–political dimension.69 
67  Shaw (1950, 1954a and b). Sir William Fletcher Shaw was the first honorary secretary of the Royal 
College of Obstetricians and Gynaecologists in 1929, later president (1938–43).
68  Dr James Andrew described his first Zeiss colposcope and setting up his regular colposcopy clinic at Bart’s 
in 1954 in a paper, ‘British colposcopy before the 1960s’ (Andrew (1975)). A copy of the paper will be 
deposited along with other records of the meeting in archives and manuscripts, Wellcome Library, London, 
in GC/253. See also Jordan (1975); Burghardt et al. (eds) (1978). 
69  See also Kolstad (1970).
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Herbert: One of the things that colposcopy did for cytology in the 1980s was 
to focus laboratories on quality control, which greatly improved when the real 
programme started in 1988. Colposcopists were seeing patients with borderline 
smears and persistent mild abnormalities and finding they had CIN3. Obviously 
not all of them, but it made cytologists focus on quality control. 
The other thing – and Jocelyn Chamberlain is here – was her excellent article 
on the reasons why screening may fail to prevent cancer, which was very 
important.70 Among those reasons were false negative cytology, low-grade 
abnormalities that were high-grade on review, and failure to follow up after 
treatment.71 When colposcopists were seeing women with what were thought 
to be minor abnormalities on cytology, it became a bit of a bone of contention 
between pathologists and cytologists. I think that was one of the reasons why 
the two organizations split and held different meetings.72 
Duncan: Dulcie was speaking about this Intercollegiate Working Party, which 
Albert has passed on to me, because I don’t think Albert was involved. It was 
under the chairmanship of Frank Sharp, who along with myself, represented 
the Royal College of Obstetricians and Gynaecologists. Dr D M D Evans 
and Professor Harold Fox represented the Royal College of Pathologists; Dr 
P B Havelock and Dr Ann McPherson from the Royal College of General 
Practitioners; and Dr Jocelyn Chamberlain and Professor Alwyn Smith from 
the Faculty of Community Medicine.73 What it did was to publish a report in 
November 1987 and it actually set out who should have smears, how often and 
when, putting together what was happening in the Department of Health in 
Scotland, which had issued a statement,74 and the DHS which had also issued 
70  Chamberlain (1986).
71  See, for example, Cuzick et al. (1994).
72  Dr Amanda Herbert wrote: ‘The BSCCP met during the BSCC annual meeting until 1982 and I think 
not thereafter.’ Note on draft transcript, 23 July 2009.
73  Although the BSCC were not officially represented on the Intercollegiate Working Party, the society 
provided two appendices to the Report (RCOG et al. (1987)): ‘Recommended code of practice for 
laboratories providing a cytopathology service’ and ‘Terminology in gynaecological cytopathology, report 
of the working party of the BSCC’, the members of which were D M D Evans (chairman), E A Hudson 
(secretary), C L Brown, M M Boddington, H E Hughes, E F Mackenzie and T Marshall, and had been 
published in the Journal of Clinical Pathology (Evans et al. (1986)).
74  Scottish Health Service Planning Council, Scientific Services Advisory Group, Subcommittee on 
Histopathology (1977). See Glossary, pages 150–1.
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a statement.75 And that led one year later to the founding of the NHS Cervical 
Screening Programme national coordinating network which was basically the 
14 English health regions, the three Celtic nations, and the private sector (the 
big 18).76 And, up until devolution, then it worked and produced a series of 
documents and Amanda Herbert edited some, I edited some, Catherine Pike 
did some as well. So that really got us all together, and it became a quality-
assured service with quality control and fail-safe mechanisms and all of that. 
That is where Euphemia McGoogan came in, the missing link, the Edinburgh 
one, who was, if you like, a second-generation cytologist, and then she took a 
lead role as well.77
McCluggage: I think we will probably touch on this later on, but we are going 
to move on to the discovery of the HPV and the development of HPV research. 
Albert Singer is going to make a few brief comments about the unknown 
male factor. 
Singer: In four minutes. It is certainly a privilege and rather humbling after 
40 years to go back and look at – as you say – the unknown male factor, and 
especially working with so many colleagues after all those years. I started off in the 
mid-1960s, in Sydney, Australia, joining up with Professor Malcolm Coppleson 
who has already been mentioned – he was a colposcopist and a gynaecological 
oncologist – and Bevan Reid who was a cell biologist, a brilliant scientist; and 
in the early 1960s they were studying the process of squamous metaplasia, the 
process by which columnar epithelium changes to squamal and during that 
time the observation was made that sperm heads were found in the regenerating 
cells. They believed that the stromal cells underneath the epithelium were the 
progenitor cells of the new squamous epithelium, and they absorbed the sperm 
DNA. That culminated in the classic pictures by Bevan Reid in the Lancet of a 
sperm fragment in a cervical cell.78 I was taken on as a research fellow in 1966, 
75  Department of Health and Social Security (DHSS) (1986a), later consolidated as DHSS (1988). It 
recommended that all women between the ages of 20 and 64 should be invited for screening within five 
years of 31 March 1988. For details of the narrowing of the age range in 2004, see note 155.
76  Dr J A Muir Gray, as chairman of the National Coordinating Network (NCN), convened a group 
of regional contacts and professional associations in cervical cancer screening about their training and 
educational needs. The resulting report, ‘Education and training needs of programme managers’ was 
published in 1989 and is no longer in print. See www.cancerscreening.nhs.uk/cervical/publications/pm-01.
html (visited 3 September 2009).
77  See Biographical notes, pages 137–8.
78  Reid (1964); see also Coppleson and Reid (1969); Singer and Reid (1976). 
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and the only other research fellow was my good friend Margaret Stanley, but she 
was 700 miles away in Adelaide. Both of us worked on the cervix and my first 
task was to imitate squamous metaplasia. 
What I did was to take women who were down for cervical cauterization, which 
destroyed the cervical epithelium and then watched the regeneration. When 
they would say to us: ‘Can I go with my husband or partner?’ we said to them, 
‘That’s all right’, because the reason was to see if we could imitate Bevan Reid’s 
original findings, and sure enough, in many of the women the regenerating 
cervical cells (we published this in publications in 1967) showed that sperm 
was taken up. And that led us to the concept that maybe it was the sperm DNA 
mixing with the endogenous DNA. But for all the tissue culture work we could 
not go much further with it. I then left in 1970 to come here; Reid continued. 
He moved away from DNA, worked mainly on basic proteins protamine and 
histones in sperm, and in 1978, in a rather contentious and controversial paper 
in the Lancet, showed that men from social class five whose wives had a very 
high rate of cervical disease, also had very high levels of sperm basic protein, 
especially protamine, and that men in social class one and two had low levels. 
The paper was accepted in the Lancet, raised obviously a lot of ethical problems, 
but he did show that there was a profound difference between the social classes 
on that subject.79 These substances profoundly influence cell surface function in 
vitro. He then went ahead and in 1987 showed indeed in tissue culture work 
that you could imitate most of the morphological features of malignant cells. 
He did time-lapse photography and showed that adding protamine, which is 
a basic protein to the cell structures, when added to the cell cultures, induced 
these changes. During the 1970s, many of us still believed that DNA in some 
form, be it in viral form or in the actual virus or indeed sperm, was responsible, 
and I wrote a letter to the BMJ on the 11 October 1969, which is 39 years ago, 
to an article on contraceptives and cervical cancer, and said that these steroids 
could prevent the entry of the proposed genital mutagen, be it in the form of 
‘spermatozoal or viral DNA’.80 Then Rawls and Melnick published their work 
on herpes simplex virus 2 (HSV-2) in Houston in 1968.81 But again we pointed 
out that probably there was more DNA from sperm origin than there was from 
viral. So there was quite a lot of activity in that field on the male. 
79  The data from Reid et al. (1978a) were re-cast in Reid et al. (1978b) as a result of the suggestions from 
Cameron and Jones (1978): 366, and showed a higher degree of significance than reported in the earlier paper.
80  Singer et al. (1969). 
81  Rawls et al. (1968).
History of Cervical Cancer and the Role of the Human Papillomavirus, 1960–2000
31
I came to England and was influenced by the lady sitting on my left (Valerie Beral). 
We had both been residents in Australia at the same hospital many years before 
and she published a classic paper in 1974 on the standardized mortality ratio for 
cervical cancer by social class and husbands’ occupation in married women.82 If 
you were a fisherman, your wife would have had a standardized mortality ratio 
(SMR) of 257, or the wife of a driver of road goods vehicles of 168; compared 
to the Oxford clergyman’s wife who was 12, or a scientist’s wife who was 17 
(Table 2, page 32). And on the basis of that and knowing what we knew about 
some of the basic work, Bevan Reid and Malcolm Coppleson joined me in writing 
a hypothesis published in the American Journal of Obstetrics and Gynecology on 
the role of the high-risk male in the aetiology of cervical cancer, a correlation of 
epidemiology and molecular biology.83 Certainly Stanley Way gave me some of 
his anecdotal comments to add to that. The high-risk male as we suggested was 
determined by occupation, as Valerie had pointed out: sexual behaviour, cigarette 
smoking, sexually transmitted infection (STI), and genital HPV infection. 
I came down to London from Sheffield in 1980 and met David Oriel at University 
College Hospital (UCH), who was a world expert on genital condyloma, and 
over the next few years he allowed a team comprised of Michael Campion and 
other research fellows to study the relationship between cervical and penile 
condyloma. Jack Cuzick and Dennis McCance also helped us and we published 
a number of papers showing that the women whose partners had penile HPV 
were at a very increased risk of cervical disease.84 So that is really the unknown 
male factor. It started off being unknown, because the only work before the 
1960s dated back to 1842 to Rigoni-Stern, who showed that nuns had a low 
rate of cervical cancer, and married and widowed women had a high rate of 
cervical cancer.85 Very little occurred in the 1950s. Isadore Rotkin wrote on 
female behaviour, on the early age of first intercourse;86 but it wasn’t until the 
sperm work and the HSV work developed that we started looking at the male 
and then eventually at warts in the 1980s.87
82  Beral (1974): data on page 1039, see Table 2, page 32; see also Wakefield et al. (1973); Anon. (1973).
83  Singer et al. (1976).
84  Campion et al. (1985); McCance et al. (1985).
85  Rigoni-Stern (1842, 1988); Griffiths (1991); Scotto and Bailar (1969); see also note 236.
86  Rotkin (1962, 1973). 
87  Singer and Stevenson (1972); Singer (1983); Walker et al. (1983a).
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Table 2: Standardized mortality ratios (SMRs) for cervical cancer in married women,  
by social class and occupation of husband, England and Wales, 1959–63. Beral (1974): 1039.
Social class Husband’s occupation SMR
I All occupations
clergymen
scientists
civil engineers
34
12
17
60
II All occupations
teachers
senior government officials
publicans & innkeepers
lodging house & hotelkeepers
64
30
40
120
150
III All occupations
clerks of works
clerks
crane & hoist operators
drivers of road goods vehicles
100
40
64
159
168
IV All occupations
shopkeepers & assistants
gardeners & groundsmen
fishermen
deck & engineroom ratings, barge & boatmen
116
71
98
257
263
V All occupations
office & window cleaners
labourers
181
95
222
McCluggage: Well, that was a very complete summary of the unknown male 
factor. Has anybody any comments about the unknown male factor?
Dr Anne Szarewski: I wanted to emphasize, perhaps, the role that Albert Singer 
played in this. I think that women in general should be very grateful that he 
highlighted the role of the male in cervical cancer, I think because there was so 
much stigma attached to it all being a ‘female thing’.88 It was really Albert’s unit, 
which I joined in 1986, that was greatly responsible for the shift in emphasis to 
say that: ‘Actually this is a joint problem, it’s not the fault of the woman’. I think 
that a lot of the research that went on in our unit helped that shift a great deal.
Miller: I wanted to comment that the epidemiologists had identified a male factor. 
There was a case control study published in the UK, I think Buckley was the 
first author, which showed this and there were several studies of epidemiologists 
88  Singer et al. (1976).
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which showed that husbands whose wives had died of cervical cancer, their 
second wife was at a greater risk.89 So there was a fair amount coming in the 
epidemiology area. Rotkin and various others were pointing out the importance 
of the male. While I am talking, could I point out that it was Alex Meisels, the 
cytopathologist in Montreal, who identified some of the cytological changes 
that later were found to be due to HPV.
Professor Margaret Stanley: There was no doubt that there was a male factor. 
The epidemiology that had been done in the first part of the century and in the 
1950s showed that.90 There were some very amusing reports in the literature. 
One of my favourites was of a guy in the US whose wife had cervix cancer and 
whose other partners lived within a relatively short distance also had cervix 
cancer.91 My boss, James Kirkland – the best gynaecological pathologist I have 
ever known, who had trained as a cytopathologist under Elizabeth Macgregor 
and went to Hans Hinselmann where he was trained as a colposcopist – had a 
very wicked sense of humour and said: ‘He didn’t even need a bike.’ So the male 
factor was known and it’s about the sociological and cultural attitudes of the 
time that you would always blame women. 
I remember being on a radio programme in Australia, where we were talking 
and I was being asked questions about cervical cancer. I trotted out the usual 
risk factors – early age of sex, usually more partners – and one lady phoned up 
in absolute fury, and she said that she had been married since she was 16, she 
had never had another partner, she had had five children, but her husband was 
a merchant seaman. I rest my case.
Patrick Walker: Before we move on to the science and the next bit, it is 
worthwhile remembering what it was like and how much HSV had actually 
dominated the agenda through the 1970s. I started working with Albert Singer 
in 1981 and he sent me along to Dulcie Coleman to work in the lab there, 
and HSV was very much ‘it’. It was intriguing at the time, I went to a meeting 
where Laura Aurelian and Irvine Kessler came over to speak, and Ralph Richart 
was there as well.92 By the very tail end of the meeting, they were struggling to 
89  Buckley et al. (1981).
90  Rotkin (1967).
91  Professor Margaret Stanley wrote: ‘It was in the American Journal of Obstetrics and Gynecology, but the 
precise reference is not in my records.’ Note on draft transcript, 1 September 2009.
92  Richart (1964) introduced the terminology of cervical intraepithelial neoplasia (CIN).
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keep the hypothesis of HSV going, and the difficulty was that they couldn’t 
find the DNA of the virus in the malignant tissue. They found the RNA and 
therefore they developed something, I think McDougall called it ‘the hit and 
run hypothesis’ (the virus got in, did the damage and then ran away again). 
As our colleague (Anthony Miller) mentioned, Meisels, Fortin and Roy’s 
paper at the same time as Eva Savia and E Purola in Finland were identifying 
cytopathological changes that could be HPV.93 
It always seemed strange to me as a young man entering the field at the time 
that now we see koilocytosis and dyskeratosis everywhere, what were people 
looking at in the 1970s during the HSV era that all of this so obviously became 
true later?
Stanley: Cytologists did recognize these funny cells, but we called them halo 
cells, we didn’t know what they were. They weren’t regarded, and Dulcie 
Coleman may wish to comment. But I want to reinforce what Patrick Walker 
said, HSV utterly dominated the agenda, and it was very much based – 
and Joan Macnab may want to comment here94 – on the serology and the 
relationship between antibody levels to HSV-2, but the thing that really should 
have killed it was that nobody could transform human cells in tissue culture, 
or primary cells other than rodent cells with HSV DNA or any fragment of 
HSV, and one has to remember that the transformation assays that were used 
to support the idea of HSV involvement were all done on Syrian hamster or 
mouse fibroblasts. Anybody who works on those knows you only have to spit 
at these cells and they will obligingly transform for you. So, that was the basis 
of the science.95
Dr John Smith: About the koilocyte: those of you who know the Papanicolaou 
Atlas of Exfoliative Cytology from 1954, will know that it contains these 
marvellous coloured pen-and-ink drawings of abnormal cells. There is a most 
fantastic illustration of a koilocyte there, though its significance, of course, was 
not realized at the time.
93  Purola and Savia (1977); Meisels et al. (1977); see also Nieminen et al. (1991). 
94  Dr Joan Macnab wrote: ‘I would like to record that the molecular analyses of cervical tumours in 
Glasgow confirmed that HSV DNA could be retained. Furthermore, HSV was re-activable from rat 
transformed cells using genetic techniques of analyses (Park et al. (1980, 1983)).’ Note on draft transcript, 
2 September 2008.
95  See, for example, Galloway et al. (1980);  Stern and Stanley (eds) (1994).
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Figure 4: Koilocytes, cells infected with HPV  
(400× magnification), stained with the Papanicolaou stain.
96
  
McCluggage: That leads us on very nicely to the discovery of HPV16 and -18 as a 
major cause of cervical cancer and precancerous lesions, so again, Albert Singer.
Singer: I feel rather humbled talking on this topic that everyone here is so 
involved with. But again I start with Coppleson and Reid in 1966. It was 
obvious to us that age of first intercourse and of ‘promiscuous adolescence’ were 
very important as behavioural characteristics. 
The first thing they got me to do was to start looking at the cervix of virginal 
girls and those of sexually active girls. Well, you will say, how can you look at 
virginal girls? In the 1960s it was usual for what was called the ‘strip and stretch’ 
of the hymen to be done under anaesthetic before a young woman married. 
And working in a big hospital in Sydney, Val Beral knows it well, many of 
96  ‘Their form indicates a transition from the navicular to the superficial type. Cells exhibiting dyskaryotic 
changes...affect chiefly  the nucleus and consist in enlargement, irregularity in form, hyperchromasia and 
bi- or multinucleation. In the superficial and navicular dyskaryotic cells a perinuclear “cavitation” is often 
present’ (Papanicolaou (1954): A.VI.9, pages a14–a15). 
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the gynaecologists had huge private practices and every time a young woman 
came in for this procedure, I would ask for permission and run along with my 
colposcope, and in the space of about ten seconds was allowed to get a picture. 
So I had a library of the cervix of virginal women, and then the sexually active 
young women, and we published this and showed that the cervix of the sexually 
active girls was smaller, but that squamous metaplasia was very active, about 
three or four times more active, but the important thing was there was atypical 
abnormal epithelium present.97 We then started to biopsy the cervix. Now, the 
population we studied was a group of women whom Coppleson had been able 
to observe, and these were young women in an institution who were offered a 
bacterial examination to exclude STI of the vagina, and during that examination 
we photographed. They were all sexually active, and I brought some of the 
original photographs taken at the time with me. We have Miss H, aged 14, 
sexual intercourse age 12. They had the most unusual changes in the cervix; we 
had never seen these. Coppleson couldn’t work it out, and he was an experienced 
colposcopist. We took biopsies of these and I remembered photos from Koss and 
Durfee’s pathology book.98 So I sent him some of these black-and-white pictures. 
‘Dear Professor Koss, In your book you call these warty atypia. What are they?’ 
And he wrote back – I still have the letter and Leo Koss has mine – and we had 
a correspondence. He said these are ‘warty atypia’; this was 1968. 
Then we had to work out these changes, and Coppleson said that indeed these were 
obviously very profound changes and held the key to the whole abnormal process 
in the cervix.99 At the time the pathologists really didn’t recognize it. I have a book 
from 1973 by Fred Langley and Archie Crompton on epithelial abnormalities.100 
There are four lines devoted to ‘warty atypia’, which were cells similar to these 
cells, which were obvious HPV.101 Koilocytes were noted in the condyloma, thus 
suggesting a possible relationship to infection. However, Patten considered these 
97  Singer (1975).
98  Koss (1961) was a ‘Citation Classic’ in Current Contents: Life sciences (1989) 32: 15, having been cited in 
over 1260 publications. See also Koss and Durfee (1956); Koss et al. (1963); Koss (1975). 
99  Coppleson (1970).
100  The lines read: ‘Cells similar to these are seen in condyloma acuminatum, thus suggesting a possible 
relation to virus infection. Indeed Koss (1968) terms these changes ‘warty atypia’. However, Patten (1969) 
states that the perinuclear clear zone has been attributed to shrinkage and Sagiroglu (1963) considers it an 
artefact.’ Langley and Crompton (1973): page opposite Fig.5.3a and b.
101  Langley and Crompton (1973): Figure 5.2.
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changes to be artefact and Langley himself said these were degenerative cells. But 
we believed that these changes all were related to viral infections. 
An offshoot of the work was that we wanted to know how the virus, or what it was 
that was causing it, got into the cervix? Reid asked if the young woman ovulated 
soon after she starts having her periods? The answer was: ‘No, young women 
don’t ovulate for a few years after.’ He said: ‘Maybe there are structures in the 
mucus that allows the entry at that time.’ Again we examined the structure on 
an electromicroscopy of cervical mucus and again the original picture showed, 
as you would expect, that at mid-cycle if you are not ovulating, you have very 
clear channels, and when you ovulate these channels are blocked. So, here was a 
possible mechanism by whatever it was ‘got into’. 
We then went on from that and really I wanted to see what happened to these 
girls as they got older. I came to this country and managed to link up with 
Sir Richard Doll, who directed two young research fellows, Martin Vessey and 
Peter Smith, to help me in a study at Holloway Prison (1970–73). I managed, 
and it’s another whole story, to get into Holloway Prison, set up the colposcopy 
clinic and examine 768 women, 38 per cent of whom had CIN and for whom 
18 per cent had CIN or cancer and the biopsy showed exactly the same result 
as we had previously.102 
Jenkins: I think one of the key things, Albert, was when the probes began to 
arrive, with the setting up of Southern blotting techniques.103
Singer: If I may have ten seconds. Dulcie Coleman was helping me and we set 
up a study with Patrick Walker.104 The main study that we did was in 1983 and 
Jack Cuzick was also involved. We wanted to know what happened to women 
with mild changes in smears, most of whom had an HPV infection. We followed 
these women for three years with no biopsy, and showed that 26 of the 100 with 
mild changes (CIN1) turned into severe disease (i.e. CIN2/3) and 85 per cent 
of these had HPV16. Dennis McCance at Guy’s Hospital did the hybridization 
and, as far as HPV16 was concerned, that was really the turning point.105
102  Subjects were from King George V Memorial Hospital, Sydney, Australia, and HM Prison, Holloway, 
London, with financial support from the National Health and Medical Research Councils in Australia and 
a project grant from the Medical Research Council, London (Singer (1975)). See also Singer (1973).
103  Melchers et al. (1991); Tidy et al. (1989). See note 108.
104  Walker et al. (1983a and b).
105  Campion et al. (1986). 
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Professor Heather Cubie: I wondered if I could give a slight virologist’s 
perspective and go back a little bit, too, because there was quite a lot of 
virology happening, looking at papillomaviruses in the 1960s, particularly 
in the Institute of Virology in Glasgow, and we were doing quite a bit in 
Edinburgh. Albert Singer has referred to what I actually think still is one of the 
sentinel differentiations, which was David Oriel and June Almeida’s electron 
microscopy work, coupled with what Marie Ogilvie did in Edinburgh, to 
separate out genital wart virus from the virus causing cutaneous warts.106 That 
was the first indication that perhaps there were different kinds of this virus, 
and through the second half of the 1960s, and the early 1970s, lots of work 
was done trying to find in vitro models, as Margaret Stanley has mentioned 
too, and cell culture systems which didn’t work. I was much involved in those 
animal models, which were jolly hard to do.107 Then molecular techniques 
came along, starting with things like hybridization with the most cumbersome 
of techniques, coupled with Southern blotting – again an Edinburgh discovery 
and yet hugely influential in being able to move forward to eventually produce 
knowledge about different types of HPV – and that was the late 1970s.108 
I wonder if I could make one more interesting point? The first international 
papillomavirus meeting was in 1975 and was held in Lyons, organized by the 
Institute Pasteur dermatologists. And, there was the beginning of an association 
of papillomavirus with cervical disease in terms of the virology at that stage.109 
Professor Saveria Campo: I wish to point out that the discovery of HPV16 
and HPV18 was made in the laboratory of Harald zur Hausen in Heidelberg, 
and it was made possible because Lutz Gissmann cloned HPV6 from a genital 
condyloma and used that molecular clone of HPV6 as a probe.110 They were 
the ones that found HPV16 and -18 in SiHa and CaSki cells, and then they 
found them in several biopsies of cervical cancer, so we mustn’t forget that they 
actually found for the first time HPV viral DNA in cervical cell lines and in 
cervical cancer specimens.111
106  Dunn and Ogilvie (1968); Oriel and Almeida (1970). See also note 84.
107  Cubie (1976).
108  Southern (1975).
109  Prunieras (ed.) (1976).
110  Gissmann and zur Hausen (1980); Dürst et al. (1983); Boshart et al. (1984).
111  zur Hausen et al. (1974); Gissmann and zur Hausen (1976).
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Stanley: I want to reinforce that and to also point out that zur Hausen had 
published a paper early in the 1970s, where he had been looking for papillomavirus 
DNA in cervical cancer biopsies.112 And the problem was that the molecular 
technologies were not advanced enough at that point for him to do it, and it 
wasn’t until 1978, when Gissmann cloned HPV11.113 This was absolutely critical, 
because without that, then the actual cloning out of HPV16 and HPV18 would 
not have happened and that was crucial. Lionel, who knows more about this 
perhaps than anyone else in the room, might want to comment.
Dr Lionel Crawford: I think the main comment is that I wish that Lutz 
Gissmann was here because I think he could really fill us in on the logic of 
what they did and the technology behind it. Certainly zur Hausen’s lab was 
extremely important in all of this and continued to be for a long period. So 
his is a name which should be very prominent in all of these studies. If I could 
make a perverse comment at the same time: zur Hausen’s generosity in giving 
everybody clones so that they could do searches with his cloned material had 
an unfortunate effect. This turned out to be a standard that everyone was using 
and the standard had in it a mutation which was effectively an assembly minus 
lesion which made it more difficult to assemble L1 into virus particles. In a 
way people would have been better off to isolating their own strains and later 
on it was found in my lab and Gissmann’s lab that most of the natural isolates 
differed from zur Hausen’s clone in a position in L1 which is critical, because 
L1 is the major coat protein.114 
McCluggage: Thank you for that. We are going to move on to Dr Campo, who 
is going to talk about the mechanisms and genes of HPV.
Campo: I work in Glasgow, and the reason I work there is because at the end 
of 1978 I read a review by Bill Jarrett, who was a veteran pathologist, on the 
fact that BPV, bovine papillomavirus, was the cause of upper gastrointestinal 
tract cancer.115 And I thought, ‘Hey, this is a real cancer virus’. I was working 
on SV40 and was absolutely fed up with working on SV40 because I couldn’t 
see where this was going to lead me. I wrote Jarrett a letter saying: ‘You have a 
112  zur Hausen et al. (1974).
113  Dartmann et al. (1986). 
114  Dr Lionel Crawford wrote: ‘I learned at this meeting that the sequence of the L1 gene in the patent 
application is not that of the zur Hausen HPV16 clone, so this point may be irrelevant to VLP production 
mentioned later.’ Note on draft transcript, 16 July 2008.
115  Jarrett et al. (1978a and b); Jarrett (1978).
History of Cervical Cancer and the Role of the Human Papillomavirus, 1960–2000
40
system and I have the molecular techniques, so why don’t I come and work with 
you?’ And he said: ‘Yes, sure, come on.’ And the rest of it is history. I went to 
Glasgow and stayed there. 
To go back to HPV. As I have said, HPV was discovered later. In fact BPV 
was one of the first cancer viruses, papillomavirus-induced cancer. It was found 
along with CRPV, the cotton-tail rabbit papillomavirus, and these were the 
days when, as has been said, nothing was known about HPV16 or HPV18.116 
It was really thought that these were different viruses from genital condyloma 
and all the studies were being done on the rabbit and the bovine virus. Anyway, 
talking about the mechanisms of HPV: if we take HPV16 as the paradigm, 
then this virus has three transforming proteins that contribute to cervical cancer 
formation and these are: E5, E6 and E7. It is now accepted that E6 and E7 are 
the major transforming proteins and E5 is an auxiliary transforming protein.117 
The thing that fascinates me is that there are viruses, a whole lot of HPV 
viruses, that do not have E6, like BPV4, and they are perfectly good at inducing 
tumours and inducing cancer. And there are viruses that do not have E5, so 
whatever E5 does – and we can talk about what E5 does later – these viruses 
can do without E5 altogether. There is a whole class of bovine viruses again, in 
which E7 does not bind the protein pRB, which is what HPV16 E7 does. So 
whereas all these proteins undoubtedly do their thing in the transformation of 
cervical keratinocytes, there are an awful lot of viruses that can do without one 
or the other of these proteins. So I find this is actually quite interesting and 
perhaps these viruses should be studied more. These proteins that operate on 
cell transformation by pushing the accelerators, disabling the brakes, preventing 
apoptosis, these very same proteins are those that disable the immune response. 
They interfere with the immunomolecules of the host and they practically make 
the infected cell, the HPV cell, invisible to the host lymphocytes. So, it’s a very 
clever system for such a small virus, it encodes two or three proteins that can do 
multiple things: one is to put the cells into proliferation and at the same time 
prevent the host’s immune system from recognizing cells that are proliferating 
when they shouldn’t.
Dr Joan Macnab: I think that’s interesting, but in my lab Henry Kitchener, 
John Murdoch and Steve Walkinshaw did a lot of work on cervical cancer with 
me. One of the issues we found – perhaps not common to the whole of the 
116  Shope (1933, 1937); Syverton (1952).
117  Münger et al. (2004); Stöppler et al. (1996).
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UK, but certainly to the west of Scotland – was the high incidence of HPV16 
in normal samples. Initially HPV16 was found in cytologically normal tissue 
distant from a tumour, but later in CIN and in tissue from normal controls 
with no evidence of cytological abormality.118 That made it very difficult for us 
as workers on HSV-2. We were in the position of having found HPV16 in a lot 
of circumstances that were difficult to explain. I think that HPV depends on 
other factors and has other aetiology in the patients in which it forms tumours. 
Co-factors could include HSV-2, which has proved to be present in cervical 
tumours, transformed cells and also to have the ability to increase expression of 
tumour-specific proteins such as the mitochondrial aspartate amino transaminase 
and up-regulate the oestrogen receptor.119 
Crawford: May I speak up from the virus’ point of view? There is no reason why 
the virus should care at all about transformation; it only cares about making 
more virus. It is perverse to only take the patient’s point of view, whereas all 
the virus wants is to produce more and more virus. So the fact that it appears 
in normal cells, produces virus progeny, goes on to infect and everything else, 
that is fine. If occasionally there is transformation, it doesn’t matter to the virus, 
but it matters a lot to the patient and to the doctor in charge. But I think one 
has to look at things from a different point of view to understand the way the 
virus works. So a lot of the things we have been talking about would not have 
interested the virus at all.
Jenkins: This issue of HPV in normal women is one of the things that has caused 
immense confusion, hasn’t it? In terms of the development of the understanding 
and the impact of the papillomavirus, the finding of virus everywhere did for 
a while lead to considerable doubts about the oncogenic role of HPV and had 
a big impact on the whole research activity, research programmes, going on at 
that time in the 1980s.
Campo: I absolutely agree with every word that Lionel Crawford has said: the 
virus wants to make more of itself, and it doesn’t care about cancer, which 
is a dead-end. Also, viruses are ‘latent’, can be latent, and papillomavirus has 
been found in normal margins of lesions; it has been found in epithelia away 
from lesions; it’s been found in clinically normal people; and this is particularly 
problematic for skin cancer. I know that we are not talking about skin cancer 
118  Macnab et al. (1986); Kitchener et al. (1991).
119  Lucasson et al. (1994); Offord et al. (1989).
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at this meeting, but non-melanoma skin cancer is a point of controversy as far 
as HPV is concerned, precisely because the cutaneous squamous cell or basal 
carcinomas are also found so frequently in clinically normal skin. But that 
doesn’t mean to say that once in a while an accident happens which is not good 
for the virus, it’s not good for the host, but it’s good for the transformed cell that 
gets selected then moves on.
Professor Julian Peto: I slightly disagree with Lionel. HPV16 is so extraordinary 
compared with other HPVs, in terms of its transformation power that something 
approaching half of all untreated women with HPV16 may develop CIN3. 
The consequence is that they remain infectious for much longer, so in the case 
of HPV16, you could argue that there has been selection for transformation, 
because it substantially increases the time that the carrier remains infectious in 
an unscreened, untreated population. 
Jenkins: A lot of this has taken a long time to be understood, hasn’t it? We are 
going back to the early days of looking at HPV. We were really unaware of a lot 
of these complications and the discovery of HPV in normal tissue as well as in 
cancerous and precancerous tissue did cause quite a stir and a lot of concern at 
the time, against the importance of HPV as an oncogenic agent.
Stanley: The problem with HPV was that infectious disease physicians and 
microbiologists were not much involved with it. It was gynaecologists and 
histopathologists, who really had very little understanding of infection and 
infectious disease, and that has always been a problem in the HPV field. The 
idea that with pathogens, with viruses, with any form of microbe, lots of 
people are exposed, lots of people are infected, relatively few actually show any 
clinical symptoms and really very few show the most severe and acute form of 
disease caused by the pathogen. That is as true of HPV as it is of even polio, for 
goodness sake.
Professor Ciaran Woodman: Somebody has to disagree with you, with the soundbite 
that 50 per cent of women with HPV16 develop CIN3; it’s too large, much too 
large. We started on our own longitudinal studies which attempted to define a 
cohort in which we could measure the incidence of HPV16 and -18 infection, and 
the proportion of those who acquired the HPV16 infection soon after the onset of 
sexual intercourse was of an order of magnitude less than 50 per cent.120
120  Tierney et al. (1993).
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Crawford:  p53 is a whole meeting on its own, so I will only talk about it 
very briefly.121 It has a very interesting history and came out of confusion, 
misunderstanding and SV40.122 
But I will talk about virus-like particles (VLPs) and I find myself in the minority 
again, not speaking about the virus, but about prevention at a much earlier 
stage than detecting early lesions and removing them. My position, for the 
sake of argument, is that we could do without all of this if we had a decent 
vaccination system, and the basis of that has to be the virus coat protein and 
virus-like particles.123 You see them in all sorts of wart virus, you see them in 
sections and in negative staining, they are particles which lack DNA, and, of 
course, you want anything that you are going to use to put into people to be 
devoid of DNA, because that removes all the worries about actually causing 
the disease, rather than preventing it. VLPs have been around for a long time, 
but producing them in quantity was felt by experts to be almost impossible. 
Even harmless sorts of warts, like the ones you get on your hands or your feet, 
couldn’t be reproduced in the sort of quantity of virus required and then the 
empty particles separated out from the full particles, on a scale that would allow 
you to do anything useful. For the important viruses like HPV16 and -18, 
it was even more ridiculous, you couldn’t get anywhere near it. There were 
certainly people who felt that the infection of epithelial cells in the state of 
terminal differentiation was essential for the production of virus particles, but 
this was not true. 
The name I want to emphasize here is Jian Zhou (1957–99).124 He felt that if 
you hooked up the virus coat protein gene (L1) to a strong enough promoter 
in vaccinia virus you could actually get it expressed in quantity in cells, not 
in terminal differentiation. He had survived the cultural revolution in China 
(1966–69)125 and when he came over to the UK he was able to show that not 
only could he produce decent quantities of HPV16 L1 but he could also show 
that in mice there was a tissue-mediated immune response. When he went to 
121  For an overview, see Thomas et al. (1999).
122  Levine (1976, 1990); Basilico (1984); Matlashewski (1989).
123  See, for example, Zhou et al. (1990, 1992, 1994).
124  Dr Jian Zhou discovered the HPV VLPs (Zhou et al. (1991)) that enabled the development of the 
cervical cancer vaccines Gardasil and Cervarix. See Figure 5, note 127 and Biographical note on page 144.
125  See, for example, Unschuld (1985); Ebrey (1996).
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Australia he continued this work and was able to produce VLPs. Admittedly 
they were sloppy for the reason that I have already mentioned, because we were 
generously given the HPV isolate from zur Hausen and that was the one being 
used. But I think this was very much where the whole vaccination story begins 
and I wish that Jian was here.
[Professor Valerie Beral asked about Zhou and Ian Frazer. She had 
thought VLPs were first produced by Ian Frazer].
Crawford: Jian had been out picking melons in the fields during the cultural 
revolution in China, and when he was allowed back into the lab he started to 
put together vaccinia constructs in which various proteins were expressed, in 
positions within the vaccinia genome where the promoter activity was extremely 
strong. One of those was L1 from HPV, and he wrote to me and asked if he 
could come to the lab. After a lot of coming and going – it was also the time 
of the general postal strike in 1971, which didn’t make life any easier – he 
came over to my lab and continued this work. Jian and his wife, Xiao-yi Sun, 
Figure 5: Dr Jian Zhou (1957–99) in Dr Lionel Crawford’s  
laboratory, Cambridge, c. 1989. 
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were used to working extremely hard and doing everything for themselves, they 
worked like crazy and moved fast. So, to my mind, Jian was the person who was 
able to generate substantial amounts of L1, although not at this stage as virus-
like. He also felt that the important thing was not to get humoral immunity, 
which you can get with bacterially produced L1, but also to put it into mice to 
get cytotoxic T cells, which he did. 
Ian Frazer was in Margaret Stanley’s lab next door during this time and we were 
having great difficulty in getting any sort of guarantee that we were going to get 
a passport for Jian since the Home Office wouldn’t do anything. They said he 
could apply after several years’ residence and that they would think about it. With 
the state of politics in China, he really needed a passport. Because the Australian 
authorities were much more flexible about this, he felt that he should get himself 
an Australian passport and be free to go wherever the good science was. When 
he got to Brisbane he continued that work and was able to produce pictures of 
VLPs, which sedimented in about the right region. They were clearly sloppy; 
they weren’t really nice. Papillomaviruses are extremely pretty, they are beautiful 
things, but his were far from beautiful. They had all the main requirements, 
and as soon as you changed over the system, used a different sequence, without 
the assembly lesion, then you started getting good quantities of good particles. 
Other groups in the US also did similar things with papillomaviruses in all sorts 
of other systems.126 I think the important breakthrough was the idea that if you 
put the L1 gene behind a really strong promoter, all the other requirements 
could be forgotten. And that turns it into a practical possibility. My feeling is – 
again I suppose I am disagreeing – that screening and everything else is all very 
well when you can afford it, but the vaccination of boys and girls worldwide 
seems to me to be the way to go in the long term, to get herd immunity at the 
stage of not being virus-infected, rather than becoming virus infected and then 
catching it at the eleventh hour or so. 
[Professor Valerie Beral asked Dr Lionel Crawford for clarification about 
who discovered VLPs, which was the breakthrough that led to the HPV 
vaccine.]
Crawford: Jian Zhou.
Cubie: I am so delighted that you have said all those things about Jian. He 
certainly was a very important person and I was privileged to be the person 
who was chairing a session, again at one of the international meetings, where 
126  University of Rochester, Georgetown University and the National Cancer Institute. See also note 127.
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Jian presented his first revelation in 1991 in Seattle. Indeed, I have often been 
chased by the patent attorneys to give the exact timing of that presentation, and 
therefore from the historical point of view it was a very important thing to be 
associated with.127 
Crawford: It was brilliant and that’s why I have made such a point of it. Because, 
I think, one needs to acknowledge the people – in spite of all the difficulties and 
all the interference, political and otherwise – who knew what was important, 
and did it. 
Stanley: Lionel is absolutely right. I have come back from Australia where we 
held the ninth anniversary of Jian’s death (2008), and we really talked a lot 
about this.128 I think Jian did something incredibly important and he drove 
it; he showed the particle and that there was activity. People had made VLPs 
for other viruses; in fact, the hepatitis B vaccine, which was developed and is 
being administered, is actually a VLP-like structure. So there were other people 
thinking about it and doing it. The baculovirus expression system for HPV 
was started in a PhD by Bob Rose in Rochester in the late 1980s,129 but Jian 
was the first person to actually publish and show a VLP.130 I think it needs to be 
recognized that the intellectual discussion and drive originated in Lionel’s lab, 
and perhaps that hasn’t been given the recognition it should.131
McCluggage: Can we move on to immune responses to HPV?
Stanley: Immune responses to HPV languished for a long time and it’s 
important to say that pretty well everything we could understand about the 
immune response to papillomaviruses came from animal viruses. If you think 
about it, the first demonstration that a vaccine would work was done in 1937 
127  For the 2007 decision of the US Court of Appeals for federal circuit 2006-1154, interference no. 
104,776, see www.cafc.uscourts.gov/opinions/06-1154.pdf (visited 6 October 2009). The work of 
Zhou et al. (1991) was not disputed. See also McNeil (2006). 
128  A memorial volume from that meeting is freely available at www.scribd.com/doc/2740521/zhou-
jianprefaces-Etc (visited 23 April 2009).
129  Rose et al. (1994a and b).
130  Zhou et al. (1992).
131  Dr Lionel Crawford FRS was made an honorary member of the Biochemical Society in 2004 and awarded 
the Royal Society’s Gabor medal in 2005 for his work on the small DNA tumour viruses, specifically the 
papova virus group, papilloma, polyoma and SV40. For a description of his work, see www.biochemist.org/
bio/02606/0063/026060063.pdf (visited 27 October 2009).
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by Richard Shope, with the cotton-tail rabbit papillomavirus (CRPV).132 The 
reason why Shope could do it was that you make a lot of virus in the cotton-tail 
rabbit, and so you could always extract the virus, which was pure, so you could 
challenge animals and show that the virus was infectious and would generate 
lesions. You could do the classic neutralization assays, which are the meat and 
drink of the virologist. In other words, have you generated an antibody response 
which will neutralize the virus and prevent it from infecting? You could do 
that in rabbits and cows. In 1937 Shope did a classic experiment. He took 
cotton-tail rabbit papillomavirus and he immunized the animal systemically. In 
other words, he infected intramuscularly. Not surprisingly, the animals didn’t 
develop papillomaviruses, because you have to infect the skin if you are going 
to generate a papillomavirus lesion or wart. Even though the animals didn’t 
make warts, they generated antibodies and Shope could show that this was 
neutralizing antibody in a classic method. What he then did was to take his 
immunized animals and tried to challenge them with virus. The immunized 
animals did not get warts, the non-immunized animals did. Now that is a classic 
experiment. It shows that if you can generate a neutralizing antibody, you will 
prevent infection with the virus.
You had to wait for the VLPs before the production of properly folded protein, 
because you have to have the protein folded to generate neutralizing antibodies. 
It took from 1937 to 1991 before the reagents were around to be able to test, 
if you like, the Shope experiment with HPV. The serology of HPV was useless 
until 1991, because we didn’t have the proper reagents to measure circulating 
antibodies, so we couldn’t do the standard things you would expect to do: 
looking at serum responses, antibody responses, to HPV. The other arm of 
the immune system, of course, cell-mediated immunity, was easier to attack, 
in the sense that we could make the proteins, we could make peptides and 
so we could start to ask questions about whether there were cytotoxic T-cell 
responses, whether it was a standard type of cell-mediated immune response 
to viruses, in other words mediated by CD8 T-cells. Here again, the virus was 
very difficult, because systemic responses to papillomaviruses turned out to be 
almost undetectable. Everybody struggled like mad in the 1980s, particularly to 
demonstrate that you could have a systemic response to HPV, either in terms of 
antibody, or in terms of T-cell. The antibody story took off as soon as we had 
VLPs, because you then had the right thing to measure. We are still struggling 
132  Shope (1937). 
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in 2008 with the cell-mediated response to HPV. We know it’s important, we 
know the clearance of lesions is regulated by CD4 TH1-type responses, we still 
don’t know what the primary cellular immune response to the virus-infected 
cell is. There are only two things you can say: that prophylactic vaccination 
works, because it has been demonstrated, but immunotherapy – which is the 
other thing that people want to generate – is very difficult because we don’t 
understand how you clear the virus. 
Campo: If I can take up this last point and continue with it. The strange thing 
is that therapy, therapeutic vaccination, works in the animal system: it works 
in the rabbit, it works in the cow, it works in the dog. There is something 
that we do not know about HPV in humans, which has prevented an effective 
therapeutic vaccination in humans. Every time we hear of a new trial: ‘Yes, it 
works; it’s very promising.’ We have to continue. But still it is nothing like a 
preventive vaccine, the prophylactic vaccine which we are talking about that 
is 100 per cent effective. Any therapeutic vaccine against HPV is not as good 
as therapeutic vaccines against animal papillomaviruses, would you say? You 
[Margaret Stanley] have done therapy in the dog, we have done therapy in the 
cow and it works.133
Stanley: The trouble is that the therapeutic approach in humans is always 
targeted to precancerous lesions and therefore it becomes an anticancer vaccine 
rather than a therapeutic vaccine against a virus infection.
Cubie: There’s another dimension to looking at immune responses, and that’s 
clearly in epidemiological studies in large numbers. As we go towards the 
introduction of the vaccination and a lot of what we were talking about earlier, 
about the cytology and the colposcopy, I think it’s really important to know 
how ubiquitous these papillomaviruses are, and, as Margaret said, once the 
VLPs were available we could do some extended serological work. Margaret 
and I worked on a group of children and found an incidence of antibodies to 
HPV16, not a very high incidence, about 7 per cent, compared with about 50 
per cent of the kids having antibodies to the skin types.134 Now, to me, that 
is a really important thing, because although the viruses that we are talking 
about in relation to cervical disease are being considered as sexually transmitted 
viruses, and the virus is undoubtedly usually sexually transmitted, it is possible 
to pick up that infection – whether it ever progresses to pathological disease – 
133  Campo et al. (1993); Moore et al. (2003).
134  Cubie et al. (1998).
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by nonsexual routes. It was serology as well as DNA detection that was able to 
show that.135
McCluggage: We are going to move on to Professor Peto, who is going to talk 
about the epidemiology, natural history and importance of HPV.
Peto: It was clear to everybody who was interested in HPV by about 1985 or 
1986, that this was the cause of cervical cancer. It took us ten years to persuade 
the rest of the world, and a lot of clinicians were still sceptical until quite recently. 
It’s extraordinary how suddenly things changed. Dulcie Coleman and I set up a 
cohort of 50 000 women in Manchester, and similar studies were done by many 
other people.136 These large, population-based studies of women undergoing 
routine screening showed that about 20 per cent of women aged 20–24 had 
oncogenic HPV, not HPV6/HPV11, but the oncogenic types. It really was rather 
extraordinary. And it also became clear from such studies that most of these were 
transient infections, implying that something of the order of 50 per cent of the 
British female population were being infected with the virus that causes cervical 
cancer by the time they were 30. Everybody in this room knew this for 20 years, 
but it didn’t become generally known until five years ago.137 Those studies also 
showed the relationship between HPV and CIN3, although the relationship 
between HPV and cancer is more difficult to demonstrate in prospective studies 
because you have to wait so long and have so many people in the study. Ciaran 
Woodman described it as a soundbite, but in our cohort,138 the cumulative risk 
of CIN3 in women with high-risk HPV and normal cytology was 28 per cent 
after 14 years.139 That’s why I questioned Lionel’s comment that transformation 
is irrelevant to natural history, at least for HPV16. At that level I think it could 
appreciably affect viral evolution. Anyway, studies of that sort demonstrated the 
prevalence of HPV, but the fact that most infections disappear within two or 
135  Professor Heather Cubie wrote: ‘Probably the most relevant work came from Drs Jenny Best and John 
Cason working at St Thomas’ Hospital in studies on primary school children. Also work done in South 
Africa by Dr Dianne Marais, and by Dr Stina Syrjänen in Finland on family transmission studies, would 
also be useful.’ Letter to Mrs Lois Reynolds, 9 September 2009. See Rice et al. (1999); Marais et al. (1997); 
Syrjänen and Puranen (2000).
136  See also Wakefield et al. (1973).
137  Zimet et al. (2006); Savard (2006).
138  Peto et al. (2004b).
139  Professor Julian Peto wrote: ‘The CIN3 risk is much higher for HPV16 than for other high-risk types 
and the 28 per cent doesn’t include CIN3 diagnosed at entry in cytologically abnormal women.’ E-mail to 
Mrs Lois Reynolds, 5 November 2009.
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three years is still slightly mysterious. Everybody has always had the idea that 
these were underlying chronic infections and nothing to worry about. 
Something which has emerged quite recently is that the progression to high-grade 
disease appears to happen much more rapidly than was previously assumed. It 
may actually develop within two or three years, or not at all, as a consequence 
of recent infection. As we are only going up to 2000 in this Witness Seminar 
and this evidence has appeared in the last eight years, I think that the defects in 
cytology historically were really very considerable. The progressive improvement 
in cytology, particularly with re-training together with the introduction of LBC, 
has raised the sensitivity of cytology to about 95 per cent for detecting CIN3. It 
used to be less than 50 per cent in a lot of places. In the surveys that Jack Cuzick 
did in various centres around Europe, the sensitivities varied from about 30 per 
cent to 80 per cent not so long ago. Now it is over 90 per cent and there’s very 
little difference between the sensitivity of HPV testing and cytology. CIN3s 
were often missed by screening, so you used to have to screen women again and 
again so that they were picked up eventually. Modern cytology is extraordinarily 
sensitive. We detected about 300 CIN3s at entry in ‘A Randomized Trial In 
Screening To Improve Cytology’ (ARTISTIC) trial, and we only detected ten 
extra CIN3s by testing everybody for HPV and colposcoping women still 
positive a year later.140 So my view of the natural history of HPV has changed 
quite dramatically in the last five years. The improvements in cytology that have 
taken place quite recently have revealed a very different pattern from what we 
thought.
Professor Peter Sasieni: Rather than debating the natural history with you, 
here is an anecdote on the history. I was asked to give a talk at the Royal College 
of Obstetricians and Gynaecologists in the mid-to-late 1990s, I don’t remember 
exactly when. I think it was David Luesley who was chairing it and decided at the 
end of it to say: ‘Let’s take a vote to see who believes that human papillomavirus 
is the cause of cervical cancer?’ I lost the vote. It wasn’t overwhelming, but I 
think about 60 per cent of the obstetricians and gynaecologists in the audience 
did not believe then that HPV was the cause of cervical cancer. It’s interesting, 
because you were saying earlier, Albert, about koilocytes and HPV morphological 
changes, and I think that for that audience it was one of the reasons why they 
didn’t believe that HPV was the cause. Because they were so used to seeing 
reports of HPV changes on smears, and knowing that it wasn’t particularly 
relevant to high-grade disease, high-grade CIN, so although it was important, 
140  Sargent et al. (ARTISTIC study group) (2008).
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the actual labelling of koilocytes as HPV changes could have had a detrimental 
effect, in terms of convincing most gynaecologists that HPV was the cause.
Jenkins: I think it is only since vaccination has begun to be studied clinically 
and to be promoted that the general public has really begun to accept, and I 
would include in that the vast majority of medical professionals, outside the 
small number of cognoscenti, that HPV is the causal agent of cervical cancer. 
Again, another personal statement: my daughter was taught in medical school, 
about five years ago, that HPV was thought by some people to be associated 
with cervical cancer, but nobody was sure about it. She came and questioned 
me on this, about what I had been doing for the last 20 years. These things did 
go on.
Singer: Patrick Walker failed to remember that we, along with Dennis McCance, 
wrote an editorial for the BMJ, ‘Genital wart virus infection: nuisance or 
potentially lethal?’141 That was more than 20 years ago, and, like you, I was 
ambushed at the Royal College of Obstetrics and Gynaecology in a 1988 debate 
entitled ‘More people live off than die from HPV’.142 That was less than 20 years 
ago, and 75 per cent of the audience believed that more people lived off HPV 
than died from it.
Peto: If you want to mention heroes in the history of HPV, Jan Walboomers, 
who unfortunately is also dead, was another extraordinary man. In the study 
which we initiated with the International Agency for Research on Cancer 
(IARC, part of the WHO), we collected cervical cancer specimens from nearly 
1000 people in 22 different countries. They were looked at using the standard 
techniques for HPV detection and 93 per cent contained it. Jan re-analysed the 
negative samples and demonstrated that they all contained HPV. We finished 
up with only two out of 930 cancers that HPV was not isolated from. Jan’s 
analysis was absolutely decisive in showing that HPV is present in essentially 
100 per cent of cancers.143 
McCluggage: The next session is about the UK national screening programme. 
I know there are several people from overseas and we would be very glad if they 
were able to comment on screening in other countries, but first Tony Miller will 
talk about evidence as to when screening works and when it does not.
141  Singer et al. (1984); see also Singer and McCance (1985).
142  Kitchener (1988).
143  Walboomers et al. (1999).
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Miller: Screening works when you get a high proportion of the at-risk 
population involved in screening. That, indeed, had been one of the big issues 
in this country (from our perception outside of the country). We were looking 
at this, as Jocelyn said earlier, in relation to the fact that Finland had initiated 
a programme in women aged 30 to 54 and achieved very high compliance, a 
most successful programme. Five-yearly screening had as much impact as in the 
US and Canada, where we had largely annual screening – and the reduction in 
mortality has been the same, 80 per cent in the US and Canada, 80 per cent in 
Finland, contrasting also with other Scandinavian countries, and with Norway 
particularly.144 I think what became clear from outside as well as from what was 
done here, is that if you made a big impact on the population and invited the 
right sort of people to come in – and in fact I believe that the genius in this 
country was to use the NHS register for that purpose – it called in the women 
and you had the impact. I don’t know how many people have looked at the 
international contrasts, but the contrasts between Finland, Canada, the US and 
the UK is the separation that occurred in the reduction, and the area between 
the curves, when the UK finally got its act together and the mortality came 
down. So you had this great gap between these countries, when mortality had 
not fallen in the UK, and when essentially a lot of women died as a result of not 
bringing forward screening.
I would like to come back to this issue of cytology sensitivity. It may well be true 
that there were some laboratories in the US, and maybe in the UK, which had 
30 per cent sensitivity. In British Columbia, where we made some very good 
estimates, it was 75 per cent. Now 75 per cent is not what Julian said, he was 
talking about 95 per cent. But 75 per cent in the context of the amount of 
screening that was done clearly resulted in detecting the majority of the disease, 
which is progressive. The only other point I think I need to make is about when 
screening did not work, that there is still in every country this great divide between 
those whom we are able to bring to screening, and those we are not. The fact 
that we have a plateau in nearly all countries in terms of reduction of mortality, 
particularly in North America, has been because we haven’t been able to bring 
recent migrants and people in the lower social classes into the programme. That’s 
a lesson that I think has got to be borne in mind in terms of vaccination. When 
you hear in reports, as we have recently, that you only get 70 per cent compliance, 
that is 70 per cent of the 70 per cent effectiveness, and you are then below 50 per 
cent. So, I think we have to be extremely cautious when we look at this. 
144  Hakama (1982); see also note 39.
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I know we are not meant to go beyond 2000, but I want to make the point that 
we all have to bear in mind – and we are thinking about this very hard at the 
moment in Canada – that we have to set out our programmes for the future, 
ensuring that the vaccinated women get screened appropriately, and ensuring 
that the unvaccinated women still continue to get screened. So screening works 
when the women at risk are screened. And that is what you have got to do to 
ensure a successful programme. 
Duncan: The Walton Report came out in 1976, and, of course, it was slightly 
counter-productive, because the women could select themselves whether they 
were high-risk or low-risk and be screened with a frequency which was different 
for the two categories.145 There was a slight blip because all screening went down, 
because nobody wanted to point a finger at themselves, and say: ‘I am “high-
risk”.’ We have had difficulties in Scotland recently with younger women who 
are not coming for screening. It’s a bit like HIV and all the protection for that. 
It’s almost like wanton risk-taking when it is not due to ignorance. So, younger 
women are not coming for screening.146 
We did look at a rural population and an urban population several years ago, 
trying to identify why women were not being screened. These were women 
who were approached up to eight times to find out why they were not coming. 
Many of them had been informed, or were well informed, and decided that they 
themselves were not at any significant risk. And so it’s quite interesting how 
people absent themselves from the screening programme. 
Sasieni: Of course, if you don’t screen a woman, you are not going to do any 
good in terms of preventing cancer, but it’s not enough to do a screening test.147 
As has been seen all over the world, it has to be an integrated programme. You 
have got to make sure that the women get the results of the smear, which doesn’t 
happen in many cases. You have got to make sure that treatment is available, 
which doesn’t always happen. In parts of Latin America, something like 80 per 
cent of women had a smear in the last three years. But if they have an abnormal 
smear, there is no treatment facility for them. They would have to fly to a major 
city to get treatment, which they can’t do, so it’s a total waste of time doing the 
smear tests. The quality of the smears is really poor, particularly because there 
are high rates of infection. So when you are looking on a global scale, there 
145  See note 48.
146  Cockcroft (2009).
147  Sasieni et al. (1996). 
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are a lot of reasons, a lot of factors, which are critical to making a screening 
programme work. 
As Margaret Wolfendale is here we should think about the smear-taking 
device.148 The extended tip spatula made a big difference in terms of the quality 
of the smears, and what you could detect: the Aylesbury spatula and a good 
laboratory. 
I think that there are a lot of other factors. Of course, when you are not covering 
the whole population you cannot have a big impact. That was the big difference 
between Norway and Finland because, I think, they were taking a similar 
number of smears, but in Norway it was the same women who were being 
screened every year and in Finland they were making sure that they had very 
high coverage with five-yearly screening. So that is important. There is so much 
more to cervical screening than doing a smear test.
Herbert: I quite agree with what Peter Sasieni said. If there isn’t good quality in 
all parts of the programme, it won’t be effective. May I say two things: the first 
about Finland. Screening every five years from age 30–55 was always attractive 
to people organizing programmes elsewhere, but in Finland they do not register 
opportunistic smears – more than 50 per cent of smears were taken outside 
the organized programme.149 So a lot of women would have been screened in 
148  Wolfendale et al. (1987); see in particular page 33 and Figure 6 above.
149  Hakama (1990).
Figure 6: Three Aylesbury spatulas and one Ayre spatula, 2009. 
The Ayre was the Department of Health spatula, replaced as the spatula of choice  
by the Aylesbury from 1984 onwards. 
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their twenties and might have had CIN3 treated. You can’t assume from the 
programme in Finland that screening every five years between the ages of 30–55 
is enough, because that was not what happened in practice. 
The other point I want to make is that people may think that screening has had 
no effect when the risk of disease had changed.150 All through the 1970s and 
1980s, there were around 4000 cancers and 2000 deaths in England and Wales, 
and people said that screening hadn’t made any difference at all. But if you look at 
CIN3 rates, there were increasing numbers of women being successfully treated 
and those women were at lower risk of getting cancer later in life. Because there 
was a younger birth cohort at greater risk and an older one in whom screening 
was to some extent working, it looked as though there was no effect. That is still 
happening in some places in Eastern Europe. Recently I showed the English 
figures for cancer incidence with the Czech figures superimposed over them and 
they are very similar to ours in 1985, when incidence was increasing.151 Screening 
may appear not to be working because the cancer rates are unchanged, but its 
effect depends on whether the risk of disease was changing.
Chamberlain: I wanted to take up something that Peter Sasieni said about 
the lack of adequate treatment. I am quite surprised at this historical meeting 
that nobody has mentioned the New Zealand experience, where there was a 
gynaecologist called Herbert Green, who believed that screening was unnecessary 
because he maintained that precancerous changes did not progress, and so he 
set out to prove it by not treating women with what was then called cervical 
carcinoma in situ.152 I actually met him once when I was working as a very 
junior assistant to Max Wilson, whom some of you will remember as one of the 
Department of Health people who argued early on for screening – Wilson of 
Wilson and Jungner’s ‘ten principles of screening’, this spelled out the criteria 
needed for screening to be successful and was published way back in the early 
1960s or maybe late 1950s. Anyway, Herbert Green came to see Max Wilson 
to tell him about his plans, and Max said: ‘That’s fine, so long as you do it as 
a randomized controlled trial comparing your untreated group with a treated 
group as the controls, with stopping rules and a data monitoring committee, 
so that everything is above board.’ Had this actually happened, we would have 
150  Draper and Cook (1983).
151  Data from Rob (2007). See also cancer registration statistics at: www.statistics.gov.uk/StatBase/Product.
asp?vlnk=7720 (visited 23 July 2009).
152  Cartwright (1988); Jones (2009).
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known the natural history of carcinoma in situ and of all CIN much, much 
sooner and more clearly than we do even today. Unfortunately Green didn’t 
have a control group, and lots of women in New Zealand went on to develop 
cervical cancer unnecessarily because of this.153 
Peto: David Skegg in New Zealand has updated the follow-up on that cohort, 
and it is about to be published.154
[Professor Valerie Beral said a major paper on the natural history of 
cervical neoplasia was published in Lancet Oncology in April.]
Peto: Forty per cent of untreated women with CIN3 develop cancer. So it is 
going to be shown at last.
Miller: I agree absolutely with what Peter Sasieni said; I should have said it 
myself. I want to come back though to the Finnish experience. The Finns have 
done quite a lot of good, looking at the impact of opportunistic screening versus 
their organized programme and there’s no question that the opportunistic 
screening is not very important, because it’s largely given to women who are 
outside the age range you want to get at. Let’s face it, there’s absolutely no 
point in starting screening at the age of 18, 19, 20. And they published this.155 
So, it is the organized programme which has had the impact, rather than the 
opportunistic screening. In terms of how far you can get away with five-yearly 
versus three-yearly or more frequent screening, I think the natural history we 
gathered from British Columbia was useful; Nick Day essentially looked at this 
and gave an answer to that many years ago.156 There’s no question that three-
yearly screening was optimal and five-yearly screening still highly effective. I 
hope we don’t go away with another impression, and some recent models done 
by Sue Goldie essentially confirm that.157 
153  For discussion of ten US surveys, see Wilson (1961); Wilson and Jungner (1968). For the ten principles 
of screening, see Glossary, pages 151–2. 
154  McCredie et al. (2008).
155  Anttila et al. (2004); Barnabas et al. (2006). England withdrew cervical screening to the age range 20–24 
in 2004, as a result of Sasieni et al. (2003), although screening of this age range continues in Scotland and 
Wales. See also Law et al. (1999); McGahan et al. (2001). Professor Anthony Miller wrote: ‘There is not 
a direct Finnish assessment of age of start, it is just that they started at age 35 and this was as effective as 
programs in North America starting at 18–20.’ E-mail to Mrs Lois Reynolds, 5 September 2009.
156  See IARC Working Group on evaluation of cervical cancer screening programmes (1986).
157  Stout et al. (2008); Garnett et al. (2006); Goldie et al. (2001, 2004). 
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Wolfendale: May I come back to what Amanda Herbert was saying about the 
risk? If you want to stop the growth of cervical cancer and if there is a higher risk 
of cervical cancer in the younger age group, then if the risk of cervical cancer 
in younger women is increasing, it is then very difficult in the early years of 
screening to reduce the overall incidence of cervical cancer. In the 1970s Martin 
Usherwood and I saw a very large increase in CIN3 in our patients in Aylesbury, 
in a population we had studied and screened since the early 1960s. We showed 
a tremendous increase in CIN3 very clearly and we felt that, although we were 
having great trouble in actually reducing the cervical cancer rate, we were in fact 
holding back what could essentially have been an epidemic.158 
Cuzick: Coming back on the question of when screening works: I think it 
emphasizes the need for continual monitoring of the screening programmes 
and not process monitoring of the detection of cytological abnormalities, but, 
like any large-scale process, monitor it by actually looking at the failures. That 
means going back and carefully looking at every case who gets cervix cancer 
and determining why the programme failed. Was it lack of coverage? Was it 
an abnormality that was not picked up? Or was there a normal screening and 
the test did not detect any abnormality? Any programme that’s going to be 
successful has to maintain this long-term monitoring function.
Herbert: We are doing a great deal of monitoring now. We should face the 
fact that peak incidence of invasive cancer is now in women aged between 
35–39; 2005 was the first year when it was higher than in women over 60. In 
my experience, something like 70 per cent of those cancers in women in their 
twenties and thirties are screen-detected early cancers, which is an additional 
benefit of screening. I quite agree with Peter Sasieni that most of these young 
women have already been screened. Most of them are interval cancers.159 There 
are fewer opportunities for preventing a cancer that develops at age 35 than at 
age 50, and a single smear may not detect every abnormality. If you go back over 
the history of the women with cancer who have previously been screened, there 
are quite a number with evidence of CIN3 fairly recently. It might have been 
158  Wolfendale et al. (1983); Peto et al. (2004a) calculated that cervical screening costs about £150 million 
per year in England and would prevent about 4500 deaths per year. The overall cost was thus about £36 000 
per life saved and £18 000 per cancer prevented, comparing all screening against none.
159  Dr Amanda Herbert wrote: ‘Sasieni et al. (2003) and Herbert et al. (2009) both show that cancers in 
young women are often “interval cancers”. Herbert et al. (2009) also show a strong association between 
interval cancers, younger age groups and early stage screen-detected cancers.’ Note on draft transcript, 
1 September 2009.
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missed on a smear – while others had inadequate smears, or had failed to have 
their latest smear or had one six years rather than three years before. Some did 
not attend for a biopsy, or had treatment and didn’t come back for follow-up. It 
tends to be CIN3 rather than CIN2 that was missed or not treated, often within 
the previous three or four years’ diagnosis. So I don’t think in a community like 
ours, when we have got to a stage when we are detecting early cancer and saving 
these young women’s lives, we can possibly not screen them in the preceding 
decade of life without increasing the rate of more advanced cancer.160
[Professor Valerie Beral commented that cervical screening in the UK 
today is working very well.]
Sasieni: I agree that the UK screening programme is extremely effective, working 
very well, but to say that it is preventing 90 per cent of cervical cancer in the 
UK is not really realistic, if coverage is only 80 per cent. If you look at the 
proportion of women aged 25 to 64 screened at least once within the last ten 
or 15 years it goes up to over 90 per cent, but that’s only for those aged 25 to 
64 years. There isn’t huge evidence that it is preventing cancer in the over-70s. 
I think, realistically, cervical cancer incidence would be two and a half times 
higher than it is, and mortality would probably be three or four times higher, 
but not ten times higher. It is very, very effective.
Herbert: If you look at the incidence in one of those first high-risk cohorts, 
born, say, in 1950, the ones who had increasing cancer rates during the 1980s, 
incidence was more than 30 per 100 000 at age 35–39. Their incidence had gone 
down 15 years later by about 70 per cent, to something like 10 per 100 000, when 
it would be expected to have increased towards a plateau, as Julian was saying. 
Peter has published a graph of mortality in different birth cohorts showing 
much the same thing.161 Treating CIN3 and early cancer prevents invasive or 
more advanced cancer later in life. Women in their fifties and sixties now, who 
were screened when they were younger, have got a very low risk of disease.
McCluggage: We are now going to talk about the organization of a national 
programme and the screening centre.
Herbert: May I go back to when it started? As we have already heard, it was 
extremely haphazard in the 1960s, with arguments about whether it was going 
to work or not, and some of the people who were promoting screening probably 
160  Sigurdsson and Sigvaldason (2007).
161  Sasieni and Adams (1999).
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thought it was going to be more effective than it was. I think that’s undoubtedly 
true, because the enthusiasts exaggerate the benefits and there was a certain 
amount of acrimony about anybody who suggested that it wouldn’t work. That 
was said to be Cochrane’s experience, when he suggested that it might not be 
so successful and people thought he was saying something terrible.162 Of course, 
we all know now that it’s not quite as effective as it might be if every case of 
CIN3 was immediately detected and effectively treated and are well aware of the 
problems and disadvantages of screening. While in England enthusiasts were 
trying to get it going and the Department of Health was distributing circulars 
without enough money attached to them, in Aberdeen, Macgregor and Baird 
got on with setting up their own programme.163 In their 1963 article they made 
the comment that it was past the stage of needing a controlled trial. They went 
out with balloons for the children and took smears from the women. As has 
already been said, they achieved good population coverage, monitored the 
outcome (using punch cards rather than computers), published a case-control 
study in 1985 and provided evidence in the UK that screening worked.164 
Meanwhile, back in England, where the government was reluctant to pay, some 
highly effective screening was being carried out. CIN3 rates show how much 
the likes of Liz Mackenzie, Erica Wachtel and Dulcie Coleman were achieving, 
although many of the smears were taken opportunistically from young women. 
We shouldn’t only look at mortality and incidence rates, we should also look 
at CIN3 rates, which were available from 1971 and went up at a much higher 
rate than the additional number of women screened.165 Margaret Wolfendale 
showed an increase in severe dyskaryosis on smears in young women,166 which 
was similar to the increases that were being reported in CIN3 as well as invasive 
cancer incidence and mortality, which gave us among the highest mortality 
162  Professor Archie Cochrane wrote: ‘I remember giving a lecture in Cardiff on screening in 1967 into 
which I introduced the (as I thought) innocuous phrase “I know of no hard evidence, at present, that cervical 
smears are effective”. To my surprise I was pilloried in the local Welsh press, who quoted many anonymous 
colleagues who thought me a “dangerous heretic” and I received many abusive letters, some from colleagues.’ 
Cochrane (1972): 26–7; see also Bryder (2008); note 44. For a review of screening procedures, see Cochrane 
and Holland (1971); Wilson et al. (1971); Macgregor and Teper (1974).
163  Macgregor and Baird (1963).
164  Macgregor et al. (1985).
165  Herbert (2000).
166  Wolfendale et al. (1983).
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anywhere in the world in women under 35.167 All that happened in the 1980s 
when it seemed as though screening wasn’t working at all; hence Knox’s article 
in the Lancet.168 It was terribly badly organized and quality control was poor. 
I remember doing a small study in 1988 when I had always been told that 90 
per cent of women with cancer had never been screened (it was a sort of old 
cytologist’s tale). I looked at our cases and saw that, yes, that was true if they 
were over 50, but if they were under 50, about half of them had been screened. 
When we looked back at the smears, there were all these small dyskaryotic 
cells, glandular abnormalities and things that were not being picked up.169 We 
massively improved our quality control, which Muir Gray facilitated before the 
screening programme began.170 
I think much of the success of screening since 1988 was due to quality control. 
Of course, there was the introduction of a computerized national register, so 
that all women aged 20–64 could be invited every five years, including those 
who had never been screened. With the old system there was no way of ‘calling’ 
women, it was only ‘recall’, so you never got the ones who didn’t turn up in the 
first place. But particularly we started re-screening negative smears, improved 
training of cytologists, BMS and pathologists and, for the first time, had 
standards for comparing practice between laboratories,171 as well as guidelines 
for ‘fail-safe’ follow-up of women with abnormalities.172 The colposcopists 
and cytologists got together and discussed discrepancies and, in Southampton 
where I was working, the critical thing for us was to look back at the smears of 
the women who had got cancer and CIN3 and that’s when we saw what had 
been missed.
167  Peto et al. (2004a): 252.
168  Anon. (1985); see also Knox (1966).
169  Herbert et al. (2009).
170  Dr Elizabeth Mackenzie wrote: ‘These local programmes were properly coordinated finally by the 
Department of Health, first by the charismatic Dr Muir Gray prior to becoming part of Julietta Patnick’s 
breast and cervical screening empire. It is now, in my humble opinion, the most successful national screening 
programme. My choice of specialty was enjoyable and fulfilling and was ideally suited to a peripatetic 
existence. My only regret, however, was that it was a struggle to get our specialty recognized in the early days 
and, as a consequence, promotion to a consultant post was often pitifully slow.’ Note on draft transcript, 
26 November 2008. See Gray (1990). 
171  Chaired by Dr Amanda Herbert and together with Dr Jane Johnson and Mrs Julietta Patnick, led a 
Royal College of Pathologists, BSCC, NHSCSP working party (RCPath et al. (1995), also known an ABC).
172  Pike and Chamberlain (1992).
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There is a well-known graph in a BMJ article by Quinn et al. showing that 
suddenly in 1988, the coverage went up and the incidence went down,173 but we 
know from Macgregor’s work in Aberdeen that it takes seven years for incidence 
to go down.174 It didn’t magically go down because the screening programme 
was launched. It was because of all the things that happened during the 1980s: 
the gradual increase in coverage and quality control, so that incidence eventually 
started going down. It went down in all the age groups eligible for screening, 
in what Bray called a ‘period-specific change’, seen in countries such as the UK 
when organized screening started, which was enough to cope with the cohort-
specific change.175 In the US and Canada they didn’t see an increase in cancer; 
it was only in places like Norway, New Zealand and England that there was an 
increase in invasive cancer in the 1980s. In Canada and the US, Finland and 
Scandinavia, there may have been an increase in CIN3, but not in cancer, because 
they were controlling it. So, I think that Julietta Patnick’s group and Muir Gray 
need credit, particularly for quality control, and for improving communication, 
so that colposcopists, histopathologists, everybody got together and discussed 
the problems.176 I think that cancer audit, as Jack has said, is probably one of 
the most important things to show us where things have gone wrong.177 I think 
that with what is happening now, we probably have one of the best screening 
programmes in the world.
McCluggage: Do you think anything useful will come out of the National 
Cervical Cancer Audit, which is now up and running?178
Herbert: I am working on our own cases at Guy’s and St Thomas’ at the 
moment. We are seeing two things in particular: first, that most of the cancers 
in young women are screen-detected and not all of those are microinvasive, and 
second – an interesting finding that was the same as in Southampton – that it’s 
the early screen-detected cancers that are more likely to be interval cancers. The 
173  Quinn et al. (1999).
174  Macgregor et al. (1994).
175  Bray et al. (2005a).
176  See Patnick (ed.) (2008b). 
177  Dr Amanda Herbert wrote: ‘Robertson and Woodend (1993) were among the first to look back at 
smears from women who developed cancer and pointed out that what has more recently been introduced 
as “rapid review” of negative and inadequate smears might allow many of these abnormalities to be noticed 
by a second screener.’ Note on draft transcript, 1 September 2009.
178  The National Cervical Cancer Audit was introduced in 2007. See Patnick (ed.) (2006).
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audit is showing, as Valerie Beral says, that we are down to rock bottom.179 We 
are down to the ones which you can’t prevent, but may detect. 
Chamberlain: I agree with what Amanda said about the importance of quality 
control and its contribution to the success of our present programme.180 But, 
even more important than laboratory-based quality control monitoring – and 
I don’t think Amanda gave quite enough emphasis to this – is the fact that 
all women in the whole country, or at least those registered with a GP, are 
now routinely invited for screening. It is this that achieves the high level of 
population coverage, which is vital. 
The template for using the NHS Central Register for cancer screening was, 
in fact, developed in the context of breast, not cervical cancer, as the method 
used in the UK Trial of Early Detection of Breast Cancer starting in 1978.181 
And subsequently in the Forrest Committee report on implementing national 
breast screening, which came out in 1986, a year before the Intercollegiate 
Cervical Screening Report,182 we recommended that this system be introduced 
nationally. In comparing the introduction of national screening for breast 
and cervical cancer in the late 1980s, Muir Gray made an amusing but very 
pertinent analogy, in which health authorities were likened to a person being 
told to knit a garment. In the case of breast cancer screening, they were given 
a clear knitting pattern, a new ball of wool and some needles, and even some 
money to pay the knitters, so all they had to do was get on with it. Whereas 
with cervical cancer screening they were presented with a worn-out 20-year-
old cardigan full of holes and they first of all had to unravel the whole thing, 
then roll up the wool, find the needles and start knitting, all without any extra 
179  Dr Amanda Herbert wrote: ‘Incidence of invasive cancer now (2005–06: figures from www.statistics.
gov.uk/StatBase/Product.asp?vlnk=7720 (visited 1 September 2009)) “peaks” in women aged 30–34 years, 
incidence in older women having declined steadily in all age groups screened. According to our experience 
in London (unpublished) and Southampton (Herbert et al. (2009)), cancers in these young women tend to 
be early-stage screen-detected interval cancers in women little older than the 20-fold higher peak (aged 25–
29 years) of incidence of CIN3, which is recorded on the same statistics website.’ Note on draft transcript, 
1 September 2009.
180  Professor Jocelyn Chamberlain wrote: ‘Indeed, Catherine Pike and I wrote one of the guidelines on this 
put out by the NHS Cervical Screening Programme in 1991.’ Note on draft transcript, 31 July 2008. See 
Pike and Chamberlain (1992).
181  See, for example, UK Trial of Early Detection of Breast Cancer Group (1981).
182  Department of Health and Social Security (1986b); NHS Breast Screening Programme (1991). See also 
Sutton (1997).
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resources.183 It is to the great credit of all the disciplines involved that it is now 
so successful. 
Cuzick: A brief comment: I think a crucial issue was this transformation from 
a policy to a programme before this reorganization. Screening was a policy 
and not a programme. In our 1984 paper we outlined the requirements for a 
programme, including that somebody needs to be in charge of a fail-safe system 
and monitor overall performance.184 This, I think, did actually outline in print 
the issues that many other people had enunciated in the early 1970s and laid 
down the important requirements for a programme, which I think did have an 
effect on this restructuring.
[Professor Valerie Beral said that there was evidence that screening did 
work. The CMO, Donald Acheson, had suggested putting the case for 
the prediction of cervical cancer incidence and mortality in England 
and Wales.]185
Sasieni: Historically, Julietta Patnick did not become involved in the start of 
this programme. For a number of years it was Elaine Farmery, who chaired 
the National Coordinating Committee with Muir Gray.186 It’s very difficult to 
know what was most important in improving coverage, but at the time, in the 
early 1990s, I believed, and I still believe, that the GP payments were extremely 
important. They had a payments system whereby there were much greater 
payments per smear in the practice that had at least 50 per cent coverage and 
greater still with over 80 per cent coverage.187 And, cynically, it’s amazing how 
very few people got much higher than 80 per cent, but virtually everywhere – 
well, lots and lots of places – 80 per cent was achieved, and it had a knock-on 
183  ‘Developing a breast screening programme was like knitting a cardigan at terrific speed. Developing a 
cervical screening programme will be like unravelling a cardigan, writing the pattern, knitting it again at 
terrific speed, while still wearing it.’ Dr Muir Gray talking about the late 1980s in NHS CSP (2003): 5.
184  ICRF Coordinating Committee on Cervical Screening (1984).
185  Beral and Booth (1986). 
186  ICRF Coordinating Committee on Cervical Screening (1984); Sasieni et al. (1996).
187  GPs are paid to encourage patients to participate in the cervical screening programme. The basic-
payment target, under the GP contract of 1990, was 50 per cent or more of eligible patients screened in the 
previous five-and-one-half years and a higher payment if 80 per cent or more were screened (Department 
of Health (1989)). Between April 1990 and October 1993 the percentage of general practitioners reaching 
the 80 per cent target rose from 53 per cent to 83 per cent, while the percentage achieving neither target 
decreased over the same period from 15 per cent to 3 per cent. Austoker (1994). 
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effect of actually removing people who didn’t exist from GP lists, because they 
realized that they could get paid more from reaching these screening targets, 
than from having dead people on their lists. So I think the GP payment was 
actually critical.
Coleman: I would like to dwell on that and say: ‘Yes, it did’; and one can be 
cynical about GPs responding to this system of payment, but on the other 
hand, there was tremendous cooperation from the people on the ground 
who were actually involved in the cytology service. The pathologists and the 
screeners were willing to subject themselves to testing twice a year and they still 
do this today. They have assessors who come round and test one’s competence 
to screen, right from the consultant down to the lowest level of cytoscreener.188 
You have to pass that test before you are allowed to screen. But I think that 
cooperation is quite extraordinary, because I don’t think it occurs in any other 
specialist field.
Herbert: The cancer audit shows that it isn’t all about reviewing the smears. 
I agree with Jocelyn Chamberlain that you have to look at the quality of the 
call-and-recall and also at what the GPs are saying to the patients, and not focus 
only on the lab.
Sasieni: We have heard quite a lot about this. The public health impact was 
perhaps first seen from the Finnish data. What was happening in the UK 
in the 1980s was that although cervical cancer mortality (the standardized 
mortality rate in this country) was falling by about 1.5 per cent per year and 
had been since the late 1950s, cervical cancer incidence was fairly static overall 
and was increasing rapidly in young women. That was mostly due to this 
epidemic of HPV infections with a knock-on effect on cervical cancer, which 
we have heard about, and it made it very difficult to determine what effect 
cervical screening that was being done outside of any organized programme 
was having. However you interpret that, there was a dramatic change: if you 
look at the trends around 1988 to 1990, the mortality within a few years was 
falling by something like between 4–6 per cent a year and it continued to fall 
at that sort of rate, really accelerating the decline. For the first time we were 
seeing a fall in the incidence and there was this phenomenon, which people 
have alluded to – which we called the ‘hockey stick’. If one followed a cohort 
188  See, for example, ‘Evaluation of Clinical Events (ECE): Guidance for assessors and trainees in 
histopathology’ from the Royal College of Pathologists (2008), freely available online at www.rcpath.org/
resources/pdf/histopathology_ece_guidance.pdf (visited 5 August 2009).
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of women, one had seen incidence increase with age at least until aged 50. 
After 1990, instead of their incidences increasing with age, in every single 
cohort, as the women aged, their cervical cancer rates came down. So some 
dramatic effects could be seen. 
The initial emphasis with the reorganization of the programme had been to 
monitor the process, which made sense because you can look at process measures 
very soon after starting a programme. In about 1989 or 1990, Jack Cuzick, 
Jocelyn Chamberlain and Muir Gray decided that we needed to look at the 
effectiveness of screening and we introduced these audits, to see where screening 
was failing.189 In other words, why were women getting cancer despite the fact 
that there was this screening programme. We did not want to attribute blame 
but to try to understand why these things were happening: how many deaths 
were inevitable? How many might be prevented by modifications? As people 
began to see what was going on, and why some of the cancers were occurring, 
greater emphasis was on quality assurance throughout the programme.190 
Historically, I don’t think we should be debating exactly how much cancer, 
and how many deaths were prevented by the screening programme. The exact 
numbers depend on agreeing what would have happened in the absence of 
screening and in the presence of an epidemic of HPV infection that is very 
difficult to determine accurately. Nevertheless, we all agree that there were 
substantial numbers and the UK screening programme became among the 
best in the world; it was as effective as any other, I think, and probably more 
cost-effective than most.
Patrick Walker: There were important collaborations and publications in the 
1990s. The first were by Ian Duncan in 1992 and 1997 with the publication 
of Guidelines for Clinical Practice and Programme Management, which brought 
together cytologists and colposcopists, and then David Luesley’s publication, 
Standards and Quality in Colposcopy, which for the first time started to give some 
evidence base to the quality of care.191 I think the other important thing about 
that time is that the programme became more woman-centred.192 It was realized 
189  For details of the ICRF committee members, see note 51; ICRF Coordinating Committee on Cervical 
Screening (1986); see also Sasieni et al. (1996).
190  NHS CSP (1996).
191  See notes 60 and 63. See also Luesley (ed.) (1996).
192  Marteau et al. (1990).
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for the first time that a lot of unnecessary anxieties were experienced by women 
involved in the screening programme.
Gray: I was actually going to touch upon the question of the anxiety. It played 
a very big part in the public perception of the screening programme, and in 
the way the press reported aspects of the screening programme. Anxiety was 
heightened by the increase in litigation that took place as we started looking 
back at smears and found that abnormalities had been missed.193 Lawyers became 
well aware that they could actually get very successful compensation through 
the courts. This whole aspect, I think, should be recorded as part of the history 
of the programme in the late 1980s and early 1990s. It had quite an impact on 
laboratories and on women.
McCluggage: It’s something I have thought about with the National Cervical 
Cancer Audit, looking back at all cancers, the potential for more litigation 
coming out of this. Is this something that we are going to be faced with?
Sasieni: There are different views. I think there is going to be more litigation 
generally. But there are two audit activities going on. One is that any woman 
who gets cervical cancer, and even breast cancer, is entitled to know everything 
about her screening history, and that’s been mandated by the Minister, so that’s 
the one that could potentially be used for litigation. 
I wanted to say two things historically. One is how the improvement in quality 
assurance led to more bad stories about cervical screening, and in the 1990s it 
seemed that every six months there was another story about a doctor taking a 
smear with his finger and about a lab that binned all the results. These things 
were happening because they had been happening for years and now they were 
being discovered.194 Quality assurance put a stop to those bad practices, you 
don’t get such stories very often nowadays. The other media-type issue, I am 
not so certain it was in the 1990s – Dr Szarewski could correct me – but 
the Coronation Street story, in terms of wanting to know what can be done 
with publicity, when Alma got cervical cancer, there was an increase in smears 
taken.195 In all these poster campaigns and other campaigns that many PCTs 
193  Wilson (2000); see also Bryder (2008).
194  See, for example, BBC News, UK Health: Thousands call cancer scare hotline, Wednesday, July 29, 
1998 Published at 17:03 GMT 18:03, freely available at http://news.bbc.co.uk/1/hi/health/141391.stm 
(visited 6 October 2009). 
195  Alma Halliwell, a character in the television soap opera, was diagnosed with cervical cancer in June 2001 
and died six weeks later. See Howe et al. (2002); Richardson et al. (2002).
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did, no-one ever monitored any detectable effect on screening uptake. The 
invitations had a huge effect on coverage, but the only publicity about screening 
which had been shown to have an impact was the Alma episode. 
Szarewski: It was a double-edged sword this, because we spent all of our time 
trying to make women less anxious about going for cervical screening. But, as 
Peter has said, the single most effective intervention in getting women to turn 
up for smears was the death of Alma in Coronation Street, which scared women 
out of their wits and attendance at screening shot up. It was written up in the 
BMJ and they concluded that it there was a demonstrable effect of that massive 
increase in anxiety caused by Alma’s death.196 In fact, the whole Alma story was 
extremely poorly done, because it actually couldn’t have been attributed to a 
failure of screening. But nevertheless, all of that went by the board, the women 
were scared stiff and turned up. 
McCluggage: We are going to move on to later developments and applying 
understanding of HPV.
Cubie: We started to talk earlier about some of the molecular techniques 
that had been developed in the 1980s and used in basic science and research 
situations. It’s still a jump to think of using tests and technology in a clinical 
situation and that had to wait a little bit longer. I think we owe quite a lot to 
someone who isn’t here, Attila Lörincz, who in the early 1990s was developing 
HPV hybridization methods that could be applied to clinical samples, both 
to sections and to smears.197 Attila very kindly shared his HPV protocols in 
1984/5, so I am not sure when he started doing this on clinical material, and 
I certainly went down the route of in situ hybridization for a while, because I 
am a diagnostic virologist, and basically we do cytology too. The difference was 
that we were looking for proteins in other viruses, and that’s not so different 
from looking for the nucleic acid of specific viruses by in situ hybridization. 
There were things coming together in the early 1980s which linked virology 
and pathology but also led to developments in tests that could be suitable for 
diagnostic situations. The in situ hybridization unfortunately was not sensitive 
enough and perhaps put a lot of our gynaecologist colleagues off the results that 
could be obtained from mass HPV testing. Attila worked to produce the hybrid 
capture assays that have been used widely in recent years in studies around 
196  Howe et al. (2003).
197  See, for example, Lörincz et al. (1986).
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the world.198 Actually, the technology for the hybrid capture assay is very good 
technology. It’s a hybridization system that detects nucleic acid by amplifying 
the detection signal rather than the molecular tests we all hear about every day, 
polymerase chain reaction (PCR), which amplifies the nucleic acid directly. So, 
I guess hybrid capture first hit the market in the late 1980s, version 1 (HC-I), 
which was not that sensitive, but actually probably clinically quite relevant, 
because we then worked out that you could have a test that was too sensitive if 
you were trying to relate it to clinical needs.199 That moved on to hybrid capture 
version 2 (HC-II), which everyone knows of or has read studies about.200 I guess 
the first randomized controlled trial using HC-II in the UK was the ‘HPV 
in addition to routine testing’ (HART) study, which Jack Cuzick set up with 
Anne Szarewski – I was involved as were others – that was reported in 2003 in 
the Lancet.201 In parallel with hybrid capture, other people were developing the 
PCR technique, particularly Jan Walboomers in the Amsterdam lab, and his 
colleague may talk more about this. They linked the PCR to a hybridization 
system which allowed them to type the virus. Those typing systems went 
beyond the screening possibilities of the hybrid capture assay and have given 
us tools that have been adapted by lots of companies, with commercial interest 
in competition now being fierce for different technologies, but that’s in the last 
decade, not before 2000.
Peto: A technical point on hybrid capture: it does have a false positive rate, 
something between 1–3 per cent. This is quite a serious problem in older 
women, because in older women the prevalence of HPV is only a few per cent. 
It’s a technical problem that still needs sorting out.
McCluggage: For those of us who don’t know, does HC-II pick up all 
HPV types?
Peto: It picks up all types. All the ones that matter. 
Cubie: It’s a screening test. It uses a pool of probes which cover many high-
risk genital types, and Julian is right to say that there is some cross-reactivity. 
It is not a false positive result though: these results are real HPV detection 
results, they are just not so clinically relevant. But a screening test – whether it 
198  See, for example, Castle et al. (2003); Cope et al. (1997).
199  Clavel et al. (1998).
200  See Glossary, page 148; (2003); also note 216.
201  Cuzick et al. (2003).
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is cytology, HPV, breast screening – will never be completely effective. You will 
always have an element of assessing sensitivity versus specificity, which is why it 
is very useful to have a range of other tests that allow us to go further and look at 
specific types of HPV. This happens in virology all the time – there’s a difference 
between a screening test and a diagnostic test – and whatever we do, we usually 
have both available. 
Jenkins: I think one of the important messages is that you can’t really over-
estimate the impact of HC-II in this field, can you? It’s had such a huge impact, 
not just in the US where it was introduced, but in the UK and globally, and 
I think, perhaps, its major contribution in many ways is bringing HPV into 
the market place and then bringing it out into public awareness, particularly 
through some of the rather aggressive marketing techniques that are being 
used.202 It is one of the ways in which HPV has been brought to the attention 
of the general public and I think these are important historical contributions, 
whereas the other testing systems have tended to remain much more research-
based, much more restricted to the laboratories and to the experts.
Duncan: With regard to HPV testing, perhaps its greatest contribution has not 
actually been put into practice yet, and that is the negative predictive value, 
because if you are cytologically negative and you are HPV-negative, then you 
really are negative. Now, that allows us to discharge older women, who are 
never going to develop cervical cancer, from the screening programme early. 
And that’s another aspect of the screening, because we at Dundee and Aberdeen 
have argued that it’s unethical to subject women to screening if they are not at 
any significant risk.203
Wolfendale: A very quick comment. You say older women don’t need screening. 
What about those who have new partners? 
Duncan: It’s all about fertile fields and in the older woman the cervix has 
matured. We wondered about the question of hormone replacement therapy 
and whether it would rejuvenate the cervix and create a transformation zone 
202  Professor David Jenkins wrote: ‘One of the main methods used was direct-to-consumer advertising in 
journals and television, as is allowed in the US, aimed at focusing women’s attention on sexually acquired 
HPV infection as an issue, encouraging women to ask for HPV testing at a clinic and to seek this additional 
test for extra reassurance about freedom of risk from cervical cancer. This was combined with active 
promotion among doctors in many countries at a time when the evidence remained inconclusive.’ Note on 
draft transcript, 11 September 2009.
203  Duncan (2004).
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again, but that does not appear to be the case. The cervix has matured and is no 
longer the fertile ground for malignant transformation.
[Professor Valerie Beral reiterated the point that older women with new 
partners could be at risk.]204
Jenkins: Can I make one comment here before we go off on to what is still a very 
active debate and certainly one which those of us who have been involved a lot 
in vaccination have to face almost every time we have to speak at any meeting. 
One intriguing issue is that we are only beginning to disclose the extent of 
natural protection against HPV in women who have successfully cleared an 
infection 30 years after the basic story of HPV was defined.205 We are still a long 
way from answering some of these key questions. 
Duncan: In the same population, we kept publishing the number of cases of 
CIN that we would have failed to detect if we had stopped screening women at 
the age of 50. And that’s without HPV testing. I think that if HPV testing were 
brought in above the age of 35, in conjunction with cytology, this would allow 
us to reduce the frequency of screening and stop earlier.
Szarewski: Scotland, of course, is a more Presbyterian society perhaps, and it 
may be that sexual activity is less frequent there, but I think when we are talking 
about new partners, with respect to Margaret Wolfendale’s question, I think we 
should mention that it’s more likely that the 55-year-old man decides to have 
a younger female partner, and, because he feels obliged to have sex occasionally 
with his wife, he passes on the HPV from the younger partner he’s having on 
the side to his older wife, who knows nothing about it for several years. 
Peto: A point on the natural history: up to the age of c. 45 or 50, the probability 
of finding CIN2 or CIN3 is pretty much the same; if you detect HPV, it is 
lower above the age of 50. It depends what you mean by older women. 
Sasieni: On the natural history: all the models looking at the time from CIN3 
to progression of cancer showed that CIN3 is more likely to progress in older 
women, and the older you get the more likely it is to progress. I suspect that is 
because it’s been persistent longer, and it’s the persistent CIN3 that’s most likely 
to progress. The importance of CIN3 in a woman in her fifties is probably 
much greater than the importance of CIN3 in a woman in her twenties. 
204  See also discussion on page 33. 
205  Jenkins (2006).
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Herbert: But what about women of 65 who are HPV-positive? Do they go 
on being screened for ever? If they are positive and cytology is negative, what 
happens to them?
Cuzick: There are a lot of cancers found in women over the age of 65; it is still a 
major unmet need. So, I think we need to be very cautious about dropping off 
screening too early, when there are so many cancers still occurring in these older 
women, and we are doing very little about it.
Peto: HPV testing really does solve an awful lot of problems, particularly in 
older women where a lot of abnormal smears have nothing to do with HPV or 
cervical cancer risk.
McCluggage: We are going to move on to talk about HPV testing in triage and 
screening.
Cuzick: Triage and screening is still a very active topic, so I will try to confine 
myself primarily to some historical comments, and I think much of the work 
in this area really owes a big debt to Albert Singer, who was one of the first to 
recognize the clinical potential of all of this early work, discovering that HPV is 
the cause of cervix cancer and looking for ways in which this could be used in a 
clinical context.206 I have been fortunate to work with a number of his scholars, 
starting with Michael Campion, Tony Hollingworth and Anne Szarewski (who 
is here today), on a range of studies, going back to the first study with Michael 
Campion in which it was found that women with low-grade smears that were 
HPV16-positive were more likely to have CIN3 on biopsy.207 In retrospect, I 
think that was done with very old technology, before we had PCR, before we 
had hybrid capture, low specified dot blots, and probably one of the reasons 
that study was so successful was there was a lot of cross-hybridization. HPV16 
detection would then be associated with all of these other types. Probably those 
early tests cross-hybridized with many different other high-risk types.208 
I think the field has very much benefited from improvements in technologies as 
we have moved on. With PCR and hybrid capture and discoveries from some of 
the studies, we have moved away from the triage concept of this work (originally 
done with the Campion studies) and begun to move forward, to think: ‘Can 
206  See, for example, Campion et al. (1988); Mould et al. (2000).
207  Campion et al. (1986). 
208  Professor Jack Cuzick wrote: ‘High-risk HPV types are now thought to include 16, 18, 31, 35, 39, 45, 
51, 52, 58 and 68.’ Note on draft transcript, 4 September 2009.
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this really be used in primary screening?’ The first study of screening in normal-
risk women with HPV, was the Margaret Pyke study, and again it was early 
technology. We screened for only four types (HPV16, -18, -31, and -33) and 
again were surprised at the first clear evidence that a lot of women were actually 
harbouring high-grade lesions that were negative on cytology.209 The only way 
we found out about it was to have another test that was positive that led to a 
colposcopy. That was the first indication that cytology was not as good as we 
had thought, because we had another test which was actually saying we needed 
to do colposcopy as well. That moved on then to a larger study in older women, 
the Hammersmith study, then the multi-centre HART study.210 So it’s still a 
very, very active area. We still don’t have HPV-introduced testing, even in triage, 
although I think the evidence for that is overwhelming. But if we are looking 
historically, I think a lot of that came out of the early work of Albert Singer. 
McCluggage: This story seems to have been going on for an awfully long time 
now, this argument for HPV testing in the cervical screening programme. Is 
some decision going to be made in the near future, or what is happening at 
the moment?
Cuzick: I am probably the last one to answer that, because I spent ten years 
trying to get HPV considered for primary screening, and yet it is still a research 
question. I am also perplexed by the fact that we have been so slow to take 
this forward. I think it is a finding of major importance, and we do need to 
take these new technologies and evaluate them thoroughly, but not slowly; we 
need to be moving much more quickly on this. Again, cytology was a little bit 
its own worst enemy to some extent. Clearly cytology was a good screening 
test, and it did a substantial amount of good, and we must fully acknowledge 
that, but sometimes, we do need to move on. It is an old technology and there 
probably are better ways of doing what cytology is able to achieve.211 I think 
that has been a difficult issue. We have something that works pretty darn well, 
but can we improve it with something that works a lot better? That’s always a 
hard sell.
Smith: Mr Chairman, I think I can partly answer your question. The NHS 
Cervical Screening Programme (CSP) has recently instituted what is known 
as sentinel sites, of which there are six sites in England, including my own 
209  Cuzick et al. (1995).
210  Cuzick et al. (2008); Cuzick et al., (HART) (2003).
211  See for example, Schiffman and Castle (2006).
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laboratory, the Sheffield Cervical Cytology Service.212 There they are looking at 
practical implementation of HPV testing for triage of low-grade abnormality 
and test of cure and that study commenced a few months ago.
McCluggage: So this was triage of what?
Smith: Low-grade abnormalities.
Jenkins: So why was the decision taken to have sentinel sites rather than to 
implement triage?
Smith: It is a pilot to look at the practical implementation, particularly the 
relationship of HPV with cytology.
Herbert: Can I say something about poor old cytology here? Most of the places 
that are implementing clinical trials of HPV as a primary screening test are 
using cytology triage. They still need cytology – because HPV may indicate a 
risk of CIN in the future, but cytology shows that an abnormality is present 
now. So, they do still need us; we don’t need to hand in our resignations yet.
Sasieni: To try to answer the question about ‘why’ they are operating sentinel 
sites rather than rolling it out nationwide. I was on the advisory committee 
looking at the results from the three primary pilots, two of which looked at 
HPV triage, and the results were not as clearcut as in the research studies.213 
There was a big question as to who was going to pay for the HPV testing. 
The Department of Health was saying: ‘There’s no extra money, the screening 
programme already costs us £170 million a year or something in that region, 
and that’s it’. It was Henry Kitchener’s idea,214 I think, to get a little bit of money 
in order to be able to do triage, continuing in the pilot sites and add Manchester 
and Liverpool. To make sure that it continued, everyone agreed that HPV triage 
212  The NHS CSP introduced HPV sentinel sites at six laboratories in autumn 2007 at Bristol, Northwick 
Park (Harrow), Liverpool, Manchester, Norwich and Sheffield. See www.cancerscreening.nhs.uk/cervical/
hpv-sentinel-sites.html (visited 22 July 2009).
213  See Legood et al. (2006); Moss et al. (Liquid-based Cytology/Human Papillomavirus Cervical Pilot 
Studies Group) (2006).
214  Professor Henry Kitchener, Manchester, led a trial in 2001 to investigate HPV as a primary screening 
test funded by the Health Technology Assessment (HTA) programme, at Manchester, Stockport, Wigan and 
Leigh and Salford and Trafford (Sargent et al. (2008)). The Medical Research Council (MRC) and NHS in 
England and Scotland funded ‘Trial of Management of Borderline and Other Low Grade Abnormal smears’ 
(TOMBOLA) study, headed by Professor Norman Waugh, which began in 1999. See Patnick (ed.) (2008a); 
see also note 228.
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shouldn’t stop, it needed to be rolled out in a much more controlled fashion, 
because the results were disappointing, and it was fairly easy to get enough 
money to do HPV triage in just five sites.
McCluggage: What about the experiences in other countries? Is there anything 
that we can learn from those? Has it been successful in other countries?
Miller: There’s a randomized trial ongoing in Finland. Matti Hakama has been 
very successful in arranging to evaluate new technology in a randomized fashion 
and the preliminary results seem to suggest that the peak difficulties are the 
specificity, the sensitivity in relation to the cytology is not greatly superior.215 He 
is beginning to look at the question of changing the relative light units (RLU) 
cut-off level,216 raising the level at which you declare a positive, and believes that 
in doing that he can achieve with HPV testing the relevant specificity associated 
with cytology. In British Columbia the decision has been taken to run a trial 
that has been initiated, comparing HPV testing every four years with a safety 
net of two years in another group with the two-year cytology, which is their 
standard. That trial has only just started; I don’t think there’s going to be much 
reported on it for a while.
Singer: Historically, as clinicians, we recognized probably about eight or nine 
years ago the enormous value of a negative HPV result with the negative 
predictive value in many trials being 99 per cent.217 Approximately 5–7 per 
cent of all women in this country have a borderline smear. In the US they have 
used it as a reflex test in women with a borderline smear or ‘atypical squamous 
cells of undetermined significance’ (ASC-US, the US equivalent218), and saved 
an enormous amount of money by excluding women with a negative test. But, 
more importantly, the anxiety of women patients is reduced and a negative 
result really does mean negative.
215  Anttila et al. (2006); Kotaniemi-Talonen et al. (2008a). 
216  Testing for HPV DNA with HC-II is a molecular biological method that tests for the presence of HPV 
DNA through a chemoluminescent reaction based on hybridization. Viral presence is measured in relative 
light units and reported as a ratio of relative light units (rlu ratio), a measure of luminescence. Samples with 
a ratio of less than 1.0 are classified as negative for high-risk HPV DNA and those 1.0 or above are positive. 
See Kotaniemi-Talonen et al. (2008b); Peyton et al. (1998).
217  Wright et al. (2004).
218  ASC-US is a classification of squamous intraepithelial lesions. For a discussion of UK and US grading, 
see Slater et al. (2005). 
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Cubie: Professor Sasieni asked: ‘Who’s going to pay?’ Doesn’t that sound familiar? 
Isn’t that what most of this story of cervical screening has been about? And how 
cytology started? Who’s going to pay? People did not know how they would fund 
screening, but started getting on with it. And, what has been achieved since 1988 
is but a series of tweaks, which are the things which Tony Miller was talking about, 
the tweaks which will need to be put in place once we actually get down to it.
Sasieni: What is going on in other places? HPV in triage of borderline or, as 
the Americans call it, ASC-US cytology, is routine in North America, I think, 
and is used elsewhere. There’s a new, fast HPV test, which is a hybrid capture 
test, for developing countries, which I believe is going to be adopted as the 
primary screening test in Colombia.219 So there is more HPV testing going on 
elsewhere. In addition to the randomized trial in Finland, there are randomized 
trials in Italy, Sweden and the Netherlands, and all four of them show higher 
sensitivity for the detection of high-grade CIN on the first round, and those 
that have published second-round results show lower detection of high grade 
CIN in the HPV arm on the second round.220 Yes, more women will be sent 
to colposcopy. The Finns have a very negative interpretation of the results, but 
their results are pretty much the same as others, and the Italians have a very 
positive interpretation of the same sort of results. 
Szarewski: I think the problem with the HPV testing is the specificity to 
which we have alluded. The trouble is that although we keep talking about 
how wonderful it is to have a negative HPV test, in the pilot studies of triage 
in the UK, it made no difference to the women themselves. When looking at 
the anxiety levels in women with borderline smears and a negative HPV test, it 
made no difference, because they didn’t understand what it meant. So if we are 
going to introduce HPV testing, which I do think is inevitable eventually, we 
mustn’t forget the real importance of education of the public, because otherwise 
it’s wasted. The patients are as anxious with a negative HPV test and a borderline 
smear as they would have been with the borderline smear, or even, in fact, a 
positive HPV test. What, then, is the point in doing it?
Professor Leslie Walker: To put this in historical perspective, in the 1970s and 
1980s there was increasing interest in the psychosocial aspect of the diagnosis 
219  See, for example, WHO (2002).
220  Ronco et al., New Technologies for Cervical Cancer Working Group (2006, 2008); Mayrand et al., 
Canadian Cervical Cancer Screening Trial Study Group (2007); Kotaniemi-Talonen et al. (2008a and b); 
Naucler et al. (2007); Bulkmans et al. (2007). 
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and the treatment of cancer, particularly in the disciplines of nursing, psychology 
and psychiatry. In the early 1980s, when the British Psychosocial Oncology 
Society was founded, I think it is fair to say that initial interest focused on 
what one might call ‘screening distress’, the effect of getting an abnormal smear 
result.221 One of the early studies by Beresford and Gervaize showed that all of 
the women that they surveyed were afraid that they would have cancer.222 Many – 
two-thirds – were afraid of the medical procedures involved in the investigation, 
and this fear showed itself in a range of behavioural changes, including sleep 
disturbance, irritability, relationship difficulties, including problems with sexual 
relationships. It was also clear even then that there were other issues for these 
women, including uncertainty about fertility and the possibility of transmission 
of disease to their partners. 
The second area of interest was investigational and procedural distress. Some 
studies showed that anticipatory anxiety was similar, or equal to, that produced 
by some types of surgery.223 Also, Campion and colleagues showed that, compared 
with a comparison group of women, six months after colposcopy, biopsy and 
laser vaporization, women had less sexual interest, less frequency of intercourse 
and more negative feelings towards their partners.224 
People have studied several ways of attempting to ameliorate this distress, 
particularly leaflets and booklets, and these have generally been of some help, 
but not for all women.225 Counselling has also been investigated, although there 
aren’t many studies.226 Women usually say that it’s helpful, but interestingly, 
most studies show that there’s no significant effect on objective measures of 
health-related quality of life. 
Then there’s the issue of gynaecological intervention for an abnormal smear, 
for example, the effects of ‘see and treat’ versus surveillance and, indeed, this 
is how my interest in this field was stimulated. Stephen Bell and colleagues in 
Aberdeen had shown that colposcopy was associated with persistent anxiety 
221  For further details, see www.bpos.org/ (visited 29 April 2009).
222  Beresford and Gervaize (1986). 
223  Rogstad (2002): particularly page 365.
224  Campion et al. (1988).
225  See, for example, www.womens-health.co.uk/smear.asp; www.womenshealthlondon.org.uk/leaflets/
cervical/cervab.html; www.bbc.co.uk/health/womens_health/issues_smeartest.shtml (visited 29 April 2009).
226  See, for example, Wolfe et al. (1992).
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following surveillance, but it wasn’t a randomized trial.227 He came to see me 
subsequently to seek advice on how to validate screening tests for clinically 
significant anxiety and depression in a further study. 
In 1998 I was very pleased to be invited by Julian Little to lead on the 
psychosocial aspects of a randomized controlled trial subsequently funded 
by the MRC (TOMBOLA).228 This was a study of over 4000 women from 
Grampian, Tayside and Nottingham, who had low-grade abnormal cytology 
and were randomized either to cytological surveillance in primary care or to 
colposcopy. Compared with surveillance, colposcopy was associated with less 
clinically significant anxiety in the short term. However, in the longer term, 
there was no difference in the levels of anxiety or depression between these 
management policies. But, more specifically, women managed by surveillance 
were more worried about the next smear being positive; they were more worried 
generally about their health; and they were more worried about whether they 
could have children in the future. 
Turning to the issue of HPV specifically, McCaffery et al. showed, and we 
have already heard a little bit about this, that women who were HPV-positive 
were more anxious and felt more worried about sexual relationships than those 
who were HPV-negative, regardless of whether their smears were normal or 
abnormal.229 
Finally, there is the issue of non-participation in the screening programme. 
Again, we have heard something about this. But in addition to socio-
demographic factors and ethnicity, there are a number of clinic-specific factors 
and psychological factors which seem to be related to this. For example, non-
participation is associated with having a fear of cancer, not having a female 
cytoscreener available, a worry about embarrassment and pain, the belief that 
screening is not going to be of any benefit and the perception of being at low 
risk of cervical cancer. 
So, to conclude, over the last 20 years or so, people have become increasingly 
aware that there is a personal cost and a psychosocial cost to cervical screening, 
and more recently to HPV testing also. And clearly there is a continuing need 
to develop ways to minimize that, and to encourage current non-participants to 
attend for screening.
227  Bell et al. (1995).
228  For further details, see Cotton et al. (2006).
229  McCaffery et al. (2004). 
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Szarewski: I am conscious that I am slipping beyond 2000 by saying this, but 
coming back to the education aspect, I think it’s ironic that the advent of the 
HPV vaccines is providing an absolutely fantastic platform for educating the 
public about HPV in general, because the press are really interested in the 
vaccines, which they have never been in any other aspect of HPV.230 So ironically, 
the vaccines are providing us with the opportunity to educate everybody about 
HPV in general.
Singer: We know as a result of the vaccine and doing many pre-introduction 
interviews in the form of an online questionnaire survey, which showed that 
a substantial amount of ignorance was present at all levels, extending from 
the administrators in the government all the way down to the actual women, 
mothers, etc.231 The most important thing now is to get knowledge of HPV 
passed on to all of them.
Mr Patrick Walker: Not to put too much of a down note on it, what we have 
been looking at over the last three or four hours is the enormous success of 
a population-based screening programme that came out of a disorganized 
and under-funded programme. The keys for success that we have seen are a 
consistent level of public investment in the organization of the programme, and 
the high coverage of the population at risk. For all of the great opportunities that 
vaccination offers for the 12- and 13-year-old women, partial implementation 
of the vaccine programme, which doesn’t have all of the viral types in a catch-up 
group, might lead to false assurance of young vaccinated women who are still 
at risk of the disease, reduced compliance with the programme, and reduced 
coverage. Ironically, this could undermine the success of the programme we 
have now, particularly if the cash-strapped primary care trusts having to invest 
in the organization, particularly of the catch-up programme, are tempted to 
reduce the budget that currently goes towards screening quality assurance.
Peto: The amount of money spent on the vaccine will be almost as much as on the 
screening programme, and we’ll have to go on screening as well until a polyvalent 
vaccine against all the common HPV types is available and affordable.232 Western 
230  See, for example, Chan and Berek (2007); FUTURE II Study Group (2007).
231  Sherris et al. (2006).
232  For an economic evaluation of the two vaccines currently in use in the UK, see Jit et al. (2008): a769; 
and other perspectives, see Franco et al. (2006). For estimates of the cost of screening compared with the 
cost of a life saved, see Bryant and Stevens (1995); Waugh and Robertson (1996); Waugh et al. (1996a and 
b); Peto et al. (2004a) and note 158. 
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governments should be collaborating to develop a cheap polyvalent vaccine as 
rapidly as possible. That would save them hundreds of millions of pounds, and 
would also prevent cervical cancer in developing countries where most of the 
cases and deaths occur and where effective screening isn’t viable.
Jenkins: I feel I have to say something on this, because that really is a gross 
oversimplification of what’s quite a complex development of vaccines, and the issue 
of multivalent and polyvalent vaccines is unfortunately not as simple as you would 
have us believe in that impassioned speech. I think if it were simple to generate 
these polyvalent vaccines, then it would have been done, and certainly both the 
vaccine companies are working on these currently.233 However, this is all going well 
beyond 2000, we are now looking at probably 2010, 2011, 2012, before any of 
these become anything like the possibility of reality, and we have to work with what 
we have got. Having said that, it is the ultimate goal; there’s no question that things 
will continue to develop beyond what we have now. If I can get back to the point 
that Anne Szarewski was making, I think one of the huge impacts of the vaccine, 
apart from its potential clinical benefits, has been that it has opened up HPV to 
the world in general, and meant that we are not a small community of eccentrics 
exploring a rather exotic virus that most people have never even heard about. 
Sasieni: To return to the personal, the screening programme in England – it 
may have been after 2000 – started this new information, informed choice. 
But there has certainly been a huge debate, some of it by Professor Peto, even 
more passionate than he has been today, about the information that should be 
provided. There were individuals whom I won’t mention by name, who seemed 
to emphasize the downside of screening the whole time, and were accused, 
I think, of causing the deaths of thousands of women by putting them off 
going for screening.234 Then there are people who felt that actually virtually all 
you needed to do was to promote the positive side of screening. There was a 
general agreement over time that we try to get a more balanced approach to the 
information, although it’s always very difficult because there is no agreement 
among the experts about what is a balanced approach to the information. 
Certainly, there was a huge change from 1988 until 1999, in terms of the 
attitude of providing information and the general feeling in society that the 
233  Professor David Jenkins wrote: ‘The two companies currently working on a polyvalent vaccine for HPV 
are GSK and Merck.’ Comment on draft transcript, 11 August 2009.
234  Raffle et al. (2003); listen to Dr Angela Raffle and Mrs Julietta Patnick discussing changes in cervical 
screening on Woman’s Hour, 22 October 2003, at: www.bbc.co.uk/radio4/womanshour/2003_42_wed_02.
shtml (visited 4 September 2009).
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medical profession should be less paternalistic. Women needed to be told the 
downside of screening, even it if puts them off attending.
Campo: Three comments: the first is that the vaccine is type-specific, and 
one thing that has, in my mind, not been extensively investigated is that L2 
protein should have been incorporated in the vaccine. It induces cross-reactive 
neutralizing antibodies, but it’s not there. It’s something that should be thought 
about. The second thing is that it is not quite so easy in terms of adding VLPs 
to the vaccine, because these are, surely, different HPV types, with a different 
incidence in different parts of the world. So while HPV16 and HPV18 are global, 
HPV58 is in Hong Kong but not in Brazil; and so on and so forth. If you want 
to add more and more VLPs I think we should start adding them differentially 
to the vaccine from Brazil, and the vaccine for Hong Kong, and I don’t think 
anybody is going to do that. My third comment is about education. Professor 
Sasieni said that people should be educated from the administrators down, and 
this is my own experience, that even doctors do not understand what the current 
vaccine is about. Treating CIN2 with the current vaccine is like throwing money 
down the drain; clearly there are doctors who do not know what the vaccine can 
do. The vaccine is fantastic, but it has to be used properly. 
Jenkins: I am very glad that everybody is discussing the vaccine, but we really 
have to limit discussion on that at the moment. Certainly, the L2 vaccine has 
been looked at. There are some issues around that; there is some recent work 
that suggests perhaps some of the differences, geographical differences, that are 
claimed in HPV types may not be as great as they appear to be and that some 
of this is due to very small studies in very special populations. Like the HPV58 
in Hong Kong, it is based on very small numbers.
Singer: We could only dream about the vaccine. There was an editorial from 
23 years ago in the British Journal of Obstetrics and Gynaecology by Dennis 
McCance and myself, talking about the association of HPV and cervical cancer 
and we weren’t sure whether the association was causal or casual. We said that 
the most satisfactory evidence or proof would be if a vaccine were produced 
against HPV in the future, which would show a reduction in the vaccinated 
women at greatest risk. This, we said, would be a difficult task.235 Thankfully, in 
the end it wasn’t as impossible as we thought it would be.
235  Singer and McCance wrote: ‘The association of HPV infections and neoplasias of the lower genital tract, 
but is this association causal or casual? The most satisfactory evidence would be if a vaccine were produced 
against HPVs and show a reduction in the vaccinated women at greatest risk. This will be a difficult task’ 
(Singer and McCance (1985): 1085).
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McCluggage: Very true words. It remains for me to say that this has been a 
very successful Witness Seminar and Dr Tansey will speak after I have finished. 
I would like to thank all the audience for their participation. I have enjoyed 
this very much and, as a non-HPV person, I have learned a lot, and I hope 
everybody else has and has enjoyed the Witness Seminar.
Tansey: Yes, I would like to thank you all very much for coming. It’s been a very 
interesting, educational, informative, and at times very amusing and entertaining 
afternoon. I also have learned an awful lot. As I mentioned at the beginning, 
this meeting is the tip of the iceberg. We will now translate the transcript of this 
Witness Seminar into readable text and we shall need your help in doing that. 
On your way home tonight, many of you will think: ‘Oh why didn’t I say so and 
so?’ You will have the opportunity of putting that into the transcript at a later 
date as a footnote. If you have any papers or references you would like us to have 
or that we could copy, please get in touch with us and let us know. 
I would like to offer the thanks of the History of Twentieth Century Medicine 
Group to David Jenkins, whose idea this was originally, and who has worked 
very closely with Lois Reynolds, Wendy Kutner and myself in planning this, 
and also thank Lois and Wendy for all their hard work in rushing around with 
the microphones, and especially to Glenn, whose timing of this meeting has 
meant that we have finished right on the dot, and to invite you all to have a 
glass of wine.
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Appendix 1
The emergence of the natural history of cervical cancer 
From Professor Leopold G koss 
Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York, NY
In 1842, an Italian physician, Domenico Rigoni-Stern, published a series of 
mortality statistics of women dying of cancer in the city of Verona.236 In this first 
epidemiological analysis, Rigoni-Stern pointed out that ‘cancer of the uterus’ was 
much more common in married women and widows than in virgins and nuns. 
This was the first suggestion that ‘cancer of the uterus’ was somehow related to 
sexual activity. It may be safely assumed that most of the women in Verona died 
of cancer of the uterine cervix because that was, at that time and remained for 
over 100 years, the most common form of cancer of the female genital tract. 
In spite of many speculations, the nature of the sexually transmitted cancerous 
agent remained a mystery.
The concept that cancer of the uterine cervix was preceded by precancerous 
states limited to the epithelium must be attributed to a 1908 paper by an 
Austrian gynaecologist, Walther Schauenstein.237 This concept was essential for 
cervix cancer prevention programmes which were based on recognition and 
elimination of precancerous states, thus preventing invasive cancer. 
Cytologic screening became one method of recognition of precancerous states. 
Although the method is attributed to George Papanicolaou, who presented a 
paper on the use of vaginal smears in detection of uterine cancer in 1928,238 
he had a predecessor, a Romanian pathologist, Aureli Babes¸, who published 
a beautifully illustrated paper on this topic in the French publication, Presse 
Medicale, prior to Papanicolaou’s presentation.239 Babes¸, using direct cervical 
samples, proposed that cancer of the cervix can be recognized in preinvasive 
stages. Papanicolaou’s primary interest was the sequence of events in the menstrual 
cycle which he could study by means of vaginal smears. He did not pursue his 
236  Rigoni-Stern (1842). See also note 85.
237  Schauenstein (1908).
238  Papanicolaou (1928).
239  Babes¸ (1928); see also note 4.
History of Cervical Cancer and the Role of the Human Papillomavirus, 1960–2000 – Appendix 1
84
observations on cancer for ten years, for lack of access to clinical material, until 
a fortuitous association with the gynaecologist, Herbert Traut, in 1938. Traut 
provided him with vaginal smears, the topic of the paper published in 1941.240 
This was the beginning of the ‘Pap smear.’ Papanicolaou never acknowledged 
Babes¸’ contribution. It is alleged that this omission cost him a Nobel award.
Direct sampling of the uterine cervix was rediscovered by a Canadian 
gynaecologist/cytologist, J Ernest Ayre in 1949.241 Among the many varieties of 
cells observed in the cervical smears, there were some that were characterized 
by large nuclei and large, clear perinuclear spaces. These cells were extensively 
studied by Ayre, who called them ‘halo cells’ and considered them to be 
precursors of cervical cancer.242 In 1960, Ayre proposed that the ‘halo cells’ may 
represent a viral manifestation in premalignancy.243
The term, koilocytes, in common use today to describe these cells, was derived 
from the term ‘koilocytotic atypia’ proposed by Koss and Durfee in 1956.244 The 
term reflected the hollow nature of the clear perinuclear space (Greek: koilos = 
cavity, kytos = cell). The histologic equivalent of koilocytes was named ‘warty 
atypia’ because of its resemblance to warts or condylomas. The suggestion that 
koilocytes were a specific manifestation of a viral infection became plausible 
with the recognition that genital condylomas were a sexually transmitted 
disease caused by a virus, as documented by Dunn and Ogilvie in 1968.245 
The cytologic similarity of condylomas to ‘warty atypia’ was noted in the first 
edition of my book in 1961.246 In two synchronous papers, Meisels and Fortin 
from Canada and Purola and Savia from Finland proposed that the koilocytes 
may be a link to condylomas, hence the viral origin of cervical cancer.247 The 
first documentation that the nuclei of koilocytes contained viral particles was 
240  Papanicolaou and Traut (1941).
241  Ayre (1949).
242  Ayre and Ayre (1949).
243  Ayre (1960).
244  Koss and Durfee (1956); see also Figure 4, page 35. 
245  Dunn and Ogilvie (1968).
246  Koss (1961); see also note 98.
247  Meisels and Fortin (1976); Purola and Savia (1977).
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presented by Laverty et al. from Australia in 1978.248 Presumably, it is this work 
that generated the interest of virologists in papillomavirus in biopsies of the 
uterine cervix and the beginning of classification of viral types, as shown by zur 
Hausen and Gissmann.249 There were many other contributors to this sequence 
of events that led to subclassification of human papillomaviruses into low-risk 
and high-risk types and to antiviral vaccines.
There are still many unanswered questions about the relationship of human 
papillomavirus to cervical cancer. The mechanism of viral penetration into 
248  Laverty et al. (1978).
249  zur Hausen (1987); Gissmann and zur Hausen (1976).
Figure 7: Dr George N Papanicolaou at the microscope.  
Photo inscribed to Leopold G koss on 23 April 1954.
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the epithelium is not known. The reason why, among many young women 
infected with human papillomavirus, only a very few progress to cancer, is 
not understood, in keeping with the unpredictable behaviour of precancerous 
lesions of the cervix in a long-term follow-up study.250 The possibility of one or 
more contributing factors explaining the relationship of viral infection to cancer 
still needs to be explored. Some of the remaining mysteries have to do with 
the presence of human papillomavirus in cancers of organs that are clearly not 
related to sexual activity, such as the cornea of the eye and the oesophagus, the 
latter particularly in China.251 
I had the rare privilege of knowing Dr Papanicolaou and working with him. 
I also got to know personally most of the key participants in the sequence of 
events briefly summarized above, stretching over the past half a century. 
Having read the text of the discussions that took place during the Witness 
Seminar, I realized that I know personally several of the participants and 
knew many whom have either died or are no longer active. In the UK, as in 
most other countries, cytological screening for cervical cancer was pioneered 
by gynecologists, because pathologists had no interest in processing the time-
consuming and poorly rewarded Pap smears. Among the pathologists, there 
were a few notable exceptions: Herbert Fidler organized a screening programme 
in Vancouver, British Columbia; James Reagan of Cleveland and Stanley Patten 
of Rochester, New York, wrote extensively about the correlation between cell 
patterns and tissues in cervical material.
The true proponents of cervical screening in the US were gynaecologists and 
the first major book on the subject was written by a cytotechnologist, Ruth 
Graham.252 Not surprisingly, the first American organization dealing with 
cytological diagnosis of cancer was named the Intersociety Cytology Council 
as it consisted of gynaecologists, cytologists and the few interested pathologists. 
Today, the organization is known as the American Society of Cytopathology. 
In the UK, the proponents of cytologic screening for cervical cancer were the 
gynaecologists, Stanley Way and Erica Wachtel. The latter was a refugee from 
Vienna, Austria, another gift from Mr Hitler to the civilized world. She was the 
mentor of Professor Dulcie Coleman. Nasseem Husain of London also played a 
250  Koss et al. (1963).
251  For a summary, see Koss (1961).
252  The second edition (Graham (1963)) of a volume originally published from the Vincent Memorial 
Hospital laboratory, Boston, published in 1950.
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major role in these events. Although there is no doubt that Harald zur Hausen, 
the recent Nobel Prizewinner, and his co-workers were instrumental in the study 
of human papillomavirus as a factor in the genesis of carcinoma of the cervix, I 
have little doubt that this work was influenced by cytological observations that 
suggested a viral origin of cervical cancer. The story is more complicated than is 
generally assumed and it was a privilege to have participated in it in some way.
I can only repeat the words of Michel de Montaigne (1533–92):253
It might well be said of me that in this book I have only made up a 
bunch of other men’s flowers, providing of my own only the string that 
ties them together.
253  Montaigne (1580).
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Appendix 2
Reminiscences on cervical screening  
From Dr Arthur Spriggs (written 12 September 2009)
I joined the pathology department at the Radcliffe Infirmary, Oxford. In the 
haematology department under Gwyn Macfarlane I began studying the cells 
of serous fluids, and started my DM thesis (1952) which became the basis of a 
monograph ‘The cytology of effusions’ (1957).254 With a grant provided by Dr A 
H T Robb-Smith (pathology) and Professor John Chassar Moir (gynaecology), 
I spent three months in the US and Canada studying the cytology of vaginal 
and cervical smears using the Papanicolaou methods; ‘cytodiagnosis’ was 
usually practised independently of the department of morbid anatomy. So 
while learning from the leading cytologists, the variably sceptical opinions of 
the local histopathologists were also sought. On my return, with the assistance 
of Michael Boddington, I inaugurated the cytodiagnostic service in Oxford. 
At first this was for gynaecological outpatients, but in the 1960s was extended 
to screening of the local population. The expanding laboratory was transferred 
to the Churchill Hospital. Grants were provided by the British Empire Cancer 
Campaign (Cancer Research Campaign from 1970) for research into various 
aspects of cytological diagnosis – in particular, cyto-histological correlation 
in sputum and stomach washings, as well as cervical smears (1953–60); 
identification of tumour cells in circulating blood, also in cerebrospinal fluid 
(1959–61); and chromosomes of human malignant cells (1960–72). It became 
apparent that each malignant tumour was a new unique clone of cells with an 
altered chromosome complement. This was most easily demonstrated in the 
cells of effusions, but from a small number of biopsy fragments from the cervix 
when there was evidence of the same process in carcinoma in situ.255 From the 
late 1960s, attempts were made to follow up cases in which a ‘positive’ cervical 
smear had escaped from further recommended procedures over at least two 
years. Some of these were found again, particularly with the collaboration of 
Professor Richard Doll’s department, and a picture could be presented showing 
the proportion regressing or progressing over the years, evidently a positive smear 
254  Spriggs (1957).
255  Spriggs et al. (1971).
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is dangerous to ignore.256 Concerning automated cytodiagnosis in the 1970s, 
the proposal which I thought achievable would be to pre-screen smears with 
a machine capable of marking any large or hyperchromatic nuclei, so that the 
screener could go at once to significant areas of the smear. We failed to achieve this 
with the apparatus then available. Before my retirement in 1984, collaborative 
studies were done with the histopathologists using immunochemical methods, 
some of which appeared promising in the identification of malignant cells in 
effusions. Following my retirement, I completed with M M Boddington a new 
fully illustrated book on the cytology of serious effusions.257
From Dr Nasseem Husain (written 2 April 2001, 16 and 31 May 2008)
I recognized the value of cytological screening both here and in many countries 
elsewhere in the world when I went on lecture tours in the US, South America, 
Europe, Asia and Japan to promote this concept. The need for a defined screening 
programme which was argued by me through the central committees of the 
Ministry of Health resulted in and the establishment of cytology screening units 
in every hospital and by general practitioners. In this I was aided and strongly 
supported by Marks and Spencers, whose medical staff I knew well and they 
were the first to create mobile screening units in this country, where around 7000 
tests per year were carried out on their female employees on a two-to-three year 
recall, conducting field analysis of different techniques and follow-up programmes 
(1967–89). Many of the smears went to local laboratories, but M&S also provided 
a magnificent laboratory for me at St Stephen’s Hospital along with the salaries of 
three technicians and half of a clerk and provided many other assets, where, as well as 
screening, we also looked at detailed morphology of chromatin patterns. Although 
many doctors took up the practice of cytology, few of them were histopathologist 
or haematologists and the practice sadly moved away from scientific cellular 
pathology and a separate specialty of cytology developed. (31 May 2008)
I was the first NHS consultant in cytopathology in the UK, being appointed 
in 1961, but was also very actively involved in the development of screening 
programmes, training of pathologists and technicians, development of 
automation techniques and in cytochemistry. (16 May 2008)
256  Kinlen and Spriggs (1978).
257  Spriggs and  Boddington (1989). Excerpt from a letter to Dr Winifred Gray, 12 September 2009, which 
will be deposited with the other records of the meeting in archives and manuscripts, Wellcome Library, 
London, at GC/253.
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I was involved in research and development of a non-wettable swab, plastic 
spatula and a more appropriately shaped knuckle-ended wooden spatula in 
the mid-1970s which has ultimately resulted in the Aylesbury spatula ten 
years later (see Figure 6, page 54). 
Trials were undertaken of an irrigation cytopipette as a self-collecting instrument 
to identify its 75–80 per cent accuracy compared with the spatula, but at about 
one-fifth the cost, and the development of our own British model of the pipette, 
to my specifications and an improved irrigation and preservative solution and 
eventually, the greater acceptability as a screening procedure in a controlled trial 
supported by the Ministry of Health (DHSS after 1968).
The development of cell preparatory techniques for automated scanners utilizing 
cell dispersal systems of mucolytic, chemical, enzymic and physical methods, 
which include a study of ultrasonics, disaggregation by sheer stress techniques 
using syringes, vortex whistle, peristaltic pumps and cell ‘spinners’ on to film 
strips and glass slides. Research into the cell coatings from 90.000 to 500.000 
molecular weight with a cell spread utilizable for any subsequent staining process 
and for use with cyst fluid, urine and fine needle aspirate samples.
An extensive study was made for use with automatic scanners to produce a 
high signal-to-noise ratio and achieve a machine-blind stain. This involved a 
review of a range of haematoxylins and DNA stains and the development of a 
quantitative fast gallocyanin of 5–10 minutes’ duration, instead of the 18-hour 
schedule of Einarson (1932), to which cytoplasmic stains could be added.
In 1965, I evaluated the claim that the Coulter cell counter with a size distribution 
plotter would demonstrate secondary peaks of large cells in neoplastic cell 
samples. This was examined in a joint venture with the Royal Marsden Hospital 
to demonstrate that the large cell was in fact a cell cluster, probably polymorphs, 
and often in association with malignancy, but that these secondary peaks would 
disappear on cell cluster disaggregation.
In 1966 we were the first to explore the use of a static cell scanner by the 
conversion of the industrial Quantimet B imaging analysing computer using a 
Vidicon television tube from an incidental light microscope to a transmission 
light instrument. A study of cells from cervical smears demonstrated that there 
were sufficient discrete neoplastic cells stained by haematoxylin which were over-
threshold, giving a raised integrated optical density, which could be registered 
by virtue of sizing and density potentiometers and be recalled for interactive 
visual assessment. These results were presented in the first automatic research 
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conference in 1968. A purpose-built scanner called the Imaco cytoscreen was 
then constructed to my specifications and funded by the DHSS. This project 
led the international field in conferences in Europe and the US for the next five 
to ten years. The further development of this scanner failed to be adequately 
supported by the DHSS and subsequently by the MRC, as I had to transfer our 
energies to the Cervifip (Cytoscan 110), an offshoot of the metaphase finder 
and chromosome analyser being developed by the MRC, first in London and 
then at the Western General Hospital, Edinburgh, 1978–89. We were closely 
involved in perfecting this diode array scanner over the last five to ten years of 
my appointment, which resulted in a sophisticated instrument with a low false 
negative signal rate achieved by the register of aneuploid and polyploidy nuclei, 
with rejection of the false positive signals due to nuclear overlaps and cell debris, 
by pattern recognition, but has not yet reached acceptable limits. Nevertheless, 
this instrument compares well with the three to four instruments developed in 
Europe and the US and can read and sort cells at the rate of about 150 000 per 
two minutes.
I had considerable experience in flow cell instruments and our comparative trials 
using flow cell analysers and microdensitometers does demonstrate the unique 
advantage of our fast static cell scanner (Cervifip), working on both the rapid 
cell detection of the rare event and also on analyzing disaggregated selective 
archival material from tissue blocks in order to study the ploidy pattern of cells 
of tumours and therefore to relate to the prognostic and the therapeutic effects 
and able to achieve a valuable prospective dimension if fine needle aspirate 
samples are used.
The limitation of morphological criteria for the diagnosis of malignancy 
encourage me to pursue a study in depth of the biochemical and functional 
parameters of neoplastic cells and it is here that our researches embraced both 
biochemical and cytochemical fields. Our study of the glucose-6-phosphate 
dehydrogenase enzyme in vaginal aspirates was based on a claim of raised 
activity in neoplasia and a survey of some 5000 case samples tested against 
traditional scrape smear cytology to confirm or disprove this thesis resulted in 
the finding that although all invasive lesions showed high levels, only about half 
the carcinoma in situ cases did so and there was an excessively high proportion of 
false positive readings. It was later found that if potassium was used as a measure 
of cellular content and therefore the source of enzyme rather than freeze dried 
weight or cytochrome, the false positive rate dropped to less than 9 per cent. 
Such a test could conceivably be used to screen for endometrial cancer.
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We were the first to study the state of the DNA in neoplasia by a slowed-down 
Feulgen hydrolysis technique at room temperature to show that there was a 
significant labile component, both in the neoplastic cell and also in the benign 
cells in their vicinity, a feature that may make the detection of malignancy 
possibly without encountering or identifying a neoplastic cell. 
The combined output of the Charing Cross and St Stephen’s cytology 
departments was about 55 000 tests per year. An increasing proportion of these 
were becoming non-gynaecological tests presenting a substantial workload in 
the fields of gastrointestinal and pulmonary brush specimens and fine needle 
aspirates. The gynaecological screening load used to come from a large area of 
south-west London and from parts of Sussex where we served about 55 different 
gynaecological screening clinics, 22 hospital clinics and about 130 general 
practitioners. On the transfer of the district to North West Thames Regional 
Health Board, the range of GPs and clinics was reduced but the volume of 
throughout dropped only marginally, while problem cervical smears and non-
gynaecological specimens, including fine needle aspirates and AIDs specimens, 
increased markedly. (2 April 2001) 
I must finally congratulate you on your initiative to choose this field of 
cytodiagnosis as a subject for a Witness Seminar, which has effectively spread 
to many other parts of the body and is now a highly sophisticated and effective 
method of early diagnosis. (31 May 2008) 
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PhD FRCPath (b. 1946) graduated 
in bacteriology in 1968, later 
receiving an MSc and PhD, all 
from University of Edinburgh. 
She has worked in either the 
University of Edinburgh (medical 
microbiology and dermatology) or 
NHS Lothian (Royal Hospital for 
Sick Children, City Hospital and 
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the Royal Infirmary of Edinburgh) 
since then, becoming a consultant 
clinical scientist in virology in 
1993. Her specialist research 
interest is human papillomavirus 
(HPV). She is a member of the 
Scottish HPV national steering 
group and epidemiology and 
surveillance subgroup and also 
of the UK NCSP HPV special 
interest group. She became 
honorary professor of research and 
research management, University 
of Edinburgh, in 2006 and visiting 
professor of virology, University of 
Glasgow, in 2008. 
Professor Jack Cuzick
PhD FMedSci (b. 1948) holds 
a PhD in mathematics and has 
been head of the Cancer Research 
UK centre for epidemiology, 
mathematics and statistics in 
London and John Snow Professor 
of Epidemiology at the Wolfson 
Institute of Preventive Medicine at 
Queen Mary, University of London 
since 2004. His current interests 
are in cancer epidemiology and 
clinical trials, with special interest 
in prevention and screening and 
he is currently involved in studies 
on the use of HPV assays for 
cervical screening. He discovered a 
method for sensing and processing 
biopotentials for early diagnosis 
of breast cancer (named on US 
patent no. 6,351,666 B1 assigned 
to the Biofield Corporation in 
2003; for precursors, see Cuzick 
et al. (1998b)); received the 
Thomson’s hottest research award 
of 2005/06 for scientists with most 
cited papers, the only UK-based 
author of 17 scientists selected 
worldwide; and has been president, 
International Society of Cancer 
Prevention since 2004.
Professor Nicholas Day
CBE FRSS FRCPath FMedSci 
FRS (b. 1939) statistician, later 
head of the unit of biostatistics 
and field studies, epidemiology 
section of the International Agency 
for Research on Cancer, in Lyons 
(1969–86), director of the MRC 
biostatistics unit, Cambridge 
(1986–89, honorary director 1989–
99), professor of public health, 
University of Cambridge (1989–99) 
and MRC research professor of 
epidemiology there (1999–2004). 
He was chairman of the MRC 
committee on the epidemiology and 
surveillance of AIDs (1988–92). See 
Breslow and Day (eds) (1987). 
Dr Ian Duncan
FRCOG FHEA (b. 1943) 
graduated in medicine at the 
University of St Andrews 
and trained in obstetrics 
and gynaecology in Dundee 
(1969–72, 1974–8), specializing 
in gynaecological oncology 
at Duke University, Durham, 
North Carolina (1972–74). He 
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was appointed senior lecturer, 
University of Dundee, in 1978, 
subsequently reader and honorary 
consultant gynaecologist/ 
oncologist until his retirement 
in 2007. He established one 
of the first colposcopy services 
in Scotland in 1974; has been 
executive member and subsequently 
president of the British Society 
for Colposcopy and Cervical 
Pathology (1985–88), the British 
Gynaecological Cancer Society 
(1988–91) and the International 
Federation for Cervical Pathology 
and Colposcopy (1993–96.) He has 
also served on the Strong advisory 
committee on the cervical cytology 
service in Scotland (1985/6), the 
intercollegiate working party on 
cervical cytology screening in the 
UK (1987), the NHS Cervical 
Screening Programme national 
coordinating network and its 
successor the NHS CSP, editing, 
drawing up and subsequent revision 
of guidelines for clinical practice 
and programme management 
(1989–97). He was chairman of 
the Scottish Cervical Screening 
Programme national advisory group 
(1998–2003).
Professor Ian Frazer
immunologist, jointly holds 
the patent with his late research 
partner, Dr Jian Zhou (1957–99), 
and was the commercial driver in 
the development of the vaccine for 
cervical cancer (Gardasil) by the 
University of Queensland team. 
He is head of the University of 
Queensland Diamantina institute 
for cancer, Princess Alexandra 
Hospital and was honoured as 
2006 Australian of the Year, 
was inaugural winner of the 
Queensland smart state premier’s 
fellowship (2006) and received 
the Balzan prize for international 
medicine. See interview by Robyn 
Williams in 2008 at www.science.
org.au/scientists/if.htm; see also 
www.di.uq.edu.au/news-archive 
(both sites visited 23 April 2009). 
Professor Lutz Gissmann
German Cancer Research 
Center, Heidelberg, Germany, 
was appointed to a postdoctoral 
position, later assistant professor, 
department of virology, University 
of Freiburg (1977–83); head of 
the German Cancer Research 
Center, genome modifications and 
carcinogenesis division, Heidelberg 
Germany (1983– ); full professor 
(1986); chairman, applied tumor 
virology programme, German 
Cancer Research Center (1991–93); 
director of research, department 
of obstetrics and gynecology, 
programme leader for viral oncology 
and full professor, Loyola University 
Medical Center, Chicago, Illinois 
(1993–97); vice president of research 
and development, MediGene AG, 
Martinsried, Germany (1998/9); 
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honorary professor, King Saud 
University, Riyadh, Saudi Arabia  
(2008– ).
Sir Muir Gray
Kt CBE MD FRCP FRCPSGlas 
FFPH (b. 1944) qualified at the 
University of Glasgow and trained 
in public health at Bristol. After 
house jobs he joined the city of 
Oxford as senior medical officer 
(1972–74); public health specialist, 
Oxfordshire HA (1974–91); 
director, health policy and public 
health, Oxford RHA (1991–94); 
Director of R&D, Anglia and 
Oxford RHA, then Anglia and 
Oxford Regional Office, NHS 
Executive, Department of Health 
(DoH) (1994–98); director of 
the Institute of Health Sciences, 
University of Oxford (1999–2002). 
He was co-ordinator of the national 
breast cancer screening programme, 
1988–91; national cervical 
screening programme (1988–94); 
and Adviser, WHO (1984–91). 
He has been programmes director, 
UK national screening committee, 
since 1995, and director of clinical 
knowledge, process and safety, 
Department of Health, since 2004. 
See Gray (1997, 2004).
Dr Winifred Gray
FRCPath (b. 1937) qualified 
in Adelaide and trained in 
cytopathology with Dr Arthur 
Spriggs in the cytology department 
in Oxford. She took up a post 
in cytology at the Northampton 
and Kettering General Hospitals; 
was one of the first to have a 
full training in pathology at the 
Radcliffe Infirmary, Oxford, 
starting in 1969, under Dr 
Rosemary Ruse’s married women’s 
retraining scheme; was consultant 
histo/cytopathologist, Wycombe 
General Hospital (1974–88) and 
John Radcliffe Hospital, Oxford 
(1988–2002), where she set up 
a cytology training school for 
technical and medical staff, which 
closed on her retirement. She 
examined in cytopathology for 
the Royal College of Pathologists 
and served on their cytopathology 
subcommittee; was editor of 
Cytopathology (1998–2002) and 
on the BSCC council. The third 
edition of her textbook (Gray and 
McKee (2003)) is in preparation.
Professor Matti Hakama
statistician and professor of 
epidemiology at the University of 
Tampere, Finland.
Professor Harald zur Hausen
MD (b. 1936) studied medicine at 
the Universities of Bonn, Hamburg 
and Düsseldorf, working as a post-
doctoral student at the Institute of 
Microbiology in Düsseldorf, assistant 
professor in the virus laboratories 
of the Children’s Hospital in 
Philadelphia, Pennsylvania; senior 
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scientist at the Institute of Virology, 
University of Würzburg and as 
chairman and professor of virology at 
the University of Erlangen-Nürnberg, 
moving to a similar position at the 
University of Freiburg in 1977; 
and as scientific director of the 
Deutsches Krebsforschungszentrum 
(German Cancer Research Center) 
in Heidelberg (1983–2003). His 
special interest is in infection-induced 
malignancies and he showed the role 
of papillomaviruses in cervical cancer 
and discovered a larger number of 
novel virus types. He shared half 
the 2008 Nobel prize in Medicine 
or Physiology with Françoise Barré-
Sinoussi and Luc Montagnier, 
recognized ‘for his discovery of 
human papilloma viruses causing 
cervical cancer’. He has been editor-
in-chief of the International Journal 
of Cancer since 2000. See also zur 
Hausen (2006).
Dr Amanda Herbert
MRCS LRCP FRCPath  
(b. 1943) qualified in medicine 
at St Mary’s Hospital, London in 
1968. Appointed as consultant 
cytopathologist and histopathologist 
at Southampton University 
Hospitals Trust (1982–98), she 
held a similar post at Guy’s and St 
Thomas’ NHS Foundation Trust 
(1998–2008), since when she works 
part-time in the same department. 
She is an honorary senior lecturer 
at Guy’s, King’s and St Thomas’ 
School of Medicine. She chaired 
the Royal College of Pathologists 
cytopathology subcommittee and 
examination panel (1993–97) and 
was a member of council and/
or officer of the BSCC almost 
continually (1984–2004). She has 
been editor of the Wiley-Blackwell 
journal Cytopathology since 2008.
Dr O A N (Nasseem) Husain
MD FRCPath FRCOG (b. 1924) 
qualified King’s College Hospital 
Medical School and military service 
in the RAMC as a specialist in 
pathology, training at Westminster 
Hospital, London. He was the first 
NHS consultant in cytopathology 
in the UK in 1961 appointed to 
the Chelsea and Kensington Group 
pathological laboratories and in 
charge of the cytodiagnostic unit at 
St Stephen’s Hospital, London, later 
Chelsea and Westminster Hospital 
(1961–91). He was co-founder 
and secretary, then chairman and 
ultimately president (1977–80) 
of the British Society of Clinical 
Cytology (BSCC). See Husain and 
Butler (1999).
Professor David Jenkins
MA MD FRCPath (b. 1946) 
studied at King’s College, 
Cambridge, and then at the Welsh 
National School of Medicine, 
Cardiff. He was assistant lecturer 
in the department of pathology, 
Cambridge University, and then 
lecturer in pathology at Westminster 
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and St Thomas’ Hospitals, London. 
He started clinical and laboratory 
research on the role of HPV in 
cervical and other cancers and 
precancer in 1984 with Albert 
Singer at the Whittington and 
Royal Northern Hospitals and 
continued at Nottingham as 
professor in pathology. He was a 
principal investigator on the MRC 
TOMBOLA trial of management 
of abnormal smears in cervical 
screening and became director of 
clinical research into prophylactic 
HPV vaccines at GlaxoSmithKline 
Biologicals based in Belgium 
from 2003 until his retirement 
in 2007. He remains an active 
scientific consultant to this vaccine 
programme and continuing 
evaluation and publication of the 
results of the large clinical trials he 
established on the HPV vaccine. 
Professor Anne Johnson 
FRCP FFPH FRCGP FMedSci 
(b. 1954) trained in medicine in 
Cambridge and Newcastle and 
specialized in epidemiology and 
public health. She was in general 
practice (1978–83), registrar in 
community medicine, NE Thames 
Regional Health Authority (1983/4), 
lecturer, Middlesex Hospital Medical 
School (part of University Hospital 
Medical School since 1987, 1985–
88); senior lecturer in epidemiology 
(1988–94), honorary consultant in 
public health medicine since 1998, 
reader in epidemiology 1994–96; 
professor of epidemiology (1996–), 
head of the department of primary 
care and population sciences, Royal 
Free and UCH Medical School 
(2002–), and director of the Division 
of Population Health, UCL (2007). 
She was visiting professor at the 
London School of Hygiene and 
Tropical Medicine (1999–2006). 
She co-directed the Medical 
Research Council-UK Centre for 
Co-ordinating Epidemiological 
Studies of HIV and AIDS from 
1985 until 1999 and was principal 
investigator on the 1990 Wellcome 
Trust-funded first National Survey 
of Sexual Attitudes and Lifestyles 
(Natsal 1990) and on MRC Natsal 
2000. She was a deputy chair of 
the MRC infection and immunity 
board (2004–07, a member of the 
Department of Trade and Industry 
expert advisory group, foresight 
detection and identification of 
infectious diseases project (2004–
07), a member of the Department of 
Health specialist advisory committee 
on antimicrobial resistance (2001–
07), a member of the working party 
on public health: Ethical Issues 
(Nuffield Council for Bioethics) in 
2007. She is a member of the Board 
of International Society of Sexually 
Transmitted Diseases Research 
(ISSTDR) and a non-executive 
director of the Whittington NHS 
Trust.
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Professor Leopold koss
MD HonFRCPath (b. 1920) 
received his MD degree from the 
University of Bern, Switzerland 
in 1946. He was chief of the 
cytology service and attending 
pathologist of the Memorial Sloan-
Kettering Cancer Center, New 
York (1952–70) and has been 
professor and chairman emeritus 
of the department of pathology, 
Montefiore Medical Center, Albert 
Einstein College of Medicine, 
Bronx, New York since 1973. His 
textbook, Diagnostic Cytology and its 
Histopathologic Bases (Koss (1961)) 
was awarded a Citation Classic in 
1989. He was made honorary fellow 
of the Royal College of Pathologists 
in 1996. See also Koss (2007). 
Professor Attila Lörincz
PhD (b. 1954) molecular biologist, 
inventor of the hybrid capture series 
of tests for HPV while senior vice-
president and chief scientific officer 
at the Digene Corporation (later 
part of QIAGEN, Gaithersburg, 
Maryland). He has been professor 
of molecular epidemiology at the 
Wolfson Institute of Preventive 
Medicine, Queen Mary, University 
of London, since 2007. 
Dr Elizabeth (Betty) Macgregor
OBE MD FRCPath FRCOG 
(1920–2005) qualified at Glasgow 
with house jobs at Glasgow Royal 
Infirmary and Western General 
Hospital. In 1958 she became a 
research assistant at Aberdeen in 
the department of obstetrics and 
gynaecology run by Sir Dugald 
Baird, who wanted a screening 
programme for cervical cancer 
established in the then stable 
population and she learned to 
take and interpret smears and to 
use the Papanicolaou staining 
technique; she was awarded an MD 
in 1963. The Aberdeen screening 
programme was one of the first 
in the UK and she established a 
punchcard system for calling and 
recalling patients. She visited GP 
surgeries to take smears, started 
to analyse them and study the 
epidemiology, publishing evidence 
after five years and encouraging 
others to follow. She was president 
of the BSCC (1980–83, Figure 1). 
See Anon. (2005); Richmond 
(2005); www.oxforddnb. 
com/view/article/96184 (visited  
16 September 2009).
Dr Elizabeth Mackenzie
FRCPath DPH (b. 1934) trained at 
St Bartholomew’s Hospital Medical 
School, London, and was consultant 
cytopathologist, Southmead 
Hospital, Bristol (1986–94; and 
head of the department of cytology, 
1987–90, 1991–94); consultant 
cytopathologist to BUPA screening 
service, The Glen BUPA Hospital, 
Bristol (1994–2007). She was 
manager of the cervical cytology 
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screening programme for Bristol & 
Weston district, Frenchay district 
and Southmead district (later 
Bristol and district health authority 
(1976–94)); was chairman of the 
regional cytological committee 
(1984); established the South West 
regional cytology training centre for 
cytoscreeners, medical laboratory 
scientific officers (MLSOs) and 
pathologists (1990); was secretary 
(1983–86) and president of the 
BSCC (1994–97); chairman of the 
South West Association of Clinical 
Pathologists (1987).
Dr Joan Macnab
PhD FRCPath qualified and 
trained at the University of 
Glasgow. She worked as a research 
assistant in infectious diseases 
(1959/60), poliomyelitis (1960/1) 
and a memorable spell as research 
assistant to Professor Guido 
Pontecorvo (1962–67) where she 
later took up an MRC scientific 
appointment. In 1967 she joined 
Professor John Subak-Sharpe, 
Director of the MRC Institute of 
Virology, University of Glasgow. As 
senior scientist and research team 
leader she took early retirement in 
1995. Her early love of genetics 
influenced her approach to virology 
research. She has been scientific 
adviser to Medical Research 
Scotland (formerly the Scottish 
Hospital Endowments Research 
Trust) since 1996.
Professor Glenn McCluggage
FRCPath (b. 1963) trained in 
medicine at Queen’s University 
of Belfast (QUB) in 1987; 
has worked as a trainee and 
consultant in histopathology in 
the Royal Group of Hospitals 
Trust, Belfast, since 1988. He was 
appointed an honorary professor 
in pathology, QUB, in 2005; has 
published approximately 250 peer-
reviewed articles and reviews in 
gynaecological pathology; and is 
president of the British Association 
of Gynaecological Pathologists 
(2007–10).
Dr Euphemia McGoogan
MPath qualified at Aberdeen 
University Medical School 
and trained at the University 
of Edinburgh department of 
pathology. She was a senior 
lecturer there and honorary 
consultant pathologist (1983–
2004); and was pathology patient 
services director for the Lothian 
University Hospitals NHS Trust 
in Edinburgh, responsible for the 
largest combined morbid anatomy, 
histopathology and cytopathology 
service in the UK. She was medical 
director, Europe, for the Cytyc 
Corporation (2004–08) and has 
owned her own consultancy service 
since 2008. She chaired an inquiry 
into cervical cytopathology at 
the Inverclyde Royal Hospital, 
Greenock (1993). See www.
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cancerscreening.nhs.uk/cervical/
publications/nhscsp22.pdf (visited 
27 January 2009).
Professor Anthony Miller
MD FRCP FRCP(C) FACE  
(b. 1931) qualified in medicine in 
1955 and specialized in internal 
medicine. He was a member of 
the scientific staff of the Medical 
Research Council’s tuberculosis 
and chest diseases unit, Brompton 
Hospital, London (1962–71). He 
directed the epidemiology unit 
of the National Cancer Institute 
of Canada (1971–86), and was 
chairman of the department 
of preventive medicine and 
biostatistics, University of Toronto 
(1992–96). He was senior scientist, 
International Agency for Research 
on Cancer, Lyons, France (1997–
99) and served as head of the 
division of clinical epidemiology, 
German Cancer Research Center, 
Heidelberg, Germany (1999–
2003), and is currently associate 
director of research at the Dalla 
Lana School of Public Health, 
University of Toronto, Canada. 
He is principal investigator of 
the Canadian national breast 
screening study and he serves as a 
consultant to the early detection 
research programme, division of 
cancer prevention, National Cancer 
Institute, Bethesda, Maryland, and 
to the World Health Organization’s 
programme in cancer control. He 
chairs the cancer risk management 
advisory committee of the Canadian 
partnership against cancer and is a 
member of its advisory committee 
on cancer control.
Professor George Papanicolaou
MD PhD (1883–1962) qualified 
in medicine at the University of 
Athens, studied philosophy of 
biologic sciences in Germany with 
August Weisman, earned his PhD 
in zoology in Munich and worked 
in France as a physiologist. He was 
appointed as a technical assistant 
in the department of anatomy, 
Cornell Medical School, at New 
York (1913–61), and consultant 
to the Strang Laboratory. While 
preparing his 1933 monograph 
on the human female sexual cycle 
‘as revealed by vaginal smear’, he 
noted abnormal cells from the 
cervix and later re-evaluated the 
vaginal smear for cancer detection 
at the suggestion of Joseph Hinsey 
in 1939. Dr Herbert Traut, from 
the department of obstetrics and 
gynecology at Cornell, collaborated 
with Papanicolaou on the 
diagnostic potential of the vaginal 
smear, later called the Pap test, 
published in 1943. Papanicolaou’s 
Atlas of Exfoliative Cytology, 
appeared in 1954, with a revision 
in 1960. See Hinsey (1962); 
Michalas (2000); Sawin (2002); 
www.papsociety.org/index.html 
(visited 22 July 2009).
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Professor Julian Peto
DSc FMedSci (b. 1945) graduated in 
mathematics from Oxford in 1967. 
He was a research scientist with Sir 
Richard Doll in Oxford (1974–83) 
and chairman of the section of 
epidemiology at the Institute of 
Cancer Research (ICR, 1983–2004). 
His Cancer Research UK chair is 
now held jointly between the ICR 
and the London School of Hygiene 
and Tropical Medicine.
Dr Catherine Pike
(b. 1920) graduated in medicine 
at the University of Glasgow in 
1943; served in the Royal Air Force 
medical service (1944–47); and 
subsequently took medical house 
and registrar posts followed by 
marriage and life in Tanganyika 
(Tanzania from 1964) until 1960. 
She was a community physician 
(child health and family planning) 
at Guildford (1960–67) when 
she retrained in cytology at St 
Thomas’ Hospital, London. 
She was appointed consultant 
cytopathologist, Royal Surrey 
County Hospital (1978–85); 
a member of the national 
coordinating network for the UK 
cervical screening programme; a 
council member, BSCC. Following 
retirement in 1985, she worked 
on a screening programme with 
Professor Jocelyn Chamberlain at 
the Institute of Cancer Research, 
Sutton until 1992.
Dame Rosemary Rue
DBE FRCP FFPHM FRCPsych 
FRCS (1928–2004), physician and 
regional medical officer (1973–84)
and regional general manager 
(1984–88) of the Oxford Regional 
Health Authority, who set up a 
married women doctors’ retraining 
scheme. See Rue (1967); note 35. 
Professor Peter Sasieni
PhD (b. 1963) studied 
mathematics at Cambridge 
University before going to the 
department of biostatistics at the 
University of Washington, where he 
obtained a PhD. His post-doctoral 
post was with Dr Jack Cuzick at 
ICRF, Bart’s, London, in 1989 
and it was there that he started 
studying cervical screening and 
became involved in the National 
Coordinating Committee. He 
moved to Queen Mary, University 
of London as professor of cancer 
epidemiology and biostatiscs in 
the Wolfson Institute of Preventive 
Medicine in 2002.
Professor Albert Singer
PhD DPhil FRCOG (b. 1938) 
attended Sydney University, 
graduating in 1960, specializing 
in obstetrics and gynaecology 
obtaining membership of the 
Royal College in 1967. He had 
joined Dr Malcolm Coppleson, a 
clinical gynaecologist and expert 
colposcopists, and Dr Bevan Reid, 
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an outstanding cellular biologist, 
in 1966, obtaining a PhD from 
Sydney University (Singer (1972)). 
He moved to Oxford in 1970 
on a scholarship to continue his 
work on high-risk women for the 
development of cervical cancer 
by studying women in a large 
London prison where evidence of 
clinical HPV as a aetiological factor 
became evident and was awarded 
an DPhil for this work (Singer 
(1973)); worked in Sheffield 
investigating possible genetic 
markers in women with cervical 
precancer while also building a 
large colposcopy unit (1973–81) 
and has been at the Whittington 
Hospital NHS Trust since 1981 as 
a gynaecologist as well as holding 
chairs in gynaecological research 
and molecular pathology at UCL. 
His unit in collaboration with basic 
science units at UCL has been 
active in both basic and clinical 
HPV research as well as examining 
the role of genetic markers for 
cervical neoplasia diagnosis. 
Dr John Smith
FRCPath MIAC (b. 1953) qualified 
at the Middlesex Hospital Medical 
School, London, and trained 
in histopathology and cytology 
at St Bartholomew’s Hospital, 
London, and in Bristol, where 
he developed a particular interest 
in cervical cytology. He has 
been consultant histopathologist 
and cytopathologist at the 
Royal Hallamshire Hospital, 
Sheffield, and honorary senior 
clinical lecturer in pathology 
in the University of Sheffield. 
He was appointed a consultant 
in Sheffield in 1987 and since 
1997 has practiced exclusively in 
gynaecological histopathology and 
cytology there. He is director of 
the East Pennine cytology training 
centre, director of the Sheffield 
Cervical Cytology Service and lead 
histopathologist at the Sheffield 
Gynaecological Cancer Centre. He 
is currently president of the BSCC 
and past chairman of the panel of 
examiners in cytology of the Royal 
College of Pathologists. He is an 
associate of the General Medical 
Council and has served on advisory 
committees of the GMC, Royal 
College of Pathologists, BSCC 
and the NHS cervical screening 
programme. He is a consultant 
adviser to the governments of 
Singapore, New Zealand and Jersey. 
Dr Arthur Spriggs
DM FRCP FRCPath (b. 1919) 
studied medicine at Oxford, 
Liverpool and Edinburgh and 
served in the Royal Army Medical 
Corps as a graded physician 
(1944–47). He joined the 
pathology department at the 
Radcliffe Infirmary, Oxford; in 
the haematology department 
under Gwyn Macfarlane he began 
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studying the cells of serous fluids, 
and his DM thesis (1952) became 
the basis of a monograph ‘The 
Cytology of Effusions’ (1957). 
He spent three months in the 
US and Canada studying the 
cytology of vaginal and cervical 
smears using the Papanicolaou 
method. On his return, with the 
assistance of Michael Boddington, 
he inaugurated the cytodiagnostic 
service in Oxford in 1958. He was 
consultant cytologist to the United 
Oxford Hospitals from 1960 until 
his retirement in 1984.
Professor Margaret Stanley
OBE FMedSci (b. 1939) attended 
the Universities of London, 
Bristol and Adelaide and has 
been professor of epithelial 
biology, department of pathology, 
University of Cambridge, since 
2003. She has served on several 
research council committees and 
was a member of the Biology and 
Biotechnology Science Research 
Council (2000–03); a member 
of Spongiform Encephalopathies 
Advisory Committee (SEAC), 
which advises the UK government 
on prion diseases. Her research 
interests concern the biology of 
cervical epithelium and how and 
why cancer of the cervix develops; 
her current research focuses on 
mechanisms of host defence and 
the development of vaccines and 
immunotherapies against human 
papillomaviruses, the cause of 
cervix cancer. She has been on 
the editorial board of Sexually 
Transmitted Infections and Reviews 
in Medical Virology since 2007  
and is a member of the  
council of the International 
Papillomavirus Society.
Mrs Marilyn Symonds
CSi FIBMS (b. 1947) commenced 
work as student medical laboratory 
technician in 1963 at Stoke 
Mandeville Hospital, Aylesbury, 
specializing in cytology. She became 
head biomedical scientist in cellular 
pathology at Stoke Mandeville 
Hospital (1989–2002) and 
honorary secretary of the BSCC 
(2001–04). She was appointed 
hospital programme coordinator for 
cervical screening, Buckinghamshire 
Hospitals NHS Trust (2000) and 
advanced biomedical scientist 
practitioner (2002).
Dr Anne Szarewski
PhD FFSRH (b. 1959) graduated 
in medicine in 1982 and has been a 
registered colposcopist since 1987. 
She joined the Imperial Cancer 
Research Fund (ICRF, Cancer 
Research UK from 2002) in 1992 
and obtained her PhD in 1997 
from the University of London. 
She has continued to work for the 
Imperial Cancer Research Fund 
and is currently clinical consultant, 
honorary senior lecturer in the 
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CRUK centre for epidemiology, 
mathematics and statistics at the 
Wolfson Institute of Preventive 
Medicine, Barts and the London 
School of Medicine and Dentistry, 
University of London. Since 2003 
she has been the editor-in-chief 
of the Journal of Family Planning 
and Reproductive Health Care and 
has been on the board of directors 
of the European Cervical Cancer 
Association (ECCA).
Professor E M (Tilli) Tansey
PhD PhD HonFRCP FMedSci 
(b. 1953) is convenor of the 
History of Twentieth Century 
Medicine Group and professor 
of the history of modern medical 
sciences at the Wellcome Trust 
Centre for the History of Medicine 
at UCL.
Professor Leslie G Walker
PhD FBPsS FIBiol (b. 1949) holds 
the chair of cancer rehabilitation in 
the postgraduate medical institute, 
University of Hull, in association 
with Hull York Medical School. 
He has been chair of the research 
committee of Breast Cancer 
Care (2004–08) and serves on a 
number of committees, including 
the Medical Research Council 
college of experts since 2008 and 
the research committee of the 
National Cancer Survivorship 
Initiative (Department of Health). 
His membership of editorial boards 
includes the European Journal of 
Psychiatry, Contemporary Hypnosis, 
Psycho-Oncology and Complementary 
Therapies in Clinical Practice. He is 
a former co-chair of the nominating 
committee of the International 
Psychosocial Oncology Society 
(2000–03) and served two terms 
of office as chairman of the British 
Psychosocial Oncology Society 
(1995–99). He was a member of 
the council of the British Society 
of Experimental and Clinical 
Hypnosis (1991–96; 2002–05), the 
population and behavioural sciences 
committee of Cancer Research UK 
and the National Cancer Research 
Institute complementary therapies 
clinical studies development group 
(2004–08).
Mr Patrick George Walker
MD FRCOG (b. 1949) has been 
a consultant gynaecologist, Royal 
Free Hospital, London since 
1986. His University of London 
MD was on ‘Human papilloma 
virus and its relationship with 
cervical intraepithelial neoplasia’ 
(1985). He was president of the 
British Society for Colposcopy 
and Cervical Pathology (2003–06) 
and secretary general (2006–08) 
of the International Federation for 
Cervical Pathology and Colposcopy 
and has been president since 2008.
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Dr Richard J Walton
(d. 1995) born and qualified in 
New Zealand. Having served with 
the Royal New Zealand Navy, 
he was awarded a British Empire 
Cancer Campaign Research 
Fellowship in 1949 and trained in 
radiotherapy at the Royal Marsden 
Hospital, Sutton, London, under 
Professor Sir David Smithers. 
After he obtained the DMRT in 
1953, Dr Malcolm MacCharles 
recruited him to Winnipeg, and 
he was appointed as head of 
radiotherapy and medical director 
of the Manitoba Cancer Treatment 
and Relief Institute (1954–57); 
the first executive director of the 
expanded and re-named Manitoba 
Cancer Treatment and Research 
Foundation (1957–73); vice-
president medical at the newly 
incorporated Health Sciences 
Centre, Winnipeg and a full 
professor in the department of 
radiology, University of Manitoba, 
Winnipeg (1973–79). He was 
chairman of the two task forces 
on cervical cancer screening 
programmes in Canada (1974–76; 
1980–82). See note 48. 
Professor Sir Stanley Way
FRCS FRCOG (d. 1988) qualified 
at the Middlesex Hospital, London; 
trained at Newcastle hospitals and 
with Papanicolaou in 1948–49, was 
lecturer (1968) in gynaecological 
oncology, University of Newcastle 
upon Tyne and consultant 
surgeon, gynaecological research 
department, Queen Elizabeth 
Hospital, Gateshead, a pioneering 
cancer unit and ran one of the 
five national cytology training 
schools. He delivered the Joseph 
Price Oration of the American 
Gynecological and Obstetrical 
Society on 10 September 1959 on 
‘Carcinoma of the vulva’; and was 
founder member, treasurer and 
then  chairman of the BSCC. See 
JKR (1988); Husain (1988).
Dr J M G (Max) Wilson
Principal medical officer at the 
Ministry of Health and joint author 
with G Jungner, chief of clinical 
chemistry department, Sahlgren’s 
Hospital, Gothenburg, Sweden, of 
Principles and Practice of Screening 
for Disease (1968).
Dr Margaret Wolfendale
MD (b. 1931) qualified at the 
Royal Free Hospital London in 
1956; was appointed registrar in 
exfoliative cytology to the Oxford 
Regional Hospital Board in 1962. 
She worked with Arthur Spriggs 
and other colleagues to establish a 
cytopathology service throughout 
the region and participated in 
many research projects, particularly 
associated with cervical screening. 
She was consultant cytopathologist 
at Stoke Mandeville Hospital, 
Aylesbury (1981–96).
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Professor Ciaran Woodman
is at the School of Cancer 
Sciences, College of Medical and 
Dental Sciences, University of 
Birmingham, Edgbaston.
Dr Jian Zhou
PhD (1957–99), patent holder 
with Ian Frazer (patent WO 
1993/002184) for a method of 
providing papilloma virus-like 
particles which may be used 
for diagnostic purposes or for 
incorporation in a vaccine for use 
in relation to infections caused by 
papilloma virus, studied medicine 
at Wenzhou Medical College after 
the cultural revolution, taking 
a master’s degree at Zhejiang 
Medical University where he 
became interested in pathology 
and in 1985, a PhD at Henan 
Medical University, where he 
became interested in molecular 
biology and virology for human 
papillomavirus (HPV) and cancer 
research, receiving his degree 
in 1994. He was a postdoctoral 
training fellow at Beijing Medical 
University; research fellow of 
ICRF tumour virus laboratory, 
department of pathology, 
University of Cambridge; NHMRC 
senior research officer, centre for 
immunology and cancer research, 
department of medicine, University 
of Queensland, Brisbane, Australia; 
assistant professor, head of 
papillomavirus structure protein 
laboratory, Loyola University 
Medical School, Chicago, Illinois; 
and Lions principal research fellow 
and head of the papillomavirus 
structure protein laboratory, 
centre for immunology and cancer 
research, department of medicine, 
Princess Alexandra Hospital, 
University of Queensland (1987–
99). He received grants for some 
20 research projects and 11 patents 
(1992–99). A memorial volume is 
freely available at www.scribd.com/
doc/2740521/zhou-jianprefaces-Etc 
(visited 23 April 2009). See  
Figure 5.
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ABC (1995, 2000)
‘Achievable standards, Benchmarks 
for reporting, Criteria for 
evaluating cervical cytopathology’, 
known as ‘ABC’, is the report of a 
working party set up by the Royal 
College of Pathologists, the British 
Society for Clinical Cytology 
and the NHS Cervical Screening 
Programme, chaired by Dr Amanda 
Herbert. First published in October 
1995 in the journal Cytopathology 
and as NHS CSP publication no. 
1, it had a second edition in 2000, 
edited by Jane Johnson and Julietta 
Patnick. Both editions clarified 
the existing guidance on reporting 
cervical smears along with proposed 
performance indicators and criteria 
for evaluating the performance of 
cervical cytopathology. The first 
edition specified a full review of 
all aspects of the screening history, 
including re-examination of 
previous cervical smears, but this 
was not included in the second 
edition, whose working party 
was chaired by Dr Jane Johnson 
(Wilson (2002)).
adenocarcinoma of the cervix
A less frequent form of cancer than 
squamous cell carcinoma, but is 
becoming relatively and absolutely 
more frequent. It is of glandular 
origin, usually arising from the 
endocervix and is more difficult to 
detect by cytology and colposcopy.
biopsy, loop
An electrified wire loop used to 
remove abnormal cells identified 
during colposcopy. The tissue 
removed is examined under a 
microscope to ensure that the 
abnormal cells have been removed.
biopsy, punch
A biopsy performed using a punch, 
an instrument to cut and remove a 
disk of tissue.
British Society for Clinical 
Cytology
Mary Egerton, Moira Murray, 
Freda Osmond-Clarke and Erica 
Wachtel, having attended the first 
International Congress on Cytology 
sponsored by the International 
Academy of Gynaecological 
Cytology in Vienna in September 
1961 considered that Great Britain 
was lagging far behind the US and 
Europe in the development of the 
speciality and that a society would 
help to establish and promote the 
practice of cytology throughout 
the UK. Consequently, a meeting 
was held at the Royal Society of 
Glossary*
* Terms in bold appear in the Glossary as separate entries
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Medicine on 1 December 1961 
to discuss the formation of a 
society. A working party chaired 
by C W Taylor (Birmingham) 
formulated statutes for a registered 
charity to promote the growth and 
development of clinical cytology 
in the UK and the organization of 
scientific meetings. Membership 
was open to all registered medical 
practitioners interested in 
cytology. See www.clinicalcytology.
co.uk/membership/history.
asp#background (visited  
3 December 2009).
carcinoma in situ (CIS)
An epithelium which displays 
disturbed differentiation 
throughout its thickness, but 
has not invaded the basement 
membrane. Formerly classified 
as preinvasive cancer, later in the 
category of pre-malignant change 
along with severe dysplasia. See  
also CIN.
cervical intraepithelial neoplasia 
(CIN1, ‑2 and ‑3)
A cytology grading system 
describing the pre-malignant 
change of cervical epithelium 
characterized by a proliferation 
of undifferentiated basal cells 
extending varying distances from 
basement membrane to surface. 
CIN1: undifferentiated stem cells 
in lower third of epithelium (mild 
dysplasia); CIN2: undifferentiated 
cells in lower two-thirds of 
epithelium (moderate dysplasia); 
CIN3: a lesion composed of 
primitive basal cells in the entire 
thickness of epithelial cells (both 
severe dysplasia and carcinoma in 
situ). See Richart (1964). 
cervical smear, smear test,  
Pap smear
A technique developed for use on 
women by Dr G N Papanicolaou 
in the 1920s, including a staining 
method named after him, to 
check the health of the cervix and 
detect early changes in the cells 
of the cervix, which may develop 
into cancer. A small disposable 
spatula (Figure 6) is used to take a 
sample of cells from the surface of 
the cervix, which are then spread 
onto a glass slide and sent to a 
laboratory to be examined under a 
microscope. The infected cells can 
be seen in Figure 4. This test was 
phased out in the UK by the end of 
2008 and replaced by liquid-based 
cytology (LBC).
condylomata acuminata
A papilloma consisting of central 
connective tissue cores of tree-like 
organization covered by epithelium 
displaying papillomavirus infection. 
The term condyloma refers to 
a clinically obvious filiform 
fungating papillomas of genital 
skin or mucous membranes and is 
infectious.
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cotton‑tail rabbit papillomavirus 
(CRPV)
Also called the Shope 
papillomavirus.
dyskaryosis
A cytological change in the nuclei 
of cells, which correspond to the 
abnormal cells seen histologically in 
CIN: mild (superficial), moderate 
(intermediate) and severe (parabasal 
and basal).
dysplasia
A reaction to damage to the 
epithelial surface of the cervix, 
which may disappear spontaneously 
or following treatment, as described 
by Reagan and Patten (1962). The 
term is more frequently used to 
describe precancerous changes now 
described as CIN and is still used in 
some places outside the UK. Mild, 
moderate and severe dysplasia 
correspond to mild, moderate and 
severe dyskaryosis and to CIN1, 2 
and 3.
genital warts
A benign epithelial proliferation 
caused by human papillomavirus 
(HPV) almost always caused by 
types of the virus that do not cause 
cancer.
electrophoresis
A process by which molecules, 
such as proteins, DNA or RNA 
fragments, can be separated 
according to size and electrical 
charge by applying an electric 
current to them. Each kind of 
molecule travels through the 
medium at a different rate, 
depending on its electrical charge 
and molecular size.
herpes simplex virus  
(HSV‑I and ‑II)
HSV-1 is responsible for oral 
infections (‘cold sores’) acquired 
mainly in childhood. HSV-2 is more 
often associated with infection in 
the genital tract and is transmitted 
by sexual contact. However, this 
separation is not absolute. HSV 
type-specific antibody tests can 
be used to identify past infection 
with a given antibody type using 
a monoclonal antibody blocking 
ELISA test (enzyme-linked 
immunosorbent assay).
human papillomaviruses (HPV)
A family of more than 200 viruses 
that cause various growths, 
including plantar warts and genital 
warts, both of which are filterable 
and easily transmitted. Genital 
warts are classed as a sexually 
transmitted infection (STI) 
acquired mainly through sexual 
contact, often called condylomata 
acuminata. These are soft and 
often occur in clusters, internally 
or externally. The virus may be 
present and transmittable in the 
absence of warts. Problems can 
result from untreated warts, which 
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can grow quite large, or, in rare 
cases, from infection of an infant 
during delivery. In addition, certain 
types of HPV are known to be 
‘oncogenic’ and are associated with 
various forms of cancer, including 
cervical, vulval and anal carcinoma 
as well as certain types of head and 
neck cancer. See also vaccine.
hybrid capture assays
A technique used to detect and 
monitor viral infections. It involves 
hybridisation of a single strand 
of target DNA to specific RNA 
probes, with the hybrid captured 
on a solid surface and detected 
using chemiluminescence. It is 
more sensitive than conventional 
Pap smears for detecting HPV 
infection and the absence of HPV 
detection correlates with a lack of 
dysplasia. See also note 26. 
hybridization
The amalgamation of two single 
complementary nucleic acid strands 
by heating to form a duplex, 
detected in a liquid or solid phase. 
Southern blotting and dot blotting 
are forms of hybridization.
Intercollegiate Working Party 
on Cervical Cytology Screening 
(1987)
Guidelines produced by a 
working party of eight under 
the chairmanship of Professor 
Frank Sharp, following the 
DHSS’s approach to the RCOG 
to look at clinical aspects of 
cervical cytopathology screening 
programme in the UK. 
Representatives were from the 
Royal College of Obstetricians 
and Gynaecologists, Pathologists, 
General Practitioners and the 
Faculty of Community Medicine. 
Their recommendations included: 
effective cervical screening 
programmes in all district health 
authorities; every adult woman 
should be screened at three-year 
intervals (20–64 years) with no 
upper age limit for those never 
having a smear; all women should 
receive the results of their tests; and 
monitoring the outcome of actions 
and feedback be implemented 
(page 31).
interval cancer 
Detected in the 3- or 5-year 
interval between test dates, where 
the previous episode was closed 
with no diagnosis of cancer.
koilocyte
A cell with a shell-like vacuole 
that looks ‘empty’ on cytological 
or histological preparations but 
contains mature infective HPV 
virus (high-risk or low-risk). See 
Ayre (1949); Koss (1987); Figure 4.
liquid‑based cytology (LBC)
A technique to take cells from the 
cervix using a special brush, which 
is rinsed into a small container 
of preservative or the head of the 
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brush snapped off and put into 
the container. The container is 
sent to the laboratory, where the 
cells are put onto a glass slide. 
Liquid-based cytology fixes the 
cells immediately and removes 
blood and inflammatory cells. 
Introduced in the UK in 2000, it 
was recommended by the National 
Institute for Clinical Excellence in 
2003 and replaced the Pap smear 
throughout the UK in 2008. 
The feasibility of HPV triage for 
borderline cytology, to correctly 
identify those women who need 
colposcopy, is supported by the 
introduction of LBC, which enables 
an HPV test to be carried out on 
the same cytology sample and to be 
restricted to those samples where 
the cytology result has proved 
abnormal. See also cervical smear.
Ministry of Health 1966 Circular
Mr Kenneth Robinson’s press 
conference on 21 October was 
reported in the BMJ ((1966) ii: 
1083) following the earlier Circular 
(Ministry of Health (1966)). The 
press release indicated the progress 
in the development of a cervical 
screening service (101 000 women 
aged 35 and over in England and 
Wales tested monthly in December 
1966 compared with 39 000 in 
December 1964; 457 trained 
technicians in June 1966 compared 
with 150 in December 1964). Mr 
Stanley Way in a letter to the BMJ 
in February 1967 (Way (1967)) 
disputed the accuracy of these 
details and noted that the new pay 
agreement for GPs from April 1967 
would include special payments for 
smear testing, although the funding 
of the expansion of the cervical 
screening services were to be borne 
by the ratepayers. Way described 
ministry involvement as likely to 
create ‘a ‘‘ministry camel” (a camel 
being an animal that looks like 
a horse which was designed by a 
committee).’ 
NHS Cervical Screening 
Programme 
Cervical screening programmes 
started in the NHS in 1964, 
although haphazard in coverage, 
and became a nationwide service in 
1988 with a computerized call and 
recall system. The policy objective 
was to reduce mortality by regular 
screening (all women aged 20–64 
every five years and those over 65 
who have not had two consecutive 
negative smears in the preceding 
ten years (DHSS (1988): paras 
2–4), although moves were made 
to ‘rationalize’ the service in 1982 
by offering two screenings to 
women aged 22–35, as a result of 
the Committee on Gynaecological 
Cytology (Penfold (1982)). See 
note 155; see also Blanks et al. 
(2000); www.cancerhelp.org.uk/
help/default.asp?page=9596#tests 
(visited 13 July 2009).
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p53 (protein 53 or tumor  
protein 53)
A gene discovered in 1979 by 
Lionel Crawford, David Lane, 
Arnold Levine, and Lloyd Old, 
that responds to DNA damage by 
stopping the cell cycle and turning-
on DNA repair mechanisms to fix 
the damage, which, once repaired, 
allows the cell to re-enter the cell 
cycle as normal. Sometimes known 
as the guardian angel gene.
Pap smear, see cervical test
papilloma
A benign epithelial tumour 
characterized by a branching 
structure.
papillomavirus
Small oncogenic DNA viruses 
that cause warty proliferations on 
epidermal and mucosal surfaces.
polymerase chain reaction (PCR)
A fast technique for making an 
unlimited number of copies of 
any piece of DNA and used to 
demonstrate the presence of HPV 
DNA. For the background to this 
1986 discovery for which Professor 
Kary Mullis shared the 1993 Nobel 
Prize for Chemistry, see http://
nobelprize.org/chemistry/ 
laureates/1993/mullis-lecture.html 
(visited 4 June 2009).
Scottish cervical screening
Cervical screening was introduced 
in Scotland in 1960 on a limited 
scale under the NHS, although 
not introduced as a population-
based programme. In 1978 
committees were established by 
the UK Department of Health 
and a review was carried out in 
Scotland resulting in the Strong 
Report (Scotland, Scientific Services 
Advisory Group, Histopathology 
Subcommittee (1988)). A 
nationwide cervical screening 
programme was introduced in 
Scotland in 1988 and the NHS 
Boards and Trusts introduced 
computerized call/recall systems in 
1988/9. Note: In July 1985, the 
Lothian Health Board put a freeze 
on smear tests because existing 
laboratory facilities were swamped 
with a backlog of 10 000 un-read 
slides. In response to public concern 
about the freeze, Edinburgh District 
Local Health Council organized 
a public meeting, jointly with 
the Edinburgh District Council 
Women’s Committee, in October 
1985, followed by the creation 
of an action group, the ‘Cervical 
Smear Campaign’ (see www.lhsa.
lib.ed.ac.uk/catalog/pdfs/GD31.pdf 
(visited 3 February 2009)). In 1992 
Dr Ian Duncan chaired a group to 
advise the National Coordinating 
Network on the management of 
14 distinct problems, including 
the use of quality assurance and 
internal audit as well as managing 
patients with HPV and CIN. These 
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recommendations were reviewed in 
1997. See Jordan et al. (eds) (1982); 
Mant et al. (1988); Schwartz et al. 
(1989).
Southern blotting method
A method for detecting the 
presence of DNA or RNA, using a 
radio-labelled probe, which permits 
the detection of a single copy of a 
human gene in a sample of DNA 
fragments, separated by size by 
gel electrophoresis, and named 
after Professor Sir Edwin Southern 
whose invention this was in 1975. 
The transfer from a gel to retentive 
paper (blotting with paper towels) 
facilitates the physical transfer of 
the nucleic acids.
vaccine (Gardasil, Merck/Sanofi 
Pasteur; Cervarix, GSk)
Following on from work done 
by Dr Jian Zhou on VLPs, 
Merck led the basic and clinical 
research programmes leading to 
the discovery and development 
of Gardasil, which was approved 
by the US FDA for clinical trials 
on women in 1997 and for use in 
humans in 2006 (and European 
Union marketing authorization). 
Gardasil protects against about 70 
per cent of human papillomavirus-
related cervical cancers (types 6, 11, 
16, and 18, including two strains 
that are responsible for nine in 10 
cases of genital warts). The Cervarix 
vaccine was developed by GSK 
using the baculovirus technology 
to produce VLPs for HPV16 and 
-18 with a proprietary adjuvant to 
give a strong immune response. 
This vaccine was introduced in the 
UK in a national programme in 
2008 following the completion of 
successful clinical trials (phase 2 and 
3) in 2006, with European Union 
marketing authorization in 2007. 
See note 3. Some disappointment 
has been expressed about the UK’s 
choice of vaccine (Kmietowicz 
(2008)).
Wilson and Jungner’s classic 
criteria for disease screening, 
report for the World Health 
Organization in 1968: 
1.  The condition sought should 
be an important health 
problem; 
2.  There should be an accepted 
treatment for patients with 
recognized disease; 
3.  Facilities for diagnosis and 
treatment should be available; 
4.  There should be a latent or 
early symptomatic stage; 
5.  There should be a suitable test 
or examination; 
6.  The test should be acceptable 
to the population; 
7.  The natural history of 
the condition, including 
development from latent to 
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declared disease, should be 
adequately understood; 
8.  There should be an agreed 
policy on whom to treat as 
patients; 
9.  The cost of case finding 
(including diagnosis and 
treatment of patients 
diagnosed) should be 
economically balanced in 
relation to possible expenditure 
on medical care as a whole; 
10.  Case finding should be a 
continuing process and not a 
‘once and for all’ project. 
See Wilson and Jungner (1968): 
26–39; Sheehy et al. (2009); 
Andermann et al. (2008).
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ABC report (RCPath et al, 1995, 
2000), 60, 145
Aberdeen, 6, 8, 13, 17, 59, 61, 69, 
76–7
acquired immunodeficiency syndrome 
(AIDS) see AIDS/HIV infection
adenocarcinoma, cervical, 25, 145
advertising, direct-to-consumer, 69
AIDS/HIV infection, 5, 25, 53
American Cancer Society, 18
American Journal of Obstetrics and 
Gynecology, 31, 33
American Society of Cytopathology, 86
animal models, 38
antibody response (humoral 
immunity), 45, 47, 48–9
anxiety, screening-related see cervical 
cytology screening
ARTISTIC trial, 50
Atlas of Exfoliative Cytology 
(Papanicolaou, 1954), 34, 35
atypical squamous cells of 
undetermined significance (ASC-
US), 74, 75
Australia, 29–30, 31, 33, 36, 37, 44, 
45, 46, 84–5
automated cervical screening, 7, 15, 
23, 90–2
Aylesbury, 22, 57
Aylesbury spatula, 54, 89–90
Ayre spatula, 54
baculovirus expression system, 46
Banbury Centre conference (1985), 
Cold Spring Harbor Laboratory, 
Long Island, New York, NY, 20
basal carcinoma, cutaneous, 42
biomedical scientists (BMS), 23–4, 60
see also laboratory technicians, medical
biopsy, cervical, 36, 37
loop, 145
punch, 3, 145
Birmingham, 11, 18, 21
BMJ see British Medical Journal
BMS see biomedical scientists
bovine papillomavirus (BPV), 39
breast cancer screening, 62–3
Bristol, 7, 8, 73
British Colposcopy Group, 27
British Columbia, Canada, 17, 18, 52, 
56, 74
British Empire Cancer Campaign 
(Cancer Research Campaign from 
1970), 88
British Journal of Obstetrics and 
Gynaecology (BJOG from 2000), 
80
British Medical Journal (BMJ), 10, 14, 
19, 30, 51, 61, 67
British Psychosocial Oncology Society, 
76
British Society for Clinical Cytology 
(BSCC), 14, 15, 16, 145–6
annual scientific meetings, 14, 18, 
28
presidents, 9
qualifications, 7, 8
training sessions, 11, 14
British Society for Colposcopy and 
Cervical Pathology (BSCCP), 24, 
25, 26, 28
Brussels, Belgium, 4
BSCC see British Society for Clinical 
Cytology
BSCCP see British Society for 
Colposcopy and Cervical 
Pathology
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Cambridge, 44
Cambridge Instruments,  
Cambridge, 7
Campbeltown, Kintyre, 6
Canada, 17–19, 52–3, 56, 61, 74
cancer viruses, 39, 40
carcinoma in situ (CIS), cervical, 25, 
55–6, 146
CD4 TH1 T cells, 48
CD8 T-cells (cytotoxic T cells), 45, 47
cell culture systems, 38
cell-mediated immunity, 45
Cervarix (GSK), 5, 43, 151
see also vaccines, HPV
cervical cancer
age-related incidence, 57, 58, 64–5
causal role of HPV, 31–9, 41, 49, 
50–1, 84–6
changing risk/incidence, 55, 57, 61, 
62, 64–5
interval, 57, 61–2, 149
mechanisms of induction by HPV, 
39–42
natural history, 37–8, 55–6, 70, 
83–7
prevention, 5, 43, 58, 83
progression of CIN to, 70
risk factors, 31, 33
unknown male factor, 29–34
cervical carcinoma in situ (CIS) see 
carcinoma in situ (CIS)
cervical cytology screening, 51–67
age range, 17, 54–5, 56
anxiety, screening-related, 66, 67, 
74, 75–7
automated, 7, 15, 23, 90–2
call-recall systems, 22, 52, 60, 62–3
compliance/coverage, 17, 52, 53, 
58, 61, 62, 63–4, 77
cost-effectiveness, 57
development, 6–14, 17, 83–7, 
88–92
effectiveness, 10, 15, 17, 18–19, 
51–8, 59, 60
HPV testing in triage, 71–5
information provision, 79–80
international perspective, 16–19, 
52–6
intervals, 7–8, 13, 18–19, 52,  
54–5, 56
laboratories, 21–4
medical staff see cytologists/
cytopathologists
monitoring/audit, 57, 61–2, 65
non-medical staff see cytoscreeners, 
non-medical
older women, 69–71
opportunistic, 54–5, 56, 59
organization, 10–12, 14, 53–4, 
58–67
post-vaccination era, 53, 78
public health impact, 61–2, 64–5
quality control, 28, 29, 60–2, 66–7
reasons for failure, 28
sensitivity, 50, 52
UK national programme see NHS 
Cervical Screening Programme
young women, 53, 56, 61–2
see also cervical smears
cervical intraepithelial neoplasia 
(CIN), 37, 146
colposcopy, 24, 25
HPV16, 41
natural history, 37–8, 55–6, 70
treatment, 25
cervical intraepithelial neoplasia grade 
1 (CIN1), 37, 146
cervical intraepithelial neoplasia grade 
2 (CIN2), 37, 80, 146
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